<SEC-DOCUMENT>0001193125-18-123721.txt : 20180420
<SEC-HEADER>0001193125-18-123721.hdr.sgml : 20180420
<ACCEPTANCE-DATETIME>20180420080057
ACCESSION NUMBER:		0001193125-18-123721
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20180514
FILED AS OF DATE:		20180420
DATE AS OF CHANGE:		20180420
EFFECTIVENESS DATE:		20180420

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARIN CORP PLC\UK
		CENTRAL INDEX KEY:			0000897448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21392
		FILM NUMBER:		18765085

	BUSINESS ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000
		BUSINESS PHONE:		353 1 6699 020

	MAIL ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARIN PHARMACEUTICALS PLC
		DATE OF NAME CHANGE:	20000201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ETHICAL HOLDINGS PLC
		DATE OF NAME CHANGE:	19930322
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>d467547ddef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML><HEAD>
<TITLE>DEF 14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROXY
STATEMENT PURSUANT TO SECTION 14(a) OF THE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the Registrant&nbsp;&nbsp;&#9746;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Filed by a Party other than the
Registrant&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Preliminary Proxy Statement </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top">Definitive Proxy Statement </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Confidential, for Use of the Commission Only (as permitted by <FONT STYLE="white-space:nowrap">Rule&nbsp;14a-6(e)(2))</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Definitive Additional Materials </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting Material Pursuant to sec. <FONT STYLE="white-space:nowrap">240.14a-11(c)</FONT> or sec. <FONT STYLE="white-space:nowrap">240.14a-12</FONT> </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>AMARIN CORPORATION PLC </B></P> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified In Its Charter) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top">No fee required. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Fee computed on table below per Exchange Act <FONT STYLE="white-space:nowrap">Rules&nbsp;14a-6(i)(1)</FONT> and <FONT STYLE="white-space:nowrap">0-11.</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Title of each class of securities to which transaction applies. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:6%;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Aggregate number of securities to which transaction applies. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:6%;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Per unit price or other underlying value of transaction computed pursuant to Exchange Act <FONT STYLE="white-space:nowrap">Rule&nbsp;0-11</FONT> (set forth the amount on which the filing fee is calculated and state how
it was determined): </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:6%;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Proposed maximum aggregate value of transaction. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:6%;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Total fee paid. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:6%;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Fee paid previously with preliminary materials. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Check box if any part of the fee is offset as provided by Exchange Act <FONT STYLE="white-space:nowrap">Rule&nbsp;0-11(a)(2)</FONT> and identify the filing for which the offsetting fee was paid previously. Identify the
previous filing by registration statement number, or the Form or Schedule and the date of its filing. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Amount Previously Paid. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:6%;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Form, Schedule or Registration State No.: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:6%;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Filing Party: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:6%;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Date Filed: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:6%;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g467547g76b14.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2 Pembroke House </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upper Pembroke Street <FONT STYLE="white-space:nowrap">28-32,</FONT> Dublin 2, Ireland </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Registered in England&nbsp;&amp; Wales under Company No.&nbsp;2353920) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOTICE IS HEREBY GIVEN</B> that the Annual General Meeting of Shareholders of Amarin Corporation plc, a public limited company registered
in England and Wales (the &#147;<B><I>Company</I></B>&#148;), will be held at The Shelbourne Hotel, 27 St. Stephen&#146;s Green, Dublin 2, Ireland on May&nbsp;14, 2018 at 2:00 p.m. local time for the purpose of considering and, if thought fit,
passing the following resolutions, each of which will be proposed as ordinary resolutions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">To <FONT STYLE="white-space:nowrap">re-elect</FONT> Mr.&nbsp;John&nbsp;F. Thero as a director; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">To <FONT STYLE="white-space:nowrap">re-elect</FONT> Mr.&nbsp;Patrick J. O&#146;Sullivan as a director; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">To hold an advisory <FONT STYLE="white-space:nowrap">(non-binding)</FONT> vote to approve the compensation of the Company&#146;s &#147;named executive officers&#148; as described in full in the &#147;Executive
Compensation Discussion and Analysis&#148; section, the tabular disclosure regarding such compensation, and the accompanying narrative disclosure on pages 21 to 38 and pages 39 to 49 of the accompanying Proxy Statement; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">To appoint Ernst&nbsp;&amp; Young LLP as auditors of the Company to hold office until the conclusion of the next general meeting at which accounts are laid before the Company and to authorize the Audit Committee of the
Board of Directors of the Company to fix the auditors&#146; remuneration as described in full on pages 9 to 10 of the accompanying Proxy Statement. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public limited
company organized under the laws of England and Wales, it is a statutory requirement that the Board of Directors of the Company lay before the Annual General Meeting the Company&#146;s statutory accounts, which are those accounts included in the
Company&#146;s Annual Report for the year ended December&nbsp;31, 2017 as prepared in conformity with U.S. Generally Accepted Accounting Principles (the &#147;<B><I>Annual Report</I></B>&#148;) and the accounts for the financial year ended
December&nbsp;31, 2017 prepared in accordance with International Financial Reporting Standards. The Company does not expect that other items of business will be considered at the Annual General Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only shareholders who held shares at the close of business on the record date, April&nbsp;18, 2018, may vote at the Annual General Meeting,
including any adjournment or postponement thereof. The accompanying Proxy Statement more fully describes the details of the business to be conducted at the Annual General Meeting. After careful consideration, our Board of Directors has unanimously
approved the proposals and recommends that you vote FOR each director nominee and FOR each other proposal described in the Proxy Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s principal executive offices are located at 2 Pembroke House, Upper Pembroke Street
<FONT STYLE="white-space:nowrap">28-32,</FONT> Dublin 2, Ireland. The registered office of Amarin Corporation plc is One New Change, London EC4M 9AF, England. A copy of the Company&#146;s Annual Report accompanies this Notice and the enclosed Proxy
Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Important Notice of Internet Availability</I></B>. The accompanying Proxy Statement and Annual Report will also be
available to the public at <B><I>http://investor.amarincorp.com</I></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We look forward to seeing you at the Annual General Meeting.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John F. Thero</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">John F. Thero</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>President and Chief Executive Officer</I></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April 20, 2018 </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; margin-left:1%; margin-right:1%; font-size:10pt; font-family:Times New Roman"><B>WHETHER OR NOT YOU EXPECT TO ATTEND THE ANNUAL GENERAL MEETING, PLEASE COMPLETE, DATE, SIGN AND RETURN THE
ENCLOSED PROXY CARD USING THE ENCLOSED RETURN ENVELOPE AS PROMPTLY AS POSSIBLE IN ORDER TO ENSURE YOUR REPRESENTATION AT THE MEETING. EVEN IF YOU HAVE VOTED BY PROXY, YOU MAY STILL VOTE IN PERSON IF YOU ATTEND THE MEETING. PLEASE NOTE, HOWEVER, THAT
IF YOUR SHARES ARE REPRESENTED BY AMERICAN DEPOSITARY SHARES AND HELD ON DEPOSIT BY CITIBANK, N.A., AS DEPOSITARY, OR IF YOUR SHARES ARE HELD OF RECORD BY A BROKER, BANK OR OTHER NOMINEE AND YOU WISH TO HAVE YOUR VOTES CAST AT THE MEETING, YOU MUST
OBTAIN, COMPLETE AND TIMELY RETURN A PROXY CARD ISSUED IN YOUR NAME FROM THAT INTERMEDIARY IN ACCORDANCE WITH ANY INSTRUCTIONS PROVIDED THEREWITH. </B></P></div> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMARIN CORPORATION PLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROXY STATEMENT FOR </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2018
ANNUAL GENERAL MEETING OF SHAREHOLDERS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_1">GENERAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_2">PROPOSALS NOS. 1 AND 2 ELECTION OF DIRECTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_3">Nomination of Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_4">Nominees and Incumbent Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_5">Directors Nominated for Election</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_6">Directors Continuing in Office</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_7">PROPOSAL NO. 3 ADVISORY VOTE ON EXECUTIVE COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_8">Background</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_9">PROPOSAL NO. 4 APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_10">Fees for Independent Registered Public Accounting
Firm&#151;E&amp;Y</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_11">ADDITIONAL BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_12">CORPORATE GOVERNANCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_13">Director Independence</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_14">Code of Business Conduct and Ethics</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_15">Shareholder Communications</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_16">BOARD OF DIRECTORS AND COMMITTEES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_17">Board Leadership Structure and Risk Oversight</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_18">Board Committees</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_19">Compensation Committee Interlocks and Insider Participation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_20">EXECUTIVE OFFICERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_21">CERTAIN RELATIONSHIPS AND RELATED-PARTY TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_22">Transactions with Related Parties</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_23">Related-Party Transaction Review and Approval</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_24">SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_25">INSIDER TRADING POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_26">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_27">EXECUTIVE COMPENSATION DISCUSSION AND ANALYSIS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_28">2017 Operating Highlights</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_29">Compensation Philosophy and Objectives</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_30">REMUNERATION COMMITTEE REPORT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_31">Summary Compensation Table</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_32">Grants of Plan-Based Awards</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_33">Option Exercises and Stock Vested</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_34">Outstanding Equity Awards at Fiscal <FONT STYLE="white-space:nowrap">Year-End
</FONT></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_35">Pension Benefits</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_36">Nonqualified Deferred Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_37">Employment, Change of Control and Severance Arrangements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_38">Potential Payments upon Change of Control Termination</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_39">CEO Pay Ratio</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_40">DIRECTOR COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_41"><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director
Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_42">REPORT OF THE AUDIT COMMITTEE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_43">SHAREHOLDER PROPOSALS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_44">DELIVERY OF PROXY MATERIALS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc467547_45">PROXY FORM</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROXY STATEMENT FOR </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2018 ANNUAL GENERAL MEETING OF SHAREHOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD ON MAY&nbsp;14, 2018 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc467547_1"></A>GENERAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Proxy Statement is furnished in connection with the solicitation of proxies by the Board of Directors (the
&#147;<B><I>Board</I></B>&#148;) of Amarin Corporation plc, a public limited company registered in England&nbsp;&amp; Wales (&#147;<B><I>Amarin</I></B>&#148;, the &#147;<B><I>Company</I></B>&#148;, &#147;<B>we</B>&#148; or
&#147;<B><I>us</I></B>&#148;) for use at the Company&#146;s 2018 Annual General Meeting of Shareholders (the &#147;<B><I>Annual General Meeting</I></B>&#148;) to be held at The Shelbourne Hotel, 27 St. Stephen&#146;s Green, Dublin 2, Ireland, on
May&nbsp;14, 2018, at 2:00 p.m. local time for the purpose of considering and, if thought fit, passing the resolutions specified in the Notice of Annual General Meeting. This Proxy Statement is being mailed to shareholders on or about April 20,
2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a proxy to be effective, it must be properly executed and dated and lodged (together with a duly signed and dated power of
attorney or other authority (if any) under which it is executed (or a notarially certified copy of such power of attorney or other authority)) at the offices of the Company&#146;s registrars, Equiniti Limited of Aspect House, Spencer Road, Lancing,
West Sussex, BN99 6DA, England (the &#147;<B><I>Registrars</I></B>&#148;) so as to be received by 8:00&nbsp;a.m. local time on May&nbsp;10, 2018. Each proxy properly tendered will, unless otherwise directed by the shareholder, be voted FOR the
nominees described in this Proxy Statement and FOR each other proposal described in the Proxy Statement, and at the discretion of the proxy holder(s) with regard to all other matters that may properly come before the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will pay all of the costs of soliciting proxies. We will provide copies of our proxy materials to Citibank, N.A. as the depositary
for our American Depositary Shares (the &#147;<B><I>Depositary</I></B>&#148;), brokerage firms, fiduciaries and custodians for forwarding to beneficial owners and will reimburse these persons for their costs of forwarding these materials. We have
engaged Okapi Partners to assist us in the distribution and solicitation of proxies for a fee of $15,000 plus expenses. Our directors, officers and employees may also solicit proxies; however, we will not pay them additional compensation for any of
these services. Proxies may be solicited by telephone, facsimile, or personal solicitation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shares Outstanding and Voting Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amarin is registered in England&nbsp;&amp; Wales and therefore subject to the United Kingdom Companies Act 2006 (the &#147;<B><I>Companies
Act</I></B>&#148;), which, together with the Articles of Association of the Company (the &#147;Articles&#148;), governs the processes for shareholder voting at Annual General Meetings. There are a number of differences between English and U.S. law
in relation to voting. At the Annual General Meeting, a resolution put to the vote of the meeting shall be decided on a show of hands unless a poll is demanded (either before a show of hands on that resolution or immediately after the result of a
show of hands on that resolution is declared) by (a)&nbsp;the chairman, (b)&nbsp;at least two shareholders entitled to vote at the meeting, (c)&nbsp;a shareholder or shareholders representing not less than
<FONT STYLE="white-space:nowrap">one-tenth</FONT> of the total voting rights of all shareholders having the right to vote at the meeting (excluding any voting rights attached to shares that are held as treasury shares) or (d)&nbsp;a shareholder or
shareholders holding shares conferring a right to vote at the meeting being shares on which an aggregate sum has been paid up equal to not less than <FONT STYLE="white-space:nowrap">one-tenth</FONT> of the total sum paid up on all shares conferring
that right (excluding any shares in the Company conferring a right to vote at the meeting that are held as treasury shares). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only holders
of record of our ordinary shares with a par value of &pound;0.50 each (&#147;<B><I>Ordinary Shares</I></B>&#148;) at the close of business on April&nbsp;18, 2018 (the &#147;<B><I>Record Date</I></B>&#148;), are entitled to notice of, and to attend
and to vote at, the Annual General Meeting. On the Record Date, approximately 295,956,415 Ordinary Shares were issued and 293,584,140 were outstanding, of which approximately 293,217,685 were held in the name of the Depositary, which issues
Company-sponsored American Depositary Receipts (&#147;<B><I>ADRs</I></B>&#148;) evidencing American Depositary Shares (&#147;<B><I>ADSs</I></B>&#148;) which, in turn, each represent one Ordinary Share. With respect to all matters to be voted on at
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Annual General Meeting, each shareholder present has only one vote unless demand is made for a vote on a poll (in which case each shareholder gets one vote per Ordinary Share held). The
presence, in person or by proxy, of at least two shareholders who hold shares as of the Record Date will constitute a quorum for the transaction of business at the Annual General Meeting. At any adjournment of the Annual General Meeting, if a quorum
is not present within fifteen minutes from the time appointed for such meeting, one person entitled to be counted in a quorum present at the adjournment shall be a quorum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Persons who hold Ordinary Shares directly on the Record Date (&#147;<B><I>record holders</I></B>&#148;) must return a proxy card or attend the
Annual General Meeting in person in order to vote on the proposals. Persons who own Ordinary Shares indirectly on the Record Date through a brokerage firm, bank or other financial institution, including persons who own Ordinary Shares in the form of
ADSs through the Depositary (&#147;<B><I>beneficial owners</I></B>&#148;) must return a voting instruction form to have their shares or the shares underlying their ADSs, as the case may be, voted on their behalf. Brokerage firms, banks or other
financial institutions that do not receive voting instructions from beneficial owners may either return a proxy leaving these shares <FONT STYLE="white-space:nowrap">un-voted</FONT> (a &#147;<B><I>broker
<FONT STYLE="white-space:nowrap">non-vote</FONT></I></B>&#148;) or vote these shares on behalf of the beneficial owners. Your brokerage firm, bank or other financial institution may vote your shares on routine matters and cannot vote your shares on
any <FONT STYLE="white-space:nowrap">non-routine</FONT> matter. The appointment of our independent registered public accounting firm (Proposal 4) is a routine matter. We encourage you to provide voting instructions to your brokerage firm, bank or
other financial institution by giving your proxy to them. This ensures that your shares will be voted at the Annual Meeting according to your instructions. You should receive directions from your brokerage firm, bank or other financial institution
about how to submit your proxy to them at the time you receive this proxy statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ADR holders are not entitled to vote directly at the
Annual General Meeting, but an Amended and Restated Deposit Agreement dated as of November&nbsp;4, 2011 (the &#147;<B><I>Deposit Agreement</I></B>&#148;), exists between the Depositary and the holders of ADRs pursuant to which registered holders of
ADRs as of the Record Date are entitled to instruct the Depositary as to the exercise of voting rights pertaining to the Ordinary Shares so represented. The Depositary has agreed that it will endeavor, insofar as practicable, to vote (in person or
by delivery to the Company of a proxy) the Ordinary Shares registered in the name of the Depositary, in accordance with the instructions of the ADR holders. In the event that the instruction card is executed but does not specify the manner in which
the Ordinary Shares represented are to be voted (i.e., by marking a vote &#147;FOR&#148;, &#147;AGAINST&#148; or any other option), the Depositary will vote in respect of each proposal as recommended by the Board which is described in the Notice of
Annual General Meeting. Instructions from the ADR holders must be sent to the Depositary so that the instructions are received by no later than 3:00 p.m. New York time on May&nbsp;7, 2018 (the &#147;<B><I>Instruction Date</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has retained the Registrars to hold and maintain its register of members. The Registrars will be engaged by the Company to send
proxy forms to all registered members appearing on that register and to take delivery of completed proxy forms posted to it in accordance with the details above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will be counted for the purpose of determining the presence or
absence of a quorum, but will not be counted for the purpose of determining the number of votes cast on a given proposal. The required vote for each of the proposals expected to be acted upon at the Annual General Meeting is described below: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Ordinary Resolutions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Proposals No.</I><I></I><I>&nbsp;1 and No.</I><I></I><I>&nbsp;2&#151;Election of directors</I>. Each director nominated for election is
elected if (i)&nbsp;on a show of hands, a majority of shareholders present in person or by proxy and voting on the proposal vote in favor of such director or (ii)&nbsp;on a poll, a majority of the shares present at the meeting in person or by proxy
and voting on the proposal are voted in favor of such director. As a result, abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect on the vote outcome. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Proposal No.</I><I></I><I>&nbsp;3&#151;Advisory
<FONT STYLE="white-space:nowrap">(non-binding)</FONT> vote to approve the compensation of the Company&#146;s named executive officers</I>. This advisory proposal will be approved if (i)&nbsp;on a show of hands, a majority of shareholders present in
person or by proxy and voting on the proposal vote in favor of the resolution or (ii)&nbsp;on a poll, a majority of the shares present at the meeting in person or by proxy and voting on the proposal are voted in favor of the resolution. As a result,
abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect on the vote outcome. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Proposal
No.</I><I></I><I>&nbsp;4</I>&#151;<I>Approval of independent registered public accounting firm</I>. This proposal will be approved if (i)&nbsp;on a show of hands, a majority of shareholders present in person or by proxy and voting on the proposal
vote in favor of the resolution or (ii)&nbsp;on a poll, a majority of the shares present at the meeting in person or by proxy and voting on the proposal are voted in favor of the resolution. As a result, abstentions and broker <FONT
STYLE="white-space:nowrap">non-votes</FONT> will have no effect on the vote outcome. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We encourage you to vote by proxy by mailing an
executed proxy card. By voting in advance of the meeting, this ensures that your shares will be voted and reduces the likelihood that the Company will be forced to incur additional expenses soliciting proxies for the Annual General Meeting. Any
record holder of our Ordinary Shares may attend the Annual General Meeting in person and may revoke the enclosed form of proxy at any time by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">executing and delivering to the corporate secretary a later-dated proxy; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">voting in person at the Annual General Meeting. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial owners of our Ordinary Shares and
ADSs representing our Ordinary Shares who wish to change or revoke their voting instructions should contact their brokerage firm, bank or other financial institution or the Depositary, as applicable, for information on how to do so. Generally,
however, beneficial owners of our Ordinary Shares and ADSs representing our Ordinary Shares who wish to change or revoke their voting instructions may do so up until 3:00 p.m. New York time on the Instruction Date. Beneficial owners who wish to
attend the Annual General Meeting and vote in person should contact their brokerage firm, bank or other financial institution holding Ordinary Shares of Amarin on their behalf in order to obtain a &#147;legal proxy&#148; which will allow them to
both attend the meeting and vote in person. Without a legal proxy, beneficial owners cannot vote at the Annual General Meeting because their brokerage firm, bank or other financial institution may have already voted or returned a broker <FONT
STYLE="white-space:nowrap">non-vote</FONT> on their behalf. Record holders of ADRs who wish to attend the Annual General Meeting and vote in person should contact the Depositary (and beneficial owners wishing to do the same should contact their
brokerage firm, bank or other financial institution holding their ADSs) to cause their ADSs to be cancelled and the underlying shares to be withdrawn in accordance with the terms and conditions of the Deposit Agreement so as to be recognized by us
as a record holder of our Ordinary Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc467547_2"></A>PROPOSALS NOS. 1 AND 2 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELECTION OF DIRECTORS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Articles provide that, at every annual general meeting, at least <FONT STYLE="white-space:nowrap">one-third</FONT> of the directors at the time shall retire from office (or, if the number of directors at the time is not a multiple of three, then the
number nearest to but not exceeding <FONT STYLE="white-space:nowrap">one-third</FONT> shall retire from office). The directors elected at the Annual General Meeting will hold office until their successors are elected and qualified, unless they
resign or their seats become vacant due to death, removal, or other cause in accordance with the Articles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described below, the Board
has nominated Mr.&nbsp;Thero and Mr.&nbsp;O&#146;Sullivan for <FONT STYLE="white-space:nowrap">re-election</FONT> at the Annual General Meeting. Each of the nominees has indicated his or her willingness to serve if
<FONT STYLE="white-space:nowrap">re-elected.</FONT> Should any of the nominees become unavailable for election at the Annual General Meeting, the persons named on the enclosed proxy as proxy holders may vote all proxies given in response to this
solicitation for the election of a substitute nominee chosen by the Board. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc467547_3"></A>Nomination of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Nominating and Corporate Governance Committee, which acts as the Company&#146;s nominating committee, reviews and recommends to the Board
potential nominees for election to the Board. In reviewing potential nominees, the Nominating and Corporate Governance Committee considers the qualifications of each potential nominee in light of the Board&#146;s existing and desired mix of
experience and expertise. Specifically, as set forth in our Nominating and Corporate Governance Committee Charter, it considers whether the nominee satisfies the following minimum criteria: has experience at a strategic or policymaking level in a
business, government, <FONT STYLE="white-space:nowrap">non-profit</FONT> or academic organization of high standing; is highly accomplished in his or her field, with superior credentials and recognition; is well regarded in the community and has a
long-term reputation for the highest ethical and moral standards; has sufficient time and availability to devote to the affairs of the Company, particularly in light of the number of boards on which the nominee may serve; has a demonstrated history
of actively contributing at board meetings (to the extent that the nominee serves or has previously served on other boards). In addition to these minimum qualifications, the Nominating and Corporate Governance Committee recommends that the Board
select persons for nomination to help ensure that: a majority of the Board shall be independent in accordance with in the listing standards of the NASDAQ Global Select Market (&#147;<B><I>NASDAQ</I></B>&#148;); each of the Company&#146;s Audit,
Remuneration and Nominating and Corporate Governance Committees shall be comprised entirely of independent directors; and at least one member of the Audit Committee shall qualify as an audit committee financial expert as defined by Securities and
Exchange Commission (&#147;<B><I>SEC</I></B>&#148;) rules. In addition, the Nominating and Corporate Governance Committee may consider whether the nominee has direct experience in the pharmaceutical, biotechnology or healthcare industries or in the
markets in which the Company operates and whether the nominee, if elected, would assist in achieving a mix of Board members that represents a diversity of background and experience. Although the Nominating and Corporate Governance Committee may
consider whether nominees assist in achieving a mix of Board members that represents a diversity of background and experience, which is not only limited to race, gender or national origin, we have no formal policy regarding board diversity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After reviewing the qualifications of potential Board candidates, the Nominating and Corporate Governance Committee presents its
recommendations to the Board, which selects the final director nominees. Upon the recommendation of the Nominating and Corporate Governance Committee, the Board nominated Mr.&nbsp;Thero and Mr.&nbsp;O&#146;Sullivan for
<FONT STYLE="white-space:nowrap">re-election</FONT> as directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Nominating and Corporate Governance Committee considers shareholder
nominees using the same criteria set forth above. Shareholders who wish to present a potential nominee to the Nominating and Corporate Governance Committee for consideration for election at a future annual general meeting of shareholders must
provide the Nominating and Corporate Governance Committee with notice of the nomination and certain information regarding the candidate within the time periods set forth below under the caption &#147;Shareholder Proposals.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc467547_4"></A>Nominees and Incumbent Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Nominating and Corporate Governance Committee has recommended, and the Board has nominated, Mr.&nbsp;Thero and Mr.&nbsp;O&#146;Sullivan to
be <FONT STYLE="white-space:nowrap">re-elected</FONT> as directors at the Annual General Meeting. The table below sets forth the following information for these nominees and the Company&#146;s continuing directors: the year each was first elected as
a director of the Company, their respective ages and the positions currently held with the Company: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="45%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:174.10pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Nominee / Director Name and Year First Became
a<BR>Director</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position(s) with the Company</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Nominees for Director:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick J. O&#146;Sullivan (2011)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John F. Thero (2014)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President, Chief Executive Officer, Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Directors Continuing in Office:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kristine Peterson (2010)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jan van Heek (2010)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lars G. Ekman M.D., Ph.D. (2008)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Stack (2012)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph S. Zakrzewski (2010)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc467547_5"></A>Directors Nominated for Election </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following persons have been nominated by the Board to be elected as directors at the Annual General Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Patrick J. O&#146;Sullivan </I>joined Amarin as a <FONT STYLE="white-space:nowrap">non-executive</FONT> director in December 2011.
Mr.&nbsp;O&#146;Sullivan has more than 40 years of pharmaceutical industry experience, including more than 30 years as Chief Executive Officer and board member of the LEO Pharma companies in Ireland and more than 10 years as a board member of the
parent company of the LEO Pharma Group in Denmark. Since 2007 Mr.&nbsp;O&#146;Sullivan has been a business consultant to the pharmaceutical industry, and he currently serves as a member of the board of directors of Allergan plc.
Mr.&nbsp;O&#146;Sullivan is a registered pharmacist who earned a Bachelor of Commerce and an M.B.A. from University College in Dublin. The Board believes that Mr.&nbsp;O&#146;Sullivan&#146;s experience from serving as an officer director of various
companies within the pharmaceutical industry, as well as his educational training in business administration, make him a valuable member of our Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>John F. Thero</I> joined Amarin in November 2009. He was promoted to President and Chief Executive Officer, and appointed to the Board,
effective January 2014. Prior to his promotion, he was Amarin&#146;s President since November 2010 before which he was Amarin&#146;s Chief Financial Officer. Mr.&nbsp;Thero has more than 25 years of senior financial and operational management
experience, including supporting the growth of life science companies for over 15 years. Mr.&nbsp;Thero has helped manage both the successful commercial growth and the successful sale of companies. In 2007, Mr.&nbsp;Thero was Chief Financial Officer
at ViaCell, Inc., where he helped guide the company to its successful sale. From 2003 to 2007, Mr.&nbsp;Thero was Senior Vice President at Acusphere, Inc., where he oversaw the successful <FONT STYLE="white-space:nowrap">build-out</FONT> and
qualification of manufacturing operations. From 1994 to 2003, in a number of senior positions at Abiomed, Inc., including Senior Vice President Business Operations and Chief Financial Officer, he helped manage the transition from a development-stage
company into a commercial entity. Mr.&nbsp;Thero began his professional career at Arthur Andersen LLP, during which time he became a Certified Public Accountant. He received a B.A. in Economics from the College of the Holy Cross. The Board believes
that Mr.&nbsp;Thero&#146;s experience in management positions at life sciences companies, as well as his experience as Amarin&#146;s President and Chief Executive Officer and, before that, as Amarin&#146;s President and Chief Financial Officer,
provide him with the appropriate qualifications and skills to serve as a member of the Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc467547_6"></A>Directors Continuing in Office </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Jan van Heek</I> joined Amarin as a <FONT STYLE="white-space:nowrap">non-executive</FONT> director in February 2010. He is currently a
Principal and Partner at BioPoint Group, where he advises biotechnology and other healthcare companies in commercial strategy development, financing and business development. Prior to establishing BioPoint, Mr.&nbsp;van Heek spent more than 18 years
at Genzyme Corporation, most recently as an Executive Vice President and Senior Advisor to the CEO and senior management team. Mr.&nbsp;van Heek is currently a board member of Minerva Neurosciences, Inc. and was a board member and Chairman of the
Audit Committee of ViaCell Corporation, a U.S. public company, from 2002 until it was sold to Perkin Elmer Corporation in 2007. He received an M.B.A. from St.&nbsp;Gallen University in Switzerland and an executive degree from Stanford Business
School. Based on Mr.&nbsp;van&nbsp;Heek&#146;s experience within the biotechnology industry and his executive experience, specifically his experience in executive officer positions at other companies in the biotechnology industry, as well as his
service on other boards of directors, the Board believes Mr.&nbsp;van Heek has the appropriate set of skills to serve as a member of our Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Lars G. Ekman, M.D., Ph.D</I>. joined Amarin as a <FONT STYLE="white-space:nowrap">non-executive</FONT> director in November 2008, and was
named Amarin&#146;s lead independent director in October 2011 and Amarin&#146;s Chairman of the Board effective January 2014. With more than 30 years of experience in the pharmaceutical industry, Dr.&nbsp;Ekman is currently an executive partner at
Sofinnova Ventures and serves as Chairman of Sophiris Bio Inc. (formerly Protox Therapeutics) as well as Chairman of Prothena Biosciences. From October 2008 to 2011 he served as <FONT STYLE="white-space:nowrap">Co-Founder</FONT> and Chief Executive
Officer of Cebix Inc. He was Executive Vice President and President of Global Research and Development at Elan Corporation plc, from January 2001 to December 2007. Prior to joining Elan, he was Executive Vice President, Research and Development at
Schwarz Pharma AG from February 1997 to December 2000, and prior to that was employed in a variety of senior scientific and clinical functions at Pharmacia, now Pfizer. Dr.&nbsp;Ekman also sits on the board of directors of Ultragenyx Pharmaceutical
Inc. and Spark Therapeutics. Dr.&nbsp;Ekman is a board-certified surgeon with a Ph.D. in experimental biology and has held several clinical and academic positions in both the United States and Europe. He obtained his Ph.D. and M.D. from the
University of Gothenburg, Sweden. Based on Dr.&nbsp;Ekman&#146;s experience within the pharmaceutical industry and his executive experience, specifically his experience as Chief Executive Officer and other executive positions in the biotechnology
industry, as well as his service on boards of directors in the biotechnology industry, the Board believes Dr.&nbsp;Ekman has the appropriate set of skills to serve as a member of our Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Kristine Peterson</I> joined Amarin as a <FONT STYLE="white-space:nowrap">non-executive</FONT> director in November 2010. Ms.&nbsp;Peterson
has more than 30 years of pharmaceutical industry experience, including 20 years at Bristol-Myers Squibb Company, where she was responsible for sales, marketing and general management in a variety of therapeutic areas, including leading the
cardiovascular and metabolic disease business unit. From June 2009 to February 2016, she served as Chief Executive Officer at Valeritas, Inc., a medical technology company committed to the development and commercialization of innovative drug
delivery solutions, with its lead product for the treatment of diabetes. Prior to joining Valeritas, Ms.&nbsp;Peterson was Company Group Chair for the biotech business at Johnson&nbsp;&amp; Johnson from May 2006 through June 2009, was an Executive
Vice President at Johnson&nbsp;&amp; Johnson from August 2004 through May 2006 and was Senior Vice President of commercial operations at Biovail Corporation from May 2003 to August 2004. Ms.&nbsp;Peterson is currently a director of Paratek
Pharmaceuticals, Inc., ImmunoGen, Inc. the Biotechnology Industry Organization and the Greater Philadelphia Life Sciences Congress. Ms.&nbsp;Peterson has an M.B.A. in Marketing from the University of Illinois. Based on Ms.&nbsp;Peterson&#146;s
leadership experience in the pharmaceutical industry and her executive experience, specifically her experience as an executive officer at other commercial stage companies in the biotechnology industry, as well as her service on other boards of
directors in the biotechnology industry and a leading biotech industry trade organization, the Board believes Ms.&nbsp;Peterson has the appropriate set of skills to serve as a member of our Board. Ms.&nbsp;Peterson&#146;s contribution to the Company
in the areas of commercialization and regulatory and political matters has been particularly helpful as the Company continues its current stage of development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>David Stack</I> joined Amarin as a <FONT STYLE="white-space:nowrap">non-executive</FONT> director in December 2012. Mr.&nbsp;Stack is
currently the President and Chief Executive Officer of Pacira Pharmaceuticals, Inc. Mr.&nbsp;Stack was a managing director of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
MPM Capital from 2005 until 2017 and a managing partner of Stack Pharmaceuticals, Inc. since 1998. From 2001 to 2004, he was President and Chief Executive Officer of The Medicines Company.
Previously, Mr.&nbsp;Stack was President and General Manager at Innovex, Inc. He was Vice President, Business Development/Marketing at Immunomedics from 1993 until 1995. Prior to that, he was with Roche Laboratories from 1981 until 1993, in various
positions including therapeutic world leader in infectious disease and director, business development and planning, infectious disease, oncology, and virology. He currently serves as a member of the board of directors of Pacira Pharmaceuticals,
Inc., PepTx, Inc., Chiasma, Inc. and Prognos AI. He was a member of the boards of directors of Molecular Insight Pharmaceuticals, Inc. from 2006 to 2010 and BioClinica, Inc. from 1999 to 2010. Mr.&nbsp;Stack holds a B.S. in Pharmacy from Albany
College of Pharmacy and a B.S. in Biology from Siena College. The Board believes that Mr.&nbsp;Stack&#146;s qualifications to sit on our Board include his extensive experience with pharmaceutical companies as an executive and director, his financial
expertise and his years of experience providing strategic and financial advisory services to pharmaceutical and biotechnology organizations in all stages of development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Joseph S. Zakrzewski</I> joined Amarin as a <FONT STYLE="white-space:nowrap">non-executive</FONT> director in January 2010. From November
2010 to December 2013, Mr.&nbsp;Zakrzewski served as Amarin&#146;s Chief Executive Officer and Chairman of the Board of Directors. From May 2007 to May 2010, Mr.&nbsp;Zakrzewski served as President and Chief Executive Officer of Xcellerex, a
privately held company focusing on commercializing its proprietary next generation manufacturing technology for biotherapeutics and from January 2005 to May 2007, Mr.&nbsp;Zakrzewski served as the Chief Operating Officer of Reliant Pharmaceuticals.
From 1988 to 2004, Mr.&nbsp;Zakrzewski served in a variety of positions at Eli Lilly and Company including as Vice President, Corporate Business Development from 2003 through 2004. In addition, Mr.&nbsp;Zakrzewski served as a Venture Partner with
Orbimed in 2010 and 2011. Mr.&nbsp;Zakrzewski is currently the Chairman of Onxeo and serves on the board of directors of Onxeo, Acceleron Pharma, and Sangamo Therapeutics as well as a number of privately held companies. Mr.&nbsp;Zakrzewski earned a
B.S. in Chemical Engineering and an M.S. in Biochemical Engineering from Drexel University as well as an M.B.A. in Finance from Indiana University. The Board believes that Mr.&nbsp;Zakrzewski should serve on our Board based on his knowledge of our
Company gained from his former position as Chief Executive Officer and his substantial experience serving as an executive officer of other pharmaceutical companies, as well as Mr.&nbsp;Zakrzewski&#146;s service as a member of boards of directors of
other pharmaceutical companies. Mr.&nbsp;Zakrzewski&#146;s contribution to the Company in the areas of operations and business development matters has been particularly helpful as the Company continues its current stage of development. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each nominee will be
elected to the Board if (i)&nbsp;on a show of hands, a majority of shareholders present in person or by proxy and voting on the proposal vote in favor of such director or (ii)&nbsp;on a poll, a majority of the shares present at the meeting in person
or by proxy and voting on the proposal are voted in favor of such director. As a result, abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect on the vote outcome. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of proxies solicited by this Proxy Statement will vote the proxies received by them as directed on the proxy card or, if no direction
is made, then FOR the election of all the nominees named in this Proxy Statement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE
&#147;FOR&#148; </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EACH OF THE NOMINEES IDENTIFIED ABOVE. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc467547_7"></A>PROPOSAL NO. 3 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ADVISORY VOTE ON EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc467547_8"></A>Background </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
recommended by our shareholders at our 2017 annual general meeting and subsequently approved by our Board, we give our shareholders the opportunity to cast an advisory <FONT STYLE="white-space:nowrap">(non-binding)</FONT> vote to approve the
compensation of the Company&#146;s &#147;named executive officers,&#148; each year (a <FONT STYLE="white-space:nowrap">so-called</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;say-on-pay&#148;</FONT></FONT> vote). At
the 2017 annual general meeting, the Company&#146;s shareholders supported the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">say-on-pay</FONT></FONT> vote with 83.4% of the votes cast in favor of the proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">say-on-pay</FONT></FONT> vote is a
<FONT STYLE="white-space:nowrap">non-binding</FONT> vote to approve the compensation of the Company&#146;s &#147;named executive officers,&#148; as described in this Proxy Statement under the &#147;Executive Compensation Discussion and
Analysis&#148; section, the tabular disclosure regarding such compensation, and the accompanying narrative disclosure on pages 21 to 38 of this Proxy Statement. Our philosophy in setting compensation policies for executive officers has two
fundamental objectives: (1)&nbsp;to attract and retain a highly skilled team of executives and (2)&nbsp;to align our executives&#146; interests with those of our shareholders by rewarding short-term and long-term performance and tying compensation
to increases in shareholder value. The Remuneration Committee believes that executive compensation should be directly linked both to continuous improvements in corporate performance <FONT STYLE="white-space:nowrap">(so-called</FONT> &#147;pay for
performance&#148;) and accomplishments that are expected to increase shareholder value. The &#147;Executive Compensation Discussion and Analysis&#148; section herein provides a more detailed discussion of the executive compensation program and
compensation philosophy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The vote under this Proposal No.&nbsp;3 is advisory, and therefore not binding on the Company, the Board or our
Remuneration Committee. However, our Board, including our Remuneration Committee, values the opinions of our shareholders and, considers changes to our executive compensation program as appropriate in response to input from shareholders and evolving
factors such as the business environment and competition for talent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shareholders will be asked at the Annual General Meeting to approve
the following resolution pursuant to this Proposal No.&nbsp;3: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>RESOLVED</B>, that the shareholders of the Company approve, on a <FONT
STYLE="white-space:nowrap">non-binding,</FONT> advisory basis, the compensation of the Company&#146;s &#145;named executive officers,&#146; as disclosed in this Proxy Statement under the &#147;Executive Compensation Discussion and Analysis&#148;
section, the compensation tables and the narrative disclosures that accompany the compensation tables.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This advisory proposal will be approved if (i)&nbsp;on a show of hands, a majority of shareholders present in person or by proxy and voting on
the proposal vote in favor of the resolution or (ii)&nbsp;on a poll, a majority of the shares present at the meeting in person or by proxy and voting on the proposal are voted in favor of the resolution. As a result, abstentions and broker <FONT
STYLE="white-space:nowrap">non-votes</FONT> will have no effect on the vote outcome. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE
&#147;FOR&#148; PROPOSAL NO. 3. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc467547_9"></A>PROPOSAL NO. 4 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Audit Committee has selected Ernst&nbsp;&amp; Young LLP (&#147;<B><I>E&amp;Y</I></B>&#148;) as our independent registered public
accounting firm for the fiscal year ending December&nbsp;31, 2018, and has further directed that we submit the selection of E&amp;Y for approval by our shareholders at the Annual General Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee reviews and <FONT STYLE="white-space:nowrap">pre-approves</FONT> all audit and
<FONT STYLE="white-space:nowrap">non-audit</FONT> services performed by its independent registered public accounting firm, as well as the fees charged for such services. All fees incurred in fiscal 2017 for services rendered by E&amp;Y were approved
in accordance with these policies. In its review of <FONT STYLE="white-space:nowrap">non-audit</FONT> service fees, the Audit Committee considers, among other things, the possible impact of the performance of such services on the auditor&#146;s
independence. The Audit Committee has determined that the <FONT STYLE="white-space:nowrap">non-audit</FONT> services performed by E&amp;Y in the fiscal year ended December&nbsp;31, 2017 were compatible with maintaining the auditor&#146;s
independence. Additional information concerning the Audit Committee and its activities can be found in the following sections of this Proxy Statement: &#147;Board Committees&#148; and &#147;Report of the Audit Committee.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">E&amp;Y commenced auditing our annual financial statements with the fiscal year ended December&nbsp;31, 2014. Representatives of E&amp;Y are
expected to be available telephonically at the Annual General Meeting, will have the opportunity to make a statement if they desire to do so and will be available to respond to appropriate shareholder questions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc467547_10"></A>Fees for Independent Registered Public Accounting Firm&#151;E&amp;Y </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the fees billed to the Company by E&amp;Y for professional services rendered for the fiscal years ended
December&nbsp;31, 2017 and 2016. Audit fees are for services relating to the years ended December&nbsp;31, 2017 and 2016 as described in (1)&nbsp;below and all <FONT STYLE="white-space:nowrap">non-audit</FONT> fees are for services invoiced in 2017
and 2016. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Audit
Fees<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>:</I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,287,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,075,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Audit-Related Fees:</I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Tax
Fees<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>:</I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><B><I>All Other Fees:</I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Total All Fees:</I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,293,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,081,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Audit fees for 2017 include fees incurred in connection with the audit of our financial statements as of December&nbsp;31, 2017, as prepared in accordance with U.S. Generally Accepted Accounting Principles
(&#147;<B><I>GAAP</I></B>&#148;), costs incurred in connection with the audit of statutory financial statements as of December&nbsp;31, 2016, as prepared in accordance with International Financial Reporting Standards
(&#147;<B><I>IFRS</I></B>&#148;), and costs incurred in connection with registration statement filings. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Tax fees consist primarily of tax advisory fees and costs incurred for the preparation of tax returns and other related statutory filings. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shareholders will be asked at the Annual General Meeting to approve the following resolution pursuant to this Proposal No.&nbsp;4: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>RESOLVED</B>, to appoint Ernst&nbsp;&amp; Young LLP as the Company&#146;s auditors to hold office from the conclusion of this meeting
until the conclusion of the next meeting at which the annual accounts are laid before the Company and to authorize the directors to agree upon the remuneration of the auditors.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that shareholders do not approve the foregoing resolution, we will need to
engage a third-party auditor who will act as our independent registered public accounting firm under U.S. law and as our statutory auditor under UK law for the fiscal year ending December&nbsp;31, 2018. We may proceed to engage such firm as our
Board and Audit Committee deem advisable, which firm may include E&amp;Y. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vote Required </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This proposal will be approved if (i)&nbsp;on a show of hands, a majority of shareholders present in person or by proxy and voting on the
proposal vote in favor of the resolution or (ii)&nbsp;on a poll, a majority of the shares present at the meeting in person or by proxy and voting on the proposal are voted in favor of the resolution. As a result, abstentions and broker <FONT
STYLE="white-space:nowrap">non-votes</FONT> will have no effect on the vote outcome. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE
&#147;FOR&#148; PROPOSAL NO. 4 </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc467547_11"></A>ADDITIONAL BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public limited company organized under the laws of England and Wales, it is a statutory requirement that the Board lay before the Annual
General Meeting the Company&#146;s statutory accounts, which are the Company&#146;s Annual Report for the year ended December&nbsp;31, 2017, as prepared in conformity with GAAP (the &#147;<B><I>Annual Report</I></B>&#148;) and the accounts for the
financial year ended December&nbsp;31, 2017, prepared in accordance with International Financial Reporting Standards (the &#147;<B><I>Statutory Accounts</I></B>&#148;). As required by the Companies Act and the Articles, the Statutory Accounts will
be made available for download in &#147;PDF&#148; format on the Company&#146;s website (<I>http://investor.amarincorp.com</I>) as soon as they are complete, but no later than April 20, 2018, which is at least
<FONT STYLE="white-space:nowrap">twenty-one</FONT> clear days in advance of the Annual General Meeting. In addition, hard copies of the Statutory Accounts may be obtained, once they are complete, by contacting the Company&#146;s investor relations
department at Amarin Corporation plc, c/o Amarin Pharma, Inc., 1430 Route 206, Bedminster, NJ 07921 or by telephone at <FONT STYLE="white-space:nowrap">(908)&nbsp;719-1315.</FONT> Shareholders of the Company will not be asked to take any action in
respect of the Statutory Accounts at the Annual General Meeting but shareholders in attendance will have opportunity to ask questions relating to the Statutory Accounts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We know of no other matters to be submitted to a vote of shareholders at the Annual General Meeting. If any other matter is properly brought
before the Annual General Meeting or any adjournment thereof, it is the intention of the persons named in the enclosed proxy to vote the shares they represent in accordance with their judgment. In order for any shareholder to nominate a candidate at
a given annual general meeting, he or she must provide timely written notice to our corporate secretary pursuant to the terms of our Articles, as described below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc467547_12"></A>CORPORATE GOVERNANCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc467547_13"></A>Director Independence </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the Company benefits from having a strong and independent Board. For a director to be considered independent, the Board must
determine that the director does not have any direct or indirect material relationship with the Company that would affect his or her exercise of independent judgment. On an annual basis, the Board reviews the independence of all directors under
guidelines established by NASDAQ and in light of each director&#146;s affiliations with the Company and members of management, as well as significant holdings of Company securities. This review considers all known relevant facts and circumstances in
making an independence determination. Based on this review, the Board has made an affirmative determination that all directors, other than Mr.&nbsp;Thero, are independent. It was determined that Mr.&nbsp;Thero lacks independence because of his
status as the Company&#146;s President and Chief Executive Officer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc467547_14"></A>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our Board and its committees, led by a group of strong and independent directors, provide the necessary leadership, wisdom and
experience that the Company needs in making sound business decisions. Our Code of Business Conduct and Ethics helps clarify the operating standards and ethics that we expect of all of our officers, directors and employees in making and implementing
those decisions. Waivers of our Code of Business Conduct and Ethics for the benefit of a director or an executive officer may only be granted by the Board or, if permitted, a committee of the Board, and will be publicly announced promptly in our SEC
filings. Waivers of our Code of Business Conduct and Ethics for the benefit of other employees may be made by our Compliance Officer, the Board or, if permitted, a committee of the Board. In furthering our commitment to these principles, we invite
you to review our Code of Business Conduct and Ethics and other corporate governance materials located on our website at <I>www.amarincorp.com</I>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc467547_15">
</A>Shareholder Communications </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, shareholders who have questions or concerns regarding the Company should contact our
Investor Relations department at <FONT STYLE="white-space:nowrap">(908)&nbsp;719-1315.</FONT> However, any shareholders who wish to address questions regarding the business or affairs of the Company directly with the Board, or any individual
director, should direct his or her questions in writing to the Lead Independent Director of the Board, Amarin Corporation plc, 2 Pembroke House, Upper Pembroke Street <FONT STYLE="white-space:nowrap">28-32,</FONT> Dublin 2 Ireland or c/o Amarin
Pharma, Inc., 1430 Route 206, Bedminster, NJ 07921. Upon receipt of any such communications, the correspondence will be directed to the appropriate person, including individual directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc467547_16"></A>BOARD OF DIRECTORS AND COMMITTEES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During our 2017 fiscal year, our Board met in person four times. Each director attended at least 75% of the aggregate of the meetings of the
Board and meetings of the committees of which he or she was a member in our last fiscal year. During fiscal year 2017, our Board had an Audit Committee, a Remuneration Committee and a Nominating and Corporate Governance Committee. All members of the
Audit, Remuneration and Nominating and Corporate Governance Committees are <FONT STYLE="white-space:nowrap">non-employee</FONT> directors who are deemed independent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All members of our Board who were directors at the time attended the 2017 Annual General Meeting of Shareholders, either in person or via
telephone. Although the Company has no formal policies regarding director attendance at annual general meetings, it encourages directors to attend annual general meetings and expects that all members of the Board will attend the 2018 Annual General
Meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc467547_17"></A>Board Leadership Structure and Risk Oversight </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Lars Ekman is our Chairman of the Board. Dr.&nbsp;Ekman is independent and all key committees of the Board are comprised solely of,
and chaired by, independent directors. The Board believes that this structure, combined with the Company&#146;s established corporate governance guidelines, provides an effective leadership structure for the Company. In addition, to ensure effective
independent oversight of the Company, the Board holds meetings of the independent directors of the Board at every meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board has
overall responsibility for the oversight of the Company&#146;s risk management process, which is designed to support the achievement of organizational objectives, including strategic objectives, to improve long-term organizational performance and
enhance shareholder value. Risk management includes not only understanding company-specific risks and the steps management implements to manage those risks, but also what level of risk is acceptable and appropriate for the Company. Management is
responsible for establishing our business strategy, identifying and assessing the related risks and implementing appropriate risk management practices. The Board periodically reviews our business strategy and management&#146;s assessment of the
related risk, and discusses with management the appropriate level of risk for the Company. The Board also delegates oversight to Board committees to oversee selected elements of risk as set forth below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the Board&#146;s risk oversight role, our Remuneration Committee reviews and evaluates the risks associated with our compensation
programs. Our Remuneration Committee has reviewed our compensation policies as generally applicable to our employees and believes that our policies do not encourage excessive and unnecessary risk-taking, and that the level of risk that they do
encourage is not reasonably likely to have a material adverse effect on Amarin. In making this determination, our Remuneration Committee considered the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s use of different types of compensation vehicles to provide a balance of long and short-term incentives with fixed and variable components; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the granting of equity based awards with time-based vesting and performance-based vesting, both of which encourage participants to look to long-term appreciation in equity values; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s annual bonus determinations for each employee being tied to achievement of company goals, which goals promote long-term value; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s system of internal control over financial reporting and code of conduct and ethics, which among other things, reduce the likelihood of manipulation of the Company&#146;s financial performance to
enhance payments under any of its incentive plans. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc467547_18"></A>Board Committees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Audit Committee. </I>The Audit Committee is currently comprised of Mr.&nbsp;van Heek (Chairman), Mr.&nbsp;O&#146;Sullivan and
Ms.&nbsp;Peterson. The Audit Committee oversees the accounting and financial reporting processes of the Company and the audits of the Company&#146;s financial statements. The Audit Committee also assists the Board in overseeing the integrity of the
Company&#146;s financial statements, the Company&#146;s compliance with legal and regulatory requirements, the external auditors&#146; qualifications and independence, the performance of the Company&#146;s internal audit function and external
auditors and performs other duties, as set forth in the Audit Committee charter. The Audit Committee charter is available on our website at <I>www.amarincorp.com</I>. The Audit Committee met by teleconference six times during our 2017 fiscal year.
All members of the Audit Committee satisfy the current independence standards promulgated by NASDAQ and the SEC and the Board has determined that Mr.&nbsp;van Heek is an &#147;audit committee financial expert,&#148; as the SEC has defined that term
in Item&nbsp;407 of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Nominating and Corporate Governance Committee</I>.
Currently, the Nominating and Corporate Governance Committee is comprised of Mr.&nbsp;O&#146;Sullivan (Chairman), Mr.&nbsp;Zakrzewski and Dr.&nbsp;Ekman. The Nominating and Corporate Governance Committee is responsible for identifying individuals
qualified to become members of the Board, consistent with criteria approved by the Board. The Nominating and Corporate Governance Committee also develops and implements policies and processes regarding corporate governance matters, assesses Board
membership needs and acts as the Company&#146;s nominating committee by reviewing potential director nominees and recommending nominees to the Board. The Nominating and Corporate Governance Committee charter is available on our website at
<I>www.amarincorp.com</I>. The Nominating and Corporate Governance Committee met in person two times and by teleconference one time during our 2017 fiscal year. All members of the Nominating and Corporate Governance Committee satisfy the current
NASDAQ independence standards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Remuneration Committee. </I>The Remuneration Committee is currently comprised of Mr.&nbsp;Stack
(Chairman), Ms.&nbsp;Peterson and Mr.&nbsp;van Heek. The Remuneration Committee, together with the Board, determines the framework for the compensation of the Company&#146;s Chief Executive Officer and such other members of executive management as
it is designated to consider. The Remuneration Committee also determines the corporate and individual performance goals under the Company&#146;s management incentive plan and achievement of these goals, as well as determines the policy for and scope
of pension arrangements, service agreements for the executive management team and termination payments. Further, the Remuneration Committee oversees any major changes in employee benefit structures throughout the Company, reviews and authorizes the
reimbursement of any claims for expenses from the Chief Executive Officer and chairman in excess of &pound;10,000 and performs other duties, as set forth in the Remuneration Committee charter. Additionally, the Remuneration Committee reviews and
evaluates the risks associated with our compensation programs. The Remuneration Committee may delegate its authority to a subcommittee composed of one or more of its members. The Remuneration Committee charter is available on our website at
<I>www.amarincorp.com</I>. The Remuneration Committee met in person three times and by teleconference three times during our 2017 fiscal year. All members of the Remuneration Committee satisfy the current NASDAQ and SEC independence standards and
qualify as &#147;outside directors&#148; pursuant to the Code. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc467547_19"></A>Compensation Committee Interlocks and Insider Participation
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the 2017 fiscal year, Mr.&nbsp;Stack (Chairman), Ms.&nbsp;Peterson and Mr.&nbsp;van Heek served as members of the Remuneration
Committee. During the last completed fiscal year, no member of the Remuneration Committee was an officer or employee of Amarin and no member of the Remuneration committee has ever served as an officer of Amarin. None of our executive officers served
as a member of the compensation committee (or board of directors serving the compensation function) of another entity where such entity&#146;s executive officers served on our Remuneration Committee. Moreover, none of our executive officers served
as a member of the board of directors or compensation committee (or other committee of the board of directors serving the compensation function) of another entity where such entity&#146;s executive officers served on our Board or Remuneration
Committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc467547_20"></A>EXECUTIVE OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current executive officers and their respective positions are set forth in the following table. Biographical information regarding each
executive officer is set forth following the table. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="67%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John F. Thero</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer (principal executive officer)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph T. Kennedy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Executive Vice President, General Counsel and Strategic Initiatives, Secretary</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael W. Kalb</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President and Chief Financial Officer, Assistant Secretary (principal financial officer and principal accounting officer)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven B. Ketchum, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President of Research and Development, Senior Vice President, and Chief Scientific Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark W. Salyer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President and Chief Commercial Officer</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>John F. Thero</I>. Please refer to Proposals No.&nbsp;1 and No.&nbsp;2 &#147;Election of Directors&#148;
for Mr.&nbsp;Thero&#146;s biography. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Joseph T. Kennedy </I>joined Amarin in December 2011 as Senior Vice President, General Counsel
and was named Amarin&#146;s Secretary and Chief Compliance Officer in February 2012. He was promoted to Executive Vice President, General Counsel and Strategic Initiatives in July 2015 and no longer serves as the company&#146;s compliance officer
for pharmaceutical industry matters as of August 2017. From March 2009 to December 2011, he was Vice President, General Counsel and Secretary of Transcept Pharmaceuticals, Inc., where he played a lead role negotiating the company&#146;s strategic
collaboration with Purdue Pharma, helped obtain U.S. Food and Drug Administration (&#147;<B><I>FDA</I></B>&#148;) approval for the company&#146;s lead product and had responsibility for all legal and compliance matters affecting the company.
Mr.&nbsp;Kennedy represented large pharmaceutical companies, developing life science companies and venture capital firms in private law practice from January 2006 to March 2009. Prior to that, Mr.&nbsp;Kennedy served as Chief Corporate Counsel, then
Vice President, Acting Chief Legal Officer with Eyetech Pharmaceuticals, Inc. His work at Eyetech included transitioning the company from private to public, legal matters related to the company&#146;s development and commercialization collaboration
with Pfizer Inc., public company and pharmaceutical industry compliance, and the sale of the company to OSI Pharmaceuticals Inc. Previously, Mr.&nbsp;Kennedy served as Vice President and U.S. Counsel, Corporate Business Development, with &Eacute;lan
Corporation, plc where he helped acquire technologies, managed legal issues related to multiple collaborations and participated in the company&#146;s sale of assets that raised over $2.0&nbsp;billion in a restructuring. Mr.&nbsp;Kennedy was honored
by the President of Ireland as one of the inaugural &#147;Irish Life Science 50&#148; which recognized Irish-Americans for their significant contributions to the life science industry and by Financial Times as a standout legal innovator in its 2016
North American Most Innovative Lawyers awards. He also serves as a member of the Business Advisory Board of Fountain Healthcare Partners, a life science venture capital fund. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Steven B. Ketchum, Ph.D</I>., joined Amarin in February 2012 as Senior Vice President and President of Research and Development. He was
named Chief Scientific Officer in January 2016. Dr.&nbsp;Ketchum has 20 years of experience in late-stage product development and clinical regulatory strategy. From 2008 to 2012, Dr.&nbsp;Ketchum served as Senior Vice President of Research and
Development for Sunesis Pharmaceuticals, Inc. where he provided strategic direction for all facets of research and development, including clinical strategy and operations, regulatory affairs, and pharmaceutical development and has served on its
board of directors since his departure. From 2005 to 2008, Dr.&nbsp;Ketchum served as Senior Vice President of Research and Development and Medical Affairs for Reliant Pharmaceuticals where he led development and support activities for Lovaza and
other commercialized cardiovascular products. Prior to 2005, Dr.&nbsp;Ketchum was Senior Vice President of Operations and Regulatory Affairs at IntraBiotics Pharmaceuticals, Inc., and also held positions of increasing responsibility in regulatory
affairs during his nearly eight-year tenure at ALZA Corporation, where he supported the development and commercialization of a number of products, including Concerta. Dr.&nbsp;Ketchum earned a Ph.D. in pharmacology from University College London and
a B.S. in biological sciences from Stanford University. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Michael W. Kalb</I> joined Amarin in June 2016 as Senior Vice President and Chief
Financial Officer. Mr.&nbsp;Kalb served as Group Vice President, Chief Financial Officer and Chief Accounting Officer of Taro Pharmaceutical Industries Ltd. from August 2014 to June 2016. Prior to that, Mr.&nbsp;Kalb was GVP, Interim CFO and CAO
from November 2010 to August 2014 and GVP, Chief Financial Officer&#151;U.S. and CAO from May 2010 to November 2010. Mr.&nbsp;Kalb joined Taro in June 2009 as VP, Chief Financial Officer&#151;U.S. He has over twenty years of financial and accounting
advisory experience. From June 2004 to June 2009, Mr.&nbsp;Kalb served as a Director in the Accounting and Financial Consulting Group of Huron Consulting Group Inc. His experience also includes over ten years at Ernst&nbsp;&amp; Young, LLP within
the Transaction Advisory Services Group and Audit and Assurance Services Group. Mr.&nbsp;Kalb received a Bachelor of Science in Accounting from the University at Albany, State University of New York. Mr.&nbsp;Kalb is a Certified Public Accountant.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Mark W.</I><I></I><I>&nbsp;Salyer </I>joined Amarin in September 2017 as the Senior Vice President and Chief Commercial Officer. He
has served in a variety of commercial leadership positions spanning 33 years in the pharmaceutical industry across several global companies in numerous therapeutic areas. Prior to joining Amarin, Mr.&nbsp;Salyer served 11 years as Executive Vice
President and General Manager for Teva Respiratory, LLC, the branded business unit of Teva Pharmaceuticals where he oversaw the formation of the unit across commercial, medical, research and development, supply chain and other functions. Prior to
Teva, he served as Chief Commercial Officer for BioDelivery Sciences. He also served four years as Commercial Officer for the U.S. and Corporate VP for Global Marketing for Altana Pharma AG based in New Jersey, US and Konstanz, Germany where he lead
numerous global commercial and development alliances with Sanofi-Aventis (Alvesco, Omnaris), Pfizer (Daxas and <FONT STYLE="white-space:nowrap">Detrol-LA),</FONT> and Wyeth (Protonix). Mr.&nbsp;Salyer started his pharmaceutical career with
GlaxoSmithKline in 1985 in financial planning and was transitioned to marketing director for migraine, cardiovascular and respiratory brands in the U.S., many attaining blockbuster status. Upon the creation of GlaxoSmithKline, he was appointed Vice
President of the Global Respiratory business based in London, England. While there, he led the global commercial development and launches of Advair/Seretide. Mr.&nbsp;Salyer has a MBA in Marketing from Duke University
<FONT STYLE="white-space:nowrap">-The</FONT> Fuqua School of Business. Since 2002, he has served as a member of Duke&#146;s Health Sector Advisory Board. Mr.&nbsp;Salyer has a BS in Accounting / Business from Virginia Polytechnic Institute and State
University. Mr.&nbsp;Salyer is a Certified Public Accountant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc467547_21"></A>CERTAIN RELATIONSHIPS AND RELATED-PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc467547_22"></A>Transactions with Related Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than the compensation arrangements described below under the captions &#147;Executive Compensation&#148; and &#147;Director
Compensation,&#148; we are not a party to any transactions between us and certain &#147;related parties,&#148; which are generally considered to be our directors and executive officers, nominees for director, holders of 5% or more of our outstanding
Ordinary Shares and members of their immediate families. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc467547_23"></A>Related-Party Transaction Review and Approval </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board has adopted policies and procedures for the review and approval of related-party transactions and has delegated to our Compliance
Officer the authority to review and approve the material terms of any proposed related-party transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to our Code of
Business Conduct and Ethics, any transaction or relationship that reasonably could be expected to give rise to a conflict of interest should be promptly reported to the Compliance Officer. Our Compliance Officer may notify the Board or a committee
thereof as deemed appropriate. Conflicts of interest may arise in the following situations: if an individual is simultaneously employed or engaged by Amarin and another business (particularly a client or business partner of Amarin); if an individual
participates in any activity that enhances or supports a competitor&#146;s position; if an individual or member of such person&#146;s immediate family accepts a gift with the intent to improperly influence the normal business relationship between
Amarin and its clients or business partners or gives to or accepts gifts from a competitor; if an individual or a member of such person&#146;s immediate family holds a financial interest in another business (particularly a client or business partner
of Amarin); and if an individual conducts business on behalf of Amarin with a business in which a family member of such individual is associated in any significant role. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc467547_24"></A>SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;16(a) of the Securities Exchange Act of 1934 (the &#147;<B><I>Exchange Act</I></B>&#148;) requires our executive
officers and directors, and persons who own more than 10% of a registered class of our equity securities, to file reports of beneficial ownership and changes in beneficial ownership with the SEC. Executive officers, directors and <FONT
STYLE="white-space:nowrap">greater-than-10%</FONT> shareholders are required by SEC regulations to furnish us with copies of all reports filed under Section&nbsp;16(a). To the Company&#146;s knowledge, based solely on the review of copies of the
reports filed with the SEC, all reports required to be filed by our executive officers, directors and <FONT STYLE="white-space:nowrap">greater-than-10%</FONT> shareholders during the fiscal year ended December&nbsp;31, 2017 were timely filed, except
for one inadvertently late filing on Form 4 for each of John F. Thero, Steven B. Ketchum, Joseph T. Kennedy, and Michael W. Kalb. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc467547_25">
</A>INSIDER TRADING POLICY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amarin has an insider trading policy that applies to all officers, directors and employees and certain
affiliated persons. Amarin&#146;s insider trading policy prohibits sale of any Amarin securities that are not owned by such persons at the time of the sale, so called short sales. Those persons subject to Amarin&#146;s insider trading policy may not
pledge Amarin&#146;s securities as collateral for a loan (or modify an existing pledge) unless the pledge has been approved by the Audit Committee of the Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc467547_26"></A>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on information available to us and filings with the SEC, the following table sets forth certain information regarding the
beneficial ownership (as defined by Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> of the Exchange Act) of our outstanding Shares for (i)&nbsp;each of our directors, (ii)&nbsp;each of our &#147;named executive officers,&#148; as defined in
Executive Compensation below, (iii)&nbsp;all of our directors and executive officers as a group, and (iv)&nbsp;persons known to us to beneficially hold more than 5% of our outstanding Ordinary Shares. Unless otherwise noted, the following
information is presented as of March&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership and percentage ownership are determined in accordance with the
rules of the SEC and include voting or investment power with respect to our Ordinary Shares. This information does not necessarily indicate beneficial ownership for any other purpose. Under these rules, Ordinary Shares issuable under stock options
or warrants that are exercisable within 60 days of March&nbsp;31, 2018 are deemed outstanding for the purpose of computing the percentage ownership of the person holding the options or warrant(s), but are not deemed outstanding for the purpose of
computing the percentage ownership of any other person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated and subject to applicable community property laws, to
our knowledge, each shareholder named in the following table possesses sole voting and investment power over their Ordinary Shares, except for those jointly owned with that person&#146;s spouse. Unless otherwise indicated below, the address of each
person listed on the table is c/o Amarin Pharma, Inc., 1430 Route 206, Bedminster, NJ 07921. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name and Address of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent&nbsp;of<BR>Class<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Greater than 5% Holders:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consonance Capital Management LP<SUP STYLE="font-size:85%; vertical-align:top"> (3)</SUP></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1370 Avenue of the Americas</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Floor 33</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New York, NY 10019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,476,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Current directors and named executive officers:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John F. Thero<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,215,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lars G. Ekman, M.D., Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">360,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kristine Peterson<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">282,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jan van Heek<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">292,698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick J. O&#146;Sullivan<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">207,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Stack<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph S. Zakrzewski<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,449,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph T. Kennedy<SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,760,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven B. Ketchum, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,298,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael W. Kalb<SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">363,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark W. Salyer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current directors and executive officers as a group (11 persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,406,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Represents Ordinary Shares, or Shares, held as of March&nbsp;31, 2018, plus Shares that may be acquired upon exercise of options exercisable within 60 days of March&nbsp;31, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Based on 293,584,140 Ordinary Shares outstanding as of March&nbsp;31, 2018. The percentage ownership and voting power for each person (or all directors and executive officers as a group) is calculated by assuming the
exercise or conversion of all options exercisable within 60 days of March&nbsp;31, 2018 held by such person and the <FONT STYLE="white-space:nowrap">non-exercise</FONT> and <FONT STYLE="white-space:nowrap">non-conversion</FONT> of all outstanding
options held by all other persons. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Based on information provided in a Schedule 13G filed by Consonance Capital Management LP on February&nbsp;14, 2018. Consists of 23,767,680 shares owned by Consonance Capital Management LP
(&#147;<I></I><B></B><B><I>Adviser</I></B><B></B><I></I>&#148;) and 708,840 shares (&#147;<I></I><B><I>Managed Account Shares</I></B><I></I>&#148;) owned by a managed account managed by Consonance Capital Opportunity Fund Management LP
(&#147;<I></I><B><I>Consonance Opportunity</I></B><I></I>&#148;). Consonance Capman GP LLC (&#147;<I></I><B><I>Capman</I></B><I></I>&#148;) is the general partner of the Adviser and Mitchell Blutt, as the manager and member of Capman and Chief
Executive Officer of the Adviser, may be deemed to control Capman and the Adviser. Capman is the general partner of Consonance Opportunity and Mitchell Blutt, as the manager and member of Capman, may be deemed to control Capman and Consonance
Opportunity. Adviser reports shared voting and dispositive power with respect to the Master Account Shares. Consonance Opportunity reports shared voting and dispositive power with respect to the Managed Account Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Includes 1,481,668 Shares directly owned and 3,733,637 Shares issuable upon the exercise of options exercisable within 60 days of March&nbsp;31, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Includes 40,000 Shares directly owned and 320,138 Shares issuable upon the exercise of options exercisable within 60 days of March&nbsp;31, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Includes 282,495 Shares issuable upon the exercise of options exercisable within 60 days of March&nbsp;31, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Includes 25,203 Shares directly owned and 267,495 Shares issuable upon the exercise of options exercisable within 60 days of March&nbsp;31, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top">Includes 207,495 Shares issuable upon the exercise of options exercisable within 60 days of March&nbsp;31, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top">Includes 177,495 Shares issuable upon the exercise of options exercisable within 60 days of March&nbsp;31, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top">Includes 226,047 Shares directly owned and 2,223,162 Shares issuable upon the exercise of options exercisable within 60 days of March&nbsp;31, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top">Includes 18,434 Shares directly owned and 1,741,608 Shares issuable upon the exercise of options exercisable within 60 days of March&nbsp;31, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top">Includes 200,973 Shares directly owned and 1,097,525 Shares issuable upon the exercise of options exercisable within 60 days of March&nbsp;31, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top">Includes 14,996 Shares directly owned and 348,357 Shares issuable upon the exercise of options exercisable within 60 days of March&nbsp;31, 2018. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc467547_27"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DISCUSSION AND ANALYSIS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following compensation discussion and analysis (&#147;<B><I>CD&amp;A</I></B>&#148;) describes the philosophy, objectives and structure of
our fiscal year 2017 executive compensation program. This section is intended to be read in conjunction with the tables that immediately follow, which provide further historical compensation information for our named executive officers
(&#147;<B><I>NEOs</I></B>&#148;), who for the fiscal year ended December&nbsp;31, 2017, were: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="73%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John F. Thero</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph T. Kennedy</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Executive Vice President, General Counsel and Strategic Initiatives, Secretary</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael W. Kalb</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President and Chief Financial Officer, Assistant Secretary</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven B. Ketchum, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President of Research and Development, Senior Vice President and Chief Scientific Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark W. Salyer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President and Chief Commercial Officer</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc467547_28"></A>2017 Operating Highlights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are very proud of the strong operating, financial and stock price performance of Amarin in 2017. As discussed more fully below, achievement
of these objectives were considered by our Remuneration Committee in determining executive compensation for 2017. Key operating highlights from the past year include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Revenue Growth and Gross Margin Improvement:</B> The Company recognized total revenue of $181.1&nbsp;million for 2017, comprised of $179.8&nbsp;million in net product revenue from U.S. sales of Vascepa<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (icosapent ethyl) and $1.3&nbsp;million in licensing revenue related to collaborations for the commercialization of Vascepa outside the United States. The net product revenue for 2017 represented
an increase of $50.9&nbsp;million over 2016. Gross margin on product revenues was 75% in 2017, versus 73% in 2016, driven by improvements in product-related costs. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g467547g27o50.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Prescription Growth:</B> The Company increased normalized prescriptions for Vascepa by 45% and 42% in 2017 compared to 2016 based on data from Symphony Health and IQVIA, respectively. In doing so, the Company
increased its market share of prescription <FONT STYLE="white-space:nowrap">omega-3</FONT> products to &gt;30% in the United States. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> on Track:</B> The Company&#146;s long-term cardiovascular outcomes study, <FONT STYLE="white-space:nowrap">REDUCE-IT,</FONT> advanced closer to completion with
clinical sites in the study instructed to begin having all living patients in the study visit their clinical site for final data collection. <FONT STYLE="white-space:nowrap">Top-line</FONT> results from this first in class study are anticipated to
be reported by the end of the third quarter of 2018. In parallel with advancing the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> study, the Company in 2017 also supported 25 scientific publications and abstract presentations. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>International Expansion:</B> The Company added a commercial partner to seek regulatory approval of, and commercialize Vascepa in, Canada. The Company supported its commercial partner in the Middle East with multiple
country filings seeking approval to commence marketing of Vascepa in those countries. And, the Company supported its partner in China in commencing a clinical trial for Vascepa in China as part of a clinical and regulatory strategy to get Vascepa
approved and commercialized in China. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Improved Net Cash Flow:</B> The Company achieved its publicly stated objective of being net cash flow positive in 2017 after excluding the benefit, on a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> basis, of net
proceeds from the Company&#146;s Q1 2017 exchangeable debt transactions, which transactions moved the earliest scheduled put date for the Company&#146;s remaining $30.0&nbsp;million in outstanding exchangeable debt to 2022, and excluding greater
than&nbsp;$40 million&nbsp;of payments for R&amp;D (primarily <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> related) and approximately&nbsp;$17 million&nbsp;of payments for financing-type costs (e.g., interest and royalties).&nbsp;This
improvement in net cash flow reflected increased sales productivity, negotiated cost savings and overall spending prioritization and control. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Superior Stock Price Performance. </B>As depicted in the graph below, over the three-year time period through December&nbsp;31, 2017, cumulative total return for Amarin&#146;s ADSs exceeded both the NASDAQ Composite
Index and NASDAQ Biotechnology Index. In particular, the total return for Amarin&#146;s ADSs well exceeded the cumulative returns for the NASDAQ Composite Index and NASDAQ Biotechnology Index in each of the past two calendar years.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g467547g98r96.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc467547_29"></A>Compensation Philosophy
and Objectives </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pay for Performance </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our philosophy in setting compensation policies for executive officers has two fundamental objectives: (1)&nbsp;to attract and retain a highly
skilled team of executives and (2)&nbsp;to align our executives&#146; interests with those of our shareholders by rewarding short-term and long-term performance and tying compensation to increases in shareholder value. The Remuneration Committee
believes that executive compensation should be directly linked both to continuous improvements in corporate performance (&#147;<B><I>pay for performance</I></B>&#148;) and accomplishments that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are expected to increase shareholder value. In furtherance of this goal, the Remuneration Committee has adhered to the following guidelines as a foundation for decisions that affect the levels of
compensation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide a competitive total compensation package that enables the Company to attract and retain highly qualified executives with the skills and experience required for the achievement of business goals;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">align compensation elements with the Company&#146;s annual goals and long-term business strategies and objectives; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">promote the achievement of key strategic and financial performance measures by linking short-term and long-term cash and equity incentives to the achievement of measurable corporate and individual performance goals; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">align executives&#146; incentives with the creation of shareholder value. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Remuneration
Committee has historically compensated executive officers with three primary compensation components: base salary, annual and short-term incentive bonuses, and long-term equity-based compensation. The Remuneration Committee believes that cash
compensation in the form of base salary and incentive bonuses provides our executives with short-term rewards for success in operations, and that long-term compensation through the grant of equity awards aligns the objectives of management with
those of our shareholders with respect to long-term performance and success. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>CEO Performance and Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Remuneration Committee believes that it is especially important to set compensation for our Chief Executive Officer in a manner that
address the two fundamental objectives described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">John F. Thero has served as our President and Chief Executive Officer since
January 2014. Before that, he served as our President and Chief Financial Officer since November 2010 and before that as our Chief Financial Officer since November 2009. Mr.&nbsp;Thero has over 25 years of executive level experience and, in the view
of the Remuneration Committee, a strong record of accomplishment before and during his tenure at the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Thero became Chief
Executive Officer in 2014 to stabilize and grow the Company following significant corporate setbacks emanating from a change in position by the FDA regarding requirements for approval of the ANCHOR indication as became evident in an FDA advisory
committee meeting in late 2013, which meeting concluded with a vote against a significant proposed label expansion for Vascepa followed by the FDA rescinding the related ANCHOR study special protocol assessment agreement. Since becoming President
and Chief Executive Officer, Mr.&nbsp;Thero has played a critical role in selecting, retaining and motivating experienced personnel throughout the Company, repositioning the Company&#146;s commercial strategy and tactics resulting in significant
product revenue growth, expanding managed care coverage for Vascepa, entering into multiple strategic transactions, pursuing and achieving multiple remedies through favorable court decisions and achieved the 2017 operating highlights described
above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2015, Mr.&nbsp;Thero&#146;s cash compensation lagged considerably behind the targeted 50th percentile of the Company&#146;s
peer group set by the Remuneration Committee. Specifically, during 2015, Mr.&nbsp;Thero&#146;s base compensation of $520,000 per year was at approximately the 25th percentile of other CEOs in our peer group. Since 2015, Mr.&nbsp;Thero&#146;s base
compensation has been progressively adjusted upwards towards the 50<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> percentile. Effective February 2017, Mr.&nbsp;Thero&#146;s base compensation was adjusted to $611,800 per year, which was at
approximately the 50th percentile of other CEOs in our peer group. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Thero&#146;s bonus potential is tied to achievement of <FONT
STYLE="white-space:nowrap">pre-defined</FONT> corporate goals for the applicable year, with no consideration given to individual performance goals. For 2017, Mr.&nbsp;Thero&#146;s target bonus potential, which was 75% of his base compensation and at
the 50th percentile for other CEOs in our peer group, was tied to achievement of meaningful and challenging corporate goals established at the start of the year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Remuneration Committee believes that Mr.&nbsp;Thero&#146;s cash compensation is strongly
aligned with corporate performance and the interests of our shareholders. Our Remuneration Committee has an established practice of paying no or partial incentive cash bonuses when the <FONT STYLE="white-space:nowrap">pre-defined</FONT> corporate
goals are not achieved or achieved only in part. For example, for 2013, Mr.&nbsp;Thero was awarded no cash bonus following the failure of the FDA to approve the ANCHOR indication, a key corporate goal for that year, and in 2015 and 2014,
Mr.&nbsp;Thero was awarded 98% and 75% of his bonus target, respectively, based on only partial achievement of the <FONT STYLE="white-space:nowrap">pre-defined</FONT> corporate goals for those years. Conversely, when
<FONT STYLE="white-space:nowrap">pre-defined</FONT> corporate goals are achieved in whole, or when <FONT STYLE="white-space:nowrap">pre-defined</FONT> &#147;stretch&#148; goals are achieved, incentive cash bonuses are paid commensurate with the
level of achievement in that year. For example, in 2017 and 2016, both years in which corporate achievement was especially strong, including the achievement of <FONT STYLE="white-space:nowrap">pre-defined</FONT> corporate goals and <FONT
STYLE="white-space:nowrap">pre-defined</FONT> stretch goals, Mr.&nbsp;Thero was awarded 117% and 122% of his bonus target, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, a substantial portion of Mr.&nbsp;Thero&#146;s compensation is in the form of equity incentive awards, which the Remuneration
Committee believes further aligns Mr.&nbsp;Thero&#146;s interests with those of our shareholders. The equity incentive awards are made in the form of stock options and restricted stock units, all subject to vesting requirements, that target the 50th
of the Company&#146;s peer group. These equity incentive awards are subject to both time-based and performance-based vesting criteria. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Time-based stock options generally vest over a four-year period. Performance-based stock options generally vest only if certain <FONT
STYLE="white-space:nowrap">pre-defined</FONT> performance criteria are achieved (<I>e.g.</I>, commercial, clinical or regulatory milestones), plus an additional time-based vesting schedule if and only if those performance milestones are achieved.
The stock options realize value only if our stock price increases after the date of grant. Time-based restricted stock units generally vest over a three- or four-year period. Performance-based restricted stock units generally vest only if certain <FONT
STYLE="white-space:nowrap">pre-defined</FONT> performance criteria are achieved (<I>e.g.</I>, commercial, clinical or regulatory milestones). Certain of the performance-based restricted stock units also include an additional time-based vesting
schedule if and only if those performance milestones are achieved. The restricted stock units realize more value the better our stock price performs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As noted in the graph below, approximately 66% of Mr.&nbsp;Thero&#146;s 2017 total compensation as reported in the Summary Compensation Table
below relates to stock options and restricted stock units and 16% of his total target compensation is performance-based, in either the form of equity awards or incentive bonus: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g467547g35a60.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In light of the Company&#146;s performance since Mr.&nbsp;Thero became CEO in January 2014, the
Company&#146;s stock price performance during his tenure as CEO, including each of the past one, two and three year periods and his compensation during that same time periods, the Remuneration Committee believes that the amount and nature of
Mr.&nbsp;Thero&#146;s compensation in 2017 and 2018 are strongly aligned with corporate performance and the interests of our shareholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Roles in Determining Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Remuneration Committee </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Remuneration
Committee, together with the Board, determines the framework for the compensation of the Company&#146;s executive officers. The Remuneration Committee also determines the corporate and individual performance goals under the Company&#146;s management
incentive plan and achievement of these goals, and determines the policy for and scope of service agreements for the executive officers and contractual severance payments. While the Remuneration Committee draws on a number of resources, including
input from the Chief Executive Officer and independent compensation consultants, to make decisions regarding the Company&#146;s executive compensation program, ultimate decision-making authority rests with the Remuneration Committee, subject in key
cases to ratification by the independent members of the Board. The Remuneration Committee relies upon the judgment of its members in making compensation decisions, after reviewing the performance of the Company and evaluating an executive&#146;s
performance during the year against established goals, operational performance, and business responsibilities. In addition, the Remuneration Committee incorporates judgment in the assessment process to respond to and adjust for the evolving business
environment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Risks Related to Compensation Policies and Practices </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the Board&#146;s risk oversight role, our Remuneration Committee reviews and evaluates the risks associated with our compensation
programs. Our Remuneration Committee has reviewed our compensation policies as generally applicable to our employees and believes that our policies do not encourage excessive and unnecessary risk-taking, and that the level of risk that they do
encourage is not reasonably likely to have a material adverse effect on Amarin. In making this determination, our Remuneration Committee considered the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s use of different types of compensation vehicles to provide a balance of long- and short-term incentives with fixed and variable components; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the granting of equity-based awards with time-based vesting and performance-based vesting, both of which encourage participants to work towards long-term appreciation in equity values; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s annual bonus determinations for each employee and vesting of performance-based equity awards being tied to achievement of Company goals, which goals promote long-term value; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s system of internal control over financial reporting and code of conduct and ethics, which among other things, reduce the likelihood of manipulation of the Company&#146;s financial performance to
enhance payments under any of its incentive plans. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Compensation Consultant </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Remuneration Committee retains the services of Radford, an Aon company, as independent external compensation consultants. The mandate of
the consultants includes assisting the Remuneration Committee in its review of executive and director compensation practices, including the competitiveness of pay levels, executive compensation design, and benchmarking with the Company&#146;s peers
in the industry. The Remuneration Committee regularly evaluates the performance of its compensation consultants, considers alternative compensation consultants, and has the final authority to engage and terminate such services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Remuneration Committee has assessed the independence of Radford pursuant to SEC rules and concluded that no conflict of interest exists
that would prevent Radford from serving as an independent consultant to the Remuneration Committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Chief Executive Officer </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Chief Executive Officer attends Remuneration Committee meetings and works with the Remuneration Committee Chairman and its compensation
consultants to develop compensation recommendations for executive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
officers (excluding the Chief Executive Officer) and other key executives, based upon individual experience and breadth of knowledge, internal considerations, individual performance during the
fiscal year, and other factors deemed relevant by the Remuneration Committee. The recommendations are then submitted to the Remuneration Committee for review and consideration. The Remuneration Committee works directly with its compensation
consultants to determine compensation actions for the Chief Executive Officer. In accordance with NASDAQ listing rules, our Chief Executive Officer is not present during voting or deliberations concerning his own compensation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Say-on-Pay</FONT></FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Annually, at our general meeting of shareholders, we hold a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote regarding the
compensation of our named executive officers, which we refer to as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">say-on-pay.</FONT></FONT> The Remuneration Committee has considered and will continue to consider the outcome of
such <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">say-on-pay</FONT></FONT> votes, including the percentage of votes cast in favor and against the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">say-on-pay</FONT></FONT> proposal, when making future compensation decisions for our named executive officers. The Remuneration Committee believes that the most relevant period of
time to assess the performance of the Company&#146;s Chief Executive Officer is the period over which he has held this position, which commenced in January 2014, during which period of time the Company&#146;s stock price significantly outperformed
both its peer group and the NASDAQ Biotechnology Index as a whole. The Remuneration Committee also relies on advice from its compensation consultant, its evaluation of Company performance against <FONT STYLE="white-space:nowrap">pre-defined</FONT>
corporate goals, its understanding of the challenges facing the Company and its observations of executive officer performance to determine executive officer compensation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At our last annual general meeting of shareholders in May 2017, the <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote of
shareholders supported the compensation of our named executive officers as reported in our 2017 proxy statement by 83.4% of the votes cast at the meeting. These votes for and against the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">say-on-pay</FONT></FONT> proposal, together with available feedback from investors, have been and will continue to be considered by the Remuneration Committee in connection with the evaluation of executive compensation.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Shareholder Outreach Program </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
make a point of annually engaging with our shareholders to solicit feedback on our executive compensation program. During 2017, we met with many of our institutional shareholders to obtain their feedback and views on matters relating to our company,
including our executive compensation program. Based on this feedback, we expect we will rely more heavily on performance-based equity compensation in future periods. For example, in 2017 and early 2018, executive officers of the company were granted
performance-based restricted stock units which are earned only if the Company&#146;s <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> cardiovascular outcomes study is deemed to be successful and product revenues reach
<FONT STYLE="white-space:nowrap">pre-defined</FONT> annual milestone levels ranging from $300&nbsp;million to $500&nbsp;million and then vest only if the recipient remains with the company for an extended period of time and upon, subject to
acceleration in the event of a change in control transaction. With these changes, we believe that our shareholders generally approve of and continue to support our core compensation principles and our executive compensation program. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Competitive Market Benchmarking </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Remuneration Committee draws on a number of resources to assist in the evaluation of the various components of the Company&#146;s executive
compensation program. While we do not establish compensation levels based solely on benchmarking, pay practices at other companies are a factor that the Remuneration Committee considers in assessing the reasonableness of compensation and ensuring
that our compensation practices are competitive in the marketplace. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our peer companies used in determining compensation actions with
respect to 2017 fiscal year compensation were selected by the Remuneration Committee with the support of Radford, which beginning in 2011 has been retained to conduct comprehensive reviews of the Company&#146;s executive compensation practices. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our peer companies for 2017 compensation evaluation were selected prior to the start of 2017
in consultation with Radford on the basis of their similarity to us in terms of competition for talent, their status as a commercial or near-commercial stage company, revenue level and other financial attributes, phase of products in development,
research and development expenditures, employee number, and market capitalization. Radford also qualitatively evaluated each company based on business focus and corporate strategy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Remuneration Committee considered the foregoing analysis in selecting the following 18 publicly-traded peer companies for use in
evaluating compensation actions in the 2017 fiscal year: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">AMAG Pharmaceuticals*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Elexis*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Repligen*</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amicus Therapeutics</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Halozyme Therapeutics</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">SciClone Pharmaceuticals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Arena Pharmaceuticals*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">ImmunoGen*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Spectrum Pharmaceuticals*</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ariad Pharmaceuticals</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Lexicon Pharmaceuticals</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Sucampo Pharmaceuticals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Corcept Therapeutics</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Merrimack Pharmaceuticals</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Supernus Pharmaceuticals</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Depomed</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Pacira Pharmaceuticals</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Vanda Pharmaceuticals</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Included in prior-year peer group. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the peer group above, the Remuneration
Committee also reviews competitive compensation data from the Radford Global Life Sciences Compensation Survey. For 2017 compensation decisions, the Radford survey group included 52 publicly traded biotechnology and pharmaceutical companies with
between 20 and 600 employees, revenue between $20&nbsp;million and $600&nbsp;million and market value between $200&nbsp;million and $2.0&nbsp;billion. Fourteen companies in our named peer group participated in this market survey. For benchmarking
purposes, Radford then developed a competitive market composite of which 50% is based on proxy data from the named peer group and 50% is based on a market survey composite. Radford then assessed Amarin&#146;s 2017 compensation against market pay
elements such as base salary, target short-term incentives as a percentage of base salary, target total cash compensation, long-term incentives and target total direct compensation. Additionally, Amarin&#146;s incumbent officers were matched to
benchmark positions according to each officer&#146;s primary responsibilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Remuneration Committee reviews the Company&#146;s list
of peer companies periodically to reflect changes in market capitalization, developments at the Company relative to its peer companies, and other factors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of compensation for 2018, the Remuneration Committee, with the advice of Radford, examined our 2017 peer group in light of our
continued growth throughout 2017, the stage of our commercialization efforts, changes in our market capitalization, and changes in the size and status of comparative companies. With reference to these and other key business metrics, the Remuneration
Committee used the following 18 companies as our 2018 peer group in evaluating compensation actions for 2018: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Acorda Therapeutics</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Eagle Pharmaceuticals</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Repligen&nbsp;Corporation*</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">AMAG&nbsp;Pharmaceuticals*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Halozyme Therapeutics*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">SciClone Pharmaceuticals*</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amicus Therapeutics*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">ImmunoGen*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Spectrum Pharmaceuticals*</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Arena Pharmaceuticals*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Lexicon Pharmaceuticals*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Sucampo Pharmaceuticals*</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Corcept Therapeutics*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Pacira Pharmaceuticals*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Supernus Pharmaceuticals*</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Depomed*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Momenta Pharmaceuticals</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Vanda Pharmaceuticals*</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Included in prior-year peer group. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Implementation of Objectives </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In fiscal 2017, our executive compensation program consisted of the following forms of compensation, each of which are described below in
greater detail: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Base Salary </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Annual Incentive Bonus </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Special Incentive Bonus Program </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Equity Compensation (subject to time and/or performance vesting) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Employee Benefit Programs </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, our Remuneration Committee aims to set executives&#146;
total cash compensation (base salary plus target bonus) at levels near the 50th percentile for executives with similar roles in the Company&#146;s peer group. Long-term incentive awards include stock options and restricted stock units and the value
of such awards is generally targeted at the 50th percentile of our peer group. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Base Salary </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Remuneration Committee aims
to set executives&#146; base salaries, in the aggregate, at levels near the 50th percentile of salaries of executives with similar roles at the Company&#146;s peer group. The Remuneration Committee believes it is important to provide adequate fixed
compensation to our executive officers working in a highly volatile and competitive industry. Our Remuneration Committee believes that the 50th percentile for base salaries is the minimum cash compensation level that will allow us to attract and
retain highly skilled executives. The Remuneration Committee&#146;s choice of this target percentile reflects consideration of our shareholders&#146; interests in paying what is necessary to attract and retain qualified executives and achieve our
corporate goals, while conserving cash and equity as much as practicable. We believe that, given the industry in which we operate and our compensation philosophy and objectives, base salaries at the 50th percentile are generally sufficient to retain
our current executives and to hire new executives when and as required. In determining appropriate base salary levels for a given executive officer, the Remuneration Committee also considers the following factors: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">individual performance of the executive, as well as overall performance of the Company, during the prior year; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">level of responsibility, including breadth, scope and complexity of the position; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">level of experience and expertise of the executive; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">internal review of the executive&#146;s compensation relative to other executives to ensure internal equity; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">executive officer compensation levels at other similar companies to ensure competitiveness. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Salaries for executive officers are determined on an individual basis at the time of hire and are set to be competitive with peer companies in
our industry. Adjustments to base salary are considered annually in light of each executive officer&#146;s individual performance, the Company&#146;s performance and compensation levels at peer companies in our industry, as well as changes in job
responsibilities or promotion. The Chief Executive Officer assists the Remuneration Committee in its annual review of the base salaries of other executive officers based on the foregoing criteria. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Changes in Base Salaries for Fiscal 2017 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2016, the Remuneration Committee approved for 2017 an average salary increase of 3.5% for all employees other than those executive
officers identified below, each of whom received individually targeted salary increases. These increases were determined to take into consideration the rate of inflation and to approximate the estimated rate of compensation increase in the
Company&#146;s peer group. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of Mr.&nbsp;Thero, a salary of $611,800, effective February&nbsp;1, 2017, was
approved. This base salary was targeted at the 50th percentile for CEOs within our peer group. In the case of Mr.&nbsp;Kennedy, a salary of $448,800, effective February&nbsp;1, 2017, was approved. This base salary was higher than the 50th percentile
for officers of similar position within our peer group; this determination was made in light of the Remuneration Committee&#146;s recognition of Mr.&nbsp;Kennedy&#146;s extensive experience and significant contributions to the Company during his
tenure with the Company, in particular in connection with our ongoing regulatory efforts, several litigation matters and continued advancement of the Company&#146;s intellectual property estate. In the case of Dr.&nbsp;Ketchum, a salary of $448,800,
effective February&nbsp;1, 2017, was approved. This base salary was higher than the 50th percentile for officers of similar position within our peer group; this determination was made in light of the Remuneration Committee&#146;s recognition of
Dr.&nbsp;Ketchum&#146;s extensive experience and significant contributions to the Company during his tenure with the Company, in particular in connection with our ongoing regulatory efforts and continued advancement of the Company&#146;s <FONT
STYLE="white-space:nowrap">REDUCE-IT</FONT> cardiovascular outcomes trial, the scope of which is larger than advanced by most peer sized companies. In the case of Mr.&nbsp;Salyer, his salary was set at $455,000 when he joined the Company in
September 2017. This base salary was targeted at approximately the 50th percentile for Chief Commercial Officers within our peer group. In the case of Mr.&nbsp;Kalb, a salary of $412,000, effective February&nbsp;1, 2017, was approved. This base
salary was targeted at approximately the 50th percentile for CFOs within our peer group. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Incentive Awards </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company also provides executive officers with the opportunity to earn annual performance-based cash bonuses, which are specifically
designed to reward executives for overall corporate performance as well as individual performance in a given year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board has adopted
a Management Incentive Compensation Plan (&#147;<B><I>MICP</I></B>&#148;), under which the Remuneration Committee each year determines and approves corporate and individual performance goals and achievement of these goals for purposes of determining
annual performance-based cash bonuses. The MICP is intended to provide structure and predictability regarding the determination of performance-based cash bonuses. Specifically, the MICP is intended to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">increase management focus on realistic goals intended to create value for shareholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">encourage management to work as a team to achieve the Company&#146;s goals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">encourage individuals to realize goals that are meaningful to the Company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top">provide incentives for management to strive for achievement above and beyond the Company goals; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top">help attract and retain high quality senior management personnel. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MICP provides that the
bonus potential for our executive officers will be established on an annual basis by the Remuneration Committee. Under the MICP, the actual amount of the bonus paid is calculated on a formulaic basis based upon achievement of <FONT
STYLE="white-space:nowrap">pre-determined</FONT> performance goals. In order to be eligible to receive a bonus, the Company must have achieved at least a specified percentage of the corporate goals for that year. The corporate goals and the relative
weighting of the corporate and individual performance goals, as well as the relative weighting for each individual of individual performance goals, are established by the Remuneration Committee on an annual basis, shortly after our Board approves
our annual operating plan. The Remuneration Committee has determined it appropriate to have our Chief Executive Officer&#146;s goals match our corporate goals and for no portion of his annual incentive bonus to be determined based on individual
performance goals. For all other executive officers, individual goals are determined on an annual basis by the Remuneration Committee based on their areas of functional responsibility. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the MICP, the Remuneration Committee reserves the right to make subjective assessments
of executive performance and to separately reward performance beyond established individual or corporate goals and targets, and to award a smaller or larger bonus than provided for in the MICP, or to award no bonus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For fiscal 2017, the bonus potential for our management employees as a percentage of base salary ranged from 75% for our President and CEO,
45% for our Executive Vice President, 40% for our Senior Vice Presidents, 30% for our Vice Presidents, and 15% for our Directors/Managers. All of the bonus potential for our President and CEO was tied to the 2017 corporate goals. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Fiscal 2017 Annual Bonus Incentive </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon
completion of fiscal 2017, the Remuneration Committee assessed the Company and our executive officer&#146;s overall performance against the achievement of corporate and individual performance goals established in 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Set forth below are the corporate goals that were approved by the Remuneration Committee in assessing overall performance for the 2017 fiscal
year, as well as the relative weighting of these goals and the Remuneration Committee&#146;s determination of achievement for each goal. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2017
Corporate Goals </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Commercial (40%)</U>: These goals established target performance for the Company regarding the commercialization of Vascepa for the
<FONT STYLE="white-space:nowrap">FDA-approved</FONT> MARINE indication. The specific goals were as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Revenues:</I> Achieve net revenue target of $170.0&nbsp;million </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Compliance</I>: Favorable outside audit report regarding compliance program and no lost claim due to untruthful or misleading statements to healthcare professionals </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Post <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> Readiness: </I>Complete sales territory and targets analysis plan; complete market research regarding MARINE indication </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> (40%)</U>: These goals established target performance for the Company regarding the <FONT
STYLE="white-space:nowrap">REDUCE-IT</FONT> cardiovascular outcomes trial. The specific goals were as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Interim Analysis Plan: </I>Perform all required procedures anticipating adjudication of targeted number of primary events by target date* </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Patient Study Drug Compliance:</I> Maintain target compliance rates of protocol-specified capsule consumption* </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Patient Retention in Study:</I> Achieve target patient retention rates in study and achieve target reduction in number of patients with no visit or vita status confirmation* </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>KOL Education / Support:</I> Form an advisory board and national / regional key opinion leader (&#147;<B><I>KOL</I></B>&#148;) groups, create engagement plans for each KOL, create relationship management tools, and
conduct periodic review with emphasis on measurable progress* </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Quality</U><U></U><U>&nbsp;&amp; Supply (10%)</U>: These goals established
target performance for the Company regarding the commercial supply. The specific goals were as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Quality</I>: Ensure uninterrupted supply of commercial material based on supply chain schedule </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Supply</I>: Purchase inventory needed for operating plan (plus safety stock) at an average price consistent with operating plan* </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Financial and Public Relations / Investor Relations (10%)</U>: These goals established target performance
for the Company regarding the operational finance performance and with respect to public and investor relations matters. The specific goals were as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Cash Outflow from Operations</I>: Ensure gross cash outflow is not greater than operating plan* </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Cash Flow Positive from Operations</I> <I>(excluding R&amp;D, interest and royalty costs)</I>: Achieve for full year 2017 </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Stock price</I>: Exceed peer group performance </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">Pre-Specified</FONT>
&#147;Stretch&#148; Goals</U>: The specific goals were as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Exceed net revenue target per 2017 Operating Plan ($170 million)</I>: Zero for &lt; 5% above net revenue target; 10% for 5% or more above net revenue target increasing ratably to 100% maximum for achievement of 50%
above net revenue target </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I><FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> stopped early for overwhelming success:</I> 50% </TD></TR></TABLE>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>*</I></TD>
<TD ALIGN="left" VALIGN="top"><I>The above-described metrics tied to the 2017 Operating Plan include highly sensitive data including cash flows, expense targets and clinical trials. We do not disclose the specific target levels for these metrics
because we believe that such disclosure would result in competitive harm to our company. We purposely set these target levels at aggressive levels. Revealing these metrics, including the reasoning for setting targets at specific levels, could
potentially reveal insights about our commercialization plans and research and other objectives that our competitors could use against us in the marketplace for similar pharmaceutical products. We believe each of these target levels were designed to
be challenging but attainable under assumed conditions if we had what we considered to be a successful year. </I></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
reviewing the Company&#146;s performance against the <FONT STYLE="white-space:nowrap">pre-specified</FONT> corporate goals set by the Remuneration Committee as described above, the Remuneration Committee determined the goals were achieved as
follows: (i)&nbsp;that each of the commercial goals was achieved at the 100% level, resulting in a weighted score of 40% for this component of the corporate goals; (ii)&nbsp;that each of the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> goals
was achieved at the 100% level, resulting in a combined weighted score of 40% for this component of the corporate goals; (iii)&nbsp;that each of the quality and supply goals was achieved at the 100% level, resulting in a combined weighted score of
10% for this component of the corporate goals; and (iv)&nbsp;that each of the financial and public relations/investor relations goals was achieved at the 100% level, resulting in a combined weighted score of 10% for this component of the corporate
goals. In total, the Remuneration Committee determined that these <FONT STYLE="white-space:nowrap">pre-defined</FONT> corporate goals were achieved at the 100% level. In addition, the Remuneration Committee determined that the <FONT
STYLE="white-space:nowrap">pre-defined</FONT> net revenue stretch goal was achieved at the 12% level (actual revenue of $179.8&nbsp;million was 105.8% above plan) and that the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> early termination
stretch goal was not achieved, resulting in a total score of 12% for the stretch goals and 112% cumulative achievement of the <FONT STYLE="white-space:nowrap">pre-defined</FONT> corporate and stretch goals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Remuneration Committee exercised its discretion, as contemplated by the MICP, to award an additional 5% to each named
executive officer in recognition of exceptional performance during 2017, in particular significant reductions in cash burn, restructuring of outstanding debt, favorable amendments to our <FONT STYLE="white-space:nowrap">co-marketing</FONT> agreement
with Kowa, consummation of a distribution agreement for the Canadian market, favorable ruling in the securities class action litigation, favorable regulatory activity regarding dietary supplements, and hiring an experienced Chief Commercial Officer.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Individual Performance-Based Cash Bonus Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>John F. Thero, President and Chief Executive Officer (principal executive officer) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Remuneration Committee calculated Mr.&nbsp;Thero&#146;s 2017 MICP bonus to be $540,000. The cash bonus award was based entirely on the
Company&#146;s achievement of the corporate goals as described above (112% level), plus an additional 5% as awarded by the Remuneration Committee for exceptional performance in 2017 as described above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Joseph T. Kennedy, Executive Vice President, General Counsel and Strategic
Initiatives, Secretary </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For Mr.&nbsp;Kennedy, individual performance goals for fiscal 2017 were focused on the areas outlined
below: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Litigation: 25% </U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"><I>ANDA litigation</I>: Manage legal resources to support progression of the ANDA litigation </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"><I>Class&nbsp;action suit</I>: Manage and secure dismissal or settlement </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"><I>IP litigation</I>: Aggressively assert Amarin patents </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Supplement Issues: 25% </U></I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">Achieve or take further legal steps to help distinguish Vascepa from dietary supplements </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>SEC
Compliance/Investor Relations: 10% </U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"><I>Statutory</I>: Ensure timely filing of SEC filings and compliance of public disclosures with applicable law </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"><I>IR</I>: Provide timely and constructive advice on investor relations issues while helping to ensure accurate disclosures consistent with industry practice </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>General Corporate: 10% </U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"><I>Operational support</I>: Ensure timely value-adding legal advice to support all Company functions, including regulatory, managed care, sales and marketing, manufacturing, human resources and general corporate
matters, the effectiveness of which will be judged by the CEO and Board </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"><I>Minutes</I>: Timely completion of committee minutes attended, conduct orderly annual meeting </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"><I>Documentation</I>: Oversee legal systems to help manage risks affecting the company and ensure access to key information as needed, including disaster recovery, document control and long-term staff turnover
considerations </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Pharmaceutical Industry Compliance: 20% </U></I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"><I>Oversight</I>: Oversee comprehensive corporate compliance program, including policies, training, monitoring and auditing of pharma compliance related functions to prevent/mitigate negative surprises
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"><I>Reporting</I>: Oversee Sunshine Act compliance reporting system and make reports when due </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"><I>Industry</I>: Stay abreast of developments on First Amendment issues and advise company on pharmaceutical industry compliance matters consistent with First Amendment settlement </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"><I><FONT STYLE="white-space:nowrap">REDUCE-IT</FONT></I>: Work with marketing to prepare campaign for <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> success </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Intellectual Property: 10% </U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"><I>Patents</I>: Obtain and defend robust patent coverage for Company products consistent with Company plan </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Company&#146;s MICP, 75% of Mr.&nbsp;Kennedy&#146;s bonus for 2017 was based on achievement of the corporate goals (in proportion to
the extent such goals were achieved) and 25% of his bonus was based on achievement of his individual goals (in proportion to the extent such goals were achieved). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Remuneration Committee approved the achievement of 2017 corporate goals at the 112%
level as described above. In reviewing the above-described individual performance goals, the Remuneration Committee determined that Mr.&nbsp;Kennedy had fully achieved all of his individual goals (100%). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Remuneration Committee thus calculated Mr.&nbsp;Kennedy&#146;s 2017 MICP bonus to be $231,143, or 114% of his target bonus amount. The
calculation was based on 75% weight given to the 112% achievement of 2017 corporate goals and 25% weight given to the 100% achievement of Mr.&nbsp;Kennedy&#146;s individual goals, plus an additional 5% as awarded by the Remuneration Committee for
exceptional performance in 2017 as described above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Steven B. Ketchum, Ph.D., President of Research and Development, Senior Vice
President, Chief Scientific Officer </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For Dr.&nbsp;Ketchum, individual performance goals for fiscal 2017 were focused on the areas
outlined below: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U><FONT STYLE="white-space:nowrap">REDUCE-IT:</FONT> 70% </U></I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"><I>Second interim analysis</I>: Perform all required procedures to support adjudication and data monitoring committee (&#147;<B><I>DMC</I></B>&#148;) review in 2H 17 of approximately 80% of primary events
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"><I>Endpoint adjudication</I>: Achieve target median time from event onset to adjudication date for all events and update clinical endpoint committee charter and submit to FDA for review and concurrence
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"><I>Data quality</I>: Prior to second interim look by DMC, sufficiently resolve data queries </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"><I>Patient study drug compliance</I>: Ensure patients are generally compliant with four (4)&nbsp;caps/day dosing </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">e)</TD>
<TD ALIGN="left" VALIGN="top"><I>Patient Retention in Study</I>: Achieve target for patients remaining active in the study as of the end of 2017 </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Additional Clinical&nbsp;&amp; <FONT STYLE="white-space:nowrap">Non-Clinical</FONT> Initiatives: 15% </U></I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"><I>Mechanistic <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical initiatives</I>: Complete planned mechanistic studies refine plans for <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> banked samples
testing </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Clinical supplies: Ensure uninterrupted trial materials for <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> and other approved studies </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Regulatory&nbsp;&amp; Quality Control: 15% </U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">China partnership: Support clinical trial application approval and initiation of registration clinical trial(s) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Other <FONT STYLE="white-space:nowrap">Ex-US</FONT> partnership: Support registration activities in Middle East and North Africa territories, achieving approval in at least one country; provide due diligence support for
any new partnership(s) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> audits: Complete clinical site audits, with prompt remediation of any relevant issues </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> sNDA format and content: Engage FDA in dialogue on review needs for clinical data and integrated summaries of safety and efficacy </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">e)</TD>
<TD ALIGN="left" VALIGN="top">Safety compliance: Submit all post-marketing, <FONT STYLE="white-space:nowrap">REDUCE-IT,</FONT> and other reports in compliance with strategic operating plans </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Company&#146;s MICP, 75% of Dr.&nbsp;Ketchum&#146;s bonus for 2017 was based on achievement of the corporate goals (in proportion to
the extent such goals were achieved) and 25% of his bonus was based on achievement of his individual goals (in proportion to the extent such goals were achieved). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Remuneration Committee approved the achievement of 2017 corporate goals based at the
112% level as described above. In reviewing the above-described individual performance goals, the Remuneration Committee concluded that Dr.&nbsp;Ketchum had achieved the individual performance goals at the 97% level (reflecting partial achievement
of the <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT> (part b) and Additional Clinical&nbsp;&amp; <FONT STYLE="white-space:nowrap">Non-Clinical</FONT> (part a) goals). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Remuneration Committee calculated Dr.&nbsp;Ketchum&#146;s 2017 MICP bonus to be $204,047, or 114% of his target bonus amount. The
calculation was based on 75% weight given to the 112% achievement of 2017 corporate goals and 25% weight given to the 97% achievement of Dr.&nbsp;Ketchum&#146;s individual goals, plus an additional 5% as awarded by the Remuneration Committee for
exceptional performance in 2017 as described above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Michael W. Kalb, Senior Vice President and Chief Financial Officer, Assistant
Secretary (principal financial officer and principal accounting officer) </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For Mr.&nbsp;Kalb, individual performance goals for
fiscal 2017 were focused on the areas outlined below as: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Financial Reporting&nbsp;&amp; Budgeting: 40% </U></I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">Manage cash balance and net operating cash flow such that it is equal to or greater than plan </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Timely completion and filing of all required SEC and foreign statutory filings </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top">Timely file all domestic and international tax returns </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top">Maintain tax compliance and professional fees for routine items </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">e)</TD>
<TD ALIGN="left" VALIGN="top">Shorten quarterly close process </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">f)</TD>
<TD ALIGN="left" VALIGN="top">Assume lead role in preparation of Board of Directors meeting presentations </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Internal Controls: 15%
</U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">Ensure no material control weaknesses from 2017 compliance testing or from 2016 compliance testing completed in 2017 </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Strategic&nbsp;&amp; Tax Matters, including Preparation for <FONT STYLE="white-space:nowrap">REDUCE-IT</FONT>
<FONT STYLE="white-space:nowrap">Read-out:</FONT> 15% </U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"><I>Structuring:</I> Work with legal in continuing initiatives to ensure adherence to Company structure; engage external advisors to assess recent rule changes and potential impact; prepare assessment and suggestions to
further strengthen structure </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"><I>Compliance:</I> Work with tax advisors to comply with all IRS, and other taxing authorities, requests for information </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"><I>Tax:</I> Complete assessment of global tax position for Amarin Corporation plc and subsidiaries considering potential changes in U.S. corporate tax law </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Commercial&nbsp;&amp; Business Development Support: 10% </U></I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">Support commercial operations, including pricing&nbsp;&amp; contracts review and negotiation and decision-making regarding managed care and marketing to achieve gross margin levels as per plan </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Support diligence, fund raising efforts and other strategic initiatives as needed including, subject to Board approval, restructuring or refinancing the debt </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Investor Relations: 20% </U></I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">Create and implement new corporate website, including improved navigation, more attractive appearance and better content </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Create plan for use of social media and, subject to approval, implement plan </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top">Amarin share price to outperformance peer group through professional communication, including roadshows or investor meetings </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Company&#146;s MICP, 75% of Mr.&nbsp;Kalb&#146;s bonus for 2017 was based on achievement of the corporate goals (in proportion to
the extent such goals were achieved) and 25% of his bonus was based on achievement of his individual goals (in proportion to the extent such goals were achieved). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Remuneration Committee approved the achievement of 2017 corporate goals based at the 112% level as described above. In reviewing the
above-described individual performance goals, the Remuneration Committee concluded that Mr.&nbsp;Kalb had achieved 96% of his individual goals (reflecting partial achievement of the Financial Reporting&nbsp;&amp; Budgeting (part f) goal). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Remuneration Committee calculated Mr.&nbsp;Kalb&#146;s 2017 MICP bonus to be $186,883, or 114% of his target bonus amount. The calculation
was based on 75% weight given to the 112% achievement of 2017 corporate goals and 25% weight given to the 96% achievement of Mr.&nbsp;Kalb&#146;s individual goals, plus an additional 5% as awarded by the Remuneration Committee for exceptional
performance in 2017 as described above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Mark W. Salyer, Senior Vice President and Chief Commercial Officer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Salyer joined the Company in September 2017. Pursuant to the terms of his employment agreement, Mr.&nbsp;Salyer was paid a $60,000 <FONT
STYLE="white-space:nowrap">sign-on</FONT> bonus in October 2017 and a cash incentive bonus of $68,250 for 2017 performance. In future periods, incentive bonus payments will be subject to the satisfaction of
<FONT STYLE="white-space:nowrap">pre-defined</FONT> corporate and individual goals under the MICP, consistent with the other executive officers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Special Incentive Bonus Programs </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From
time to time, the Remuneration Committee establishes special bonus programs to incentivize individual performance toward goals that are judged by the Remuneration Committee as important for corporate progress, very difficult to achieve, and of
significant shareholder value if achieved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2016, the Remuneration Committee approved and implemented a special long-term
incentive bonus program for Mr.&nbsp;Kennedy. This program was amended in May 2017. Under this program, as amended, Mr.&nbsp;Kennedy is eligible to receive a <FONT STYLE="white-space:nowrap">one-time,</FONT> cash bonus payment in the amount of
(i)&nbsp;$100,000 upon the achievement of a <FONT STYLE="white-space:nowrap">pre-specified</FONT> goal tied to progress on an initiative related to activities affecting the competitive positioning of Vascepa and (ii)&nbsp;$200,000 upon the
completion of such initiative, in each case, on or before December&nbsp;31, 2019. Mr.&nbsp;Kennedy must be continuously employed by the Company through the payment date in order to be eligible to receive the special bonus payment, provided that if
he is terminated by the Company without cause prior to the achievement of any such milestone or any such payment date he shall also remain eligible to receive such payment. In December 2017, the Remuneration Committee awarded Mr.&nbsp;Kennedy a
$100,000 bonus under this program in recognition of certain regulatory actions initiated by the FDA relative to medical foods, dietary supplements and synthetic omega 3s. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Options and Restricted Stock Units.</I> As an additional component of our compensation program, executive officers are eligible to
receive equity compensation, which have historically been in the form of stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
options and restricted stock units. The Remuneration Committee grants stock options and restricted stock units to executive officers to aid in their retention, to motivate them to assist with the
achievement of both near-term and long-term corporate objectives and to align their interests with those of our shareholders by creating a return tied to the performance of our stock price. In determining the form, date of issuance and value of a
grant, the Remuneration Committee considers the contributions and responsibilities of each executive officer, appropriate incentives for the achievement of our long-term growth, the size and value of grants made to other executives at peer companies
holding comparable positions, individual achievement of designated performance goals, and the Company&#146;s overall performance relative to corporate objectives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that equity awards, through stock options and restricted stock units, align the objectives of management with those of our
shareholders with respect to long-term performance and success. We believe that equity awards serve as useful performance-recognition mechanisms with respect to key employees, as most awards are subject to time-based vesting provisions. Stock
options are typically awarded to executive officers upon their hiring. We believe that such equity awards encourage executive officers to remain with the Company and also focus on our long-term performance as well as the achievement of specific
performance goals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Equity Award Grant Policy.</I> We have an equity award grant policy that formalizes our process for granting
equity-based awards to officers and employees. Under our equity award grant policy, all grants to executive officers must be approved by our Board or Remuneration Committee and all grants to other employees must be granted within guidelines approved
by our Board or Remuneration Committee. All stock options will have an exercise price equal to the fair market value of our Ordinary Shares, calculated based on our closing market price on the applicable grant date. Under our equity award grant
policy, equity awards will generally be granted as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">grants made in conjunction with the hiring of a new employee or the promotion of an existing employee will generally be made at meetings of the Remuneration Committee, and effective on the first trading day of the month
following the later of (1)&nbsp;the hire date or the promotion date or (2)&nbsp;the date on which such grant is approved; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">grants made to existing employees other than in connection with a promotion will be made, if at all, on an annual basis and generally shall be made effective on the first trading day of the month following the date on
which such grant is approved. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Equity Grants Awarded in Fiscal 2017 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In considering annual equity awards for our executive officers in 2017, our Remuneration Committee aimed to grant equity at a level generally
targeted at the 50th percentile of the Company&#146;s peer group. Equity awards in 2017 were comprised of a mix of time-based stock options (vesting over a four-year period), time-based restricted stock unit awards (vesting over a three-year period)
and performance-based restricted stock unit awards (vesting tied to the achievement of <FONT STYLE="white-space:nowrap">pre-defined</FONT> performance milestones (specifically the achievement of both (i)&nbsp;a successful outcome of the <FONT
STYLE="white-space:nowrap">REDUCE-IT</FONT> study and <FONT STYLE="white-space:nowrap">(ii)&nbsp;pre-defined</FONT> commercial sales milestones), and subsequent to such achievement, time-based vesting and acceleration in the event of a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-in-control).</FONT></FONT> Equity awards in 2017 were granted with a view towards both retaining and incentivizing our executives in future periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The grant date fair values of the equity awards granted to executive officers for the 2017 fiscal year are reflected in the Summary
Compensation Table below and the number of shares subject to equity awards granted in 2017 are reflected in the Grants of Plan-Based Awards table below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the Black-Scholes option-pricing model required under Financial Accounting Standards Board (&#147;<B><I>FASB</I></B>&#148;)
Accounting Standards Codification (&#147;<B><I>ASC</I></B>&#148;) Topic 718 and reflected further below, historical variable assumptions and other variables can cause model prices to be more or less than the actual value of an option when exercised
or in an ultimate exit. Actual option value is instead based on stock performance which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
can vary significantly from these historical variable assumption based valuation estimates. Because the actual value is based on stock performance, the Remuneration Committee believes that the
equity awards granted create added and important alignment of management with our other shareholders regarding our long-term growth. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employee
Benefit Programs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Executive officers are eligible to participate in all of our employee benefit plans, including medical, dental,
group life, disability and accidental death and dismemberment insurance, in each case on the same basis as other employees, subject to applicable law. We also provide vacation and other paid holidays to all employees, including executive officers,
all of which we believe to be comparable to those provided at peer companies. These benefit programs are designed to enable us to attract and retain our workforce in a competitive marketplace. Health, welfare and vacation benefits ensure that we
have a productive and focused workforce through reliable and competitive health and other benefits. Our executive officers participate in the same employee benefit plans as other employees in the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our retirement savings plan (&#147;<B><I>401(k)</I></B><B><I></I></B><B><I>&nbsp;Plan</I></B>&#148;) is a
<FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement savings plan, pursuant to which all employees, including the named executive officers, are able to contribute certain amounts of their annual compensation, subject to limits prescribed
by the Internal Revenue Service, which are eligible for a discretionary percentage match, in cash, as defined in the 401(k) Plan and determined by the Board of Directors. We recognized $0.4&nbsp;million of related compensation expense for the year
ended December&nbsp;31, 2017. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tax and Accounting Considerations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Deductibility of Executive Compensation.</I> In making compensation decisions affecting our executive officers, the Remuneration Committee
considers our ability to deduct under applicable federal corporate income tax law compensation payments made to executives. Specifically, the Remuneration Committee considers the requirements and impact of Section&nbsp;162(m) of the Code. With
respect to taxable years before January&nbsp;1, 2018, remuneration in excess of $1&nbsp;million was exempt from this deduction limit if it qualified as &#147;performance-based compensation&#148; within the meaning of Section&nbsp;162(m) and was
payable pursuant to a binding written agreement in effect on November&nbsp;2, 2017. Recently-enacted tax legislation, effective for taxable years beginning after December&nbsp;31, 2017, (1) expands the scope of Section&nbsp;162(m) such that all
named executive officers are &#147;covered employees&#148; and anyone who was a named executive officer in any year after 2016 will remain a covered employees for as long as he or she (or his or her beneficiaries) receive compensation from the
Company and (2)&nbsp;eliminates the exception to the deduction limit for commission-based compensation and performance-based compensation except with respect to certain grandfathered arrangements in effect as of November&nbsp;2, 2017 that are not
subsequently materially modified. Accordingly, compensation paid to our named executive officers in excess of $1&nbsp;million will not be deductible unless it qualifies for the transition relief applicable to certain arrangements in place as of
November&nbsp;2, 2017, as described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Remuneration Committee believes that stockholder interests are best served if the
Committee retains maximum flexibility to design executive compensation programs that meet stated business objectives. The Remuneration Committee considers the Section&nbsp;162(m) rules as a factor in determining compensation, but does not
necessarily limit compensation to amounts deductible under Section&nbsp;162(m). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Ownership Guidelines </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board believes it is important to align the interests of our executive officers with those of its shareholders. To this end, in March 2013,
the Board established Stock Ownership Guidelines for its executive officers. The guidelines require that each executive officer maintain an equity interest in the Company with a value at least equal to a multiple of the executive officer&#146;s base
salary, as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Target</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3x annual base salary</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other Executive Officers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1x annual base salary</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Equity interests that count toward the satisfaction of the ownership guidelines include the value of Ordinary
Shares beneficially owned (other than unvested restricted stock) or issuable upon the settlement of vested restricted stock units. The calculation of an individual&#146;s equity interest, however, does not include the value of stock options (whether
or not vested), unvested restricted stock, and unvested restricted stock units, except unvested deferred stock units. Executive officers have five years from the date of the policy adoption in March 2013 or later commencement of their appointment as
an executive officer to attain these ownership levels. If an executive officer does not meet the applicable guideline by the end of the five-year period, the officer is required to hold a minimum of 50% to 100% of the shares resulting from any
future equity awards until the applicable guideline is met, net of shares sold or withheld to exercise stock options and pay withholding taxes. The Remuneration Committee, however, may make exceptions for any officer on whom this requirement could
impose a financial hardship. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this Proxy Statement, all of the Company&#146;s named executive officers have satisfied
these ownership guidelines, or have time to do so, other than Mr.&nbsp;Kennedy who owns or holds the right to acquire in excess of 3.4&nbsp;million ordinary shares of the Company (in the form of Ordinary Shares, stock options and restricted stock
units which options and restricted stock units are not included toward satisfaction of the ownership guidelines). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we have
instituted Stock Ownership Guidelines for our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. For information regarding these guidelines, see the section entitled &#147;<I>Director
<FONT STYLE="white-space:nowrap">Compensation&#151;Non-Employee</FONT> Director Compensation.</I>&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clawback </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this Proxy Statement, we do not have a formal compensation recovery policy, often referred to as a &#147;clawback&#148;
policy, which would typically provide that the officers or directors subject to the policy must reimburse the Company for any bonus or other incentive-based or equity-based compensation improperly received. The Remuneration Committee intends to
adopt a formal clawback policy once the final rules relating to such policies are issued pursuant to the Dodd-Frank Act. The Company has not had an accounting restatement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc467547_30"></A>REMUNERATION COMMITTEE REPORT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The information contained in this report shall not be deemed to be (1)&nbsp;&#147;soliciting material,&#148; (2)&nbsp;&#147;filed&#148;
with the SEC, (3)&nbsp;subject to Regulations 14A or 14C of the Exchange Act, or (4)&nbsp;subject to the liabilities of Section&nbsp;18 of the Exchange Act. This report shall not be deemed incorporated by reference into any of our other filings
under the Exchange Act or the Securities Act of 1933, as amended, except to the extent that the Company specifically incorporates it by reference into such filing. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Remuneration Committee of the Board of Directors has reviewed and discussed the Executive Compensation Discussion and Analysis contained
in this Proxy Statement with management. Based on such review and discussion, we have recommended to the Board of Directors that the Executive Compensation Discussion and Analysis be included in this Proxy Statement for the fiscal year ended
December&nbsp;31, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Submitted by the Remuneration Committee of the Board of Directors </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">David Stack (Chairman) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Jan van Heek </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Kristine Peterson </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc467547_31"></A>2017 Summary Compensation Table </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information concerning the compensation of the named executive officers for the fiscal years ended
December&nbsp;31, 2017, 2016 and 2015. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Name and</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal<BR>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus&nbsp;($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards&nbsp;($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards&nbsp;($)<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive
Plan<BR>Compensation&nbsp;($)<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">John F. Thero</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">609,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,098,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,160,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">513,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,408,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ROWSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">President and</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:9pt; font-family:Times New Roman">Chief Executive</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; font-size:9pt; font-family:Times New Roman">Officer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">575,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">504,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">561,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">530,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,171,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">518,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,621,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,995,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">631,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,773,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Joseph T. Kennedy</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">447,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">330,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">320,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,457,294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ROWSPAN="4"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Executive Vice President,</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">General Counsel and</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Strategic Initiatives,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Secretary</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">432,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">227,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">912,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">419,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,436</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,321,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,796,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">486,564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,077,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Steven&nbsp;B.&nbsp;Ketchum,&nbsp;Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">447,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">280,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,198,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ROWSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:9pt; font-family:Times New Roman">President of Research and Development, Senior&nbsp;Vice&nbsp;President and Chief Scientific Officer</P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">432,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">871,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">419,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,940</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,183,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,604,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">311,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,538,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Michael W. Kalb<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,899</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,220</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">280,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177,984</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,144,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:9pt; font-family:Times New Roman">Senior Vice&nbsp;President and&nbsp;Chief Financial Officer, Assistant Secretary</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">978,489</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">93,200</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1,271,689</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Mark W. Salyer<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,627,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,897,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:9pt; font-family:Times New Roman">Senior Vice President and Chief Commercial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The amounts reported in the &#147;Bonus&#148; column for 2017 consists of discretionary cash bonuses awarded under the MICP for exceptional performance in 2017 as described above under &#147;Compensation Discussion and
Analysis&#151;Cash Incentive Awards.&#148; In addition, the amount reported for 2017 for Mr.&nbsp;Salyer for 2017 includes a <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus of $60,000 and an annual cash bonus of $65,000, each paid pursuant to
the terms of his employment agreement with the Company. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">This column reflects the aggregate grant date fair value of time- and milestone-based vesting restricted stock unit awards granted in each year calculated in accordance with FASB ASC 718, excluding the effect of
estimated forfeitures, assuming achievement of all vesting conditions. For milestone-based restricted stock units, the value reported reflects the value of the award at the grant date based upon the probable outcome of the performance conditions. As
achievement of the performance criteria was deemed not probable on the grant date, such grant date fair value was $0. The value of the 2017 milestone-based restricted stock unit awards at the grant date, assuming that the highest level of
performance conditions will be achieved, is $0 for Mr.&nbsp;Thero, $795,600 for Mr.&nbsp;Kennedy, and $673,200 for each of Dr.&nbsp;Ketchum, Mr.&nbsp;Kalb, and Mr.&nbsp;Salyer. Assumptions used in the calculations for these amounts are set forth in
Note 12 to our consolidated financial statements included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed with the SEC on February&nbsp;27, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">This column reflects the aggregate grant date fair value of time- and milestone-based stock option awards granted in each year and calculated in accordance with FASB ASC 718, excluding the effect of estimated
forfeitures, assuming achievement of all vesting conditions. Assumptions used in the calculations for these amounts are set forth in Note 12 to our consolidated financial statements included in our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> filed with the SEC on February&nbsp;27, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">This column reflects payments made under the Management Incentive Compensation Plan and special incentive bonus programs in respect of the year earned. See the discussion regarding annual and special incentive
compensation in &#147;Executive Compensation Discussion and Analysis&#148; for further information regarding the performance measures. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Kalb joined the Company on June&nbsp;30, 2016. His annualized base salary for 2016 was $400,000. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Salyer joined the Company on September&nbsp;11, 2017. His annualized base salary for 2017 was $455,000. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Narrative to the Summary Compensation Table </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amounts reported in the Summary Compensation Table, including base salary, stock awards, option awards, and payments made under the
Management Incentive Compensation Plan, are described more fully under &#147;Executive Compensation Discussion and Analysis.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc467547_32"></A>Grants of Plan-Based Awards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information regarding grants of plan-based option awards to the named executive officers during fiscal
year 2017: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant&nbsp;Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other Option<BR>Awards:<BR>Number&nbsp;of&nbsp;Securities<BR>Underlying&nbsp;Options&nbsp;(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise<BR>Price of<BR>Option<BR>Awards<BR>($/Sh)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date<BR>Fair Value<BR>of&nbsp;Option<BR>Awards&nbsp;($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John F. Thero</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2017</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">550,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,160,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph T. Kennedy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2017</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven B. Ketchum, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2017</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">280,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael W. Kalb</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2017</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">280,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark W. Salyer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/2/2017</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">700,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,627,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">This column reflects the aggregate grant date fair value of option awards granted in 2017, and is calculated in accordance with FASB ASC 718, using the Black-Scholes option-pricing model, excluding the effect of
estimated forfeitures. Assumptions used in the calculations for these amounts are set forth in Note 12 to our financial statements included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed with the SEC on
February&nbsp;27, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">These options vest monthly over 48 months beginning on February&nbsp;28, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Twenty-five percent (25%) of the shares underlying the option vest on September&nbsp;11, 2018, and the remaining 75% of the shares vest monthly over 36 months beginning October&nbsp;11, 2018. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information regarding grants of plan-based restricted stock unit awards subject to time-based vesting
to the named executive officers during fiscal year 2017: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant&nbsp;Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other Stock<BR>Awards:<BR></B><br><B>Number&nbsp;of&nbsp;Shares</B><br><B>of Stock or<BR>Units&nbsp;(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date<BR>Fair Value<BR>of Stock<BR>Awards&nbsp;($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John F. Thero</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">359,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,098,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph T. Kennedy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">330,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven B. Ketchum, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael W. Kalb</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark W. Salyer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">This column reflects the aggregate grant date fair value of time-based restricted stock unit awards granted in 2017, for which settlement in shares was contingent upon shareholder approval of an increase in the share
pool at the Annual General Meeting of Shareholders held on May&nbsp;15, 2017, adjusted based on the closing price per share of our ADSs on such date when shareholder approval was obtained, calculated in accordance with FASB ASC 718, excluding the
effect of estimated forfeitures. Assumptions used in the calculations for these amounts are set forth in Note 12 to our financial statements included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed with the SEC on
February&nbsp;27, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">These restricted stock unit awards vest in three equal annual installments on each of January&nbsp;31, 2018, January&nbsp;31, 2019 and January&nbsp;31, 2020. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information regarding grants of plan-based restricted
stock unit awards subject to performance-based vesting to the named executive officers during fiscal year 2017; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated&nbsp;Future&nbsp;Payouts<BR>Under Equity<BR>Incentive&nbsp;Plan&nbsp;Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant&nbsp;Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Target (#)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant&nbsp;Date<BR>Fair Value<BR>of Stock<BR>Awards&nbsp;($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John F. Thero</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph T. Kennedy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/15/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">260,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven B. Ketchum, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/15/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael W. Kalb</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/15/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark W. Salyer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/15/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><A NAME="toc467547_32"></A>(1)</TD>
<TD ALIGN="left" VALIGN="top">There is no threshold for these awards and the target equates to the maximum. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">This column reflects the aggregate grant date fair value, calculated in accordance with FASB ASC 718, based upon the probable outcome of the performance conditions. As achievement of the performance criteria was deemed
not probable on the grant date, such grant date fair value was $0. The value of the 2017 milestone-based restricted stock unit awards at the grant date, assuming that the highest level of performance conditions will be achieved is set forth in
footnote 2 to the Summary Compensation Table. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">This amount represents restricted stock unit awards that vest upon achievement of certain financial and clinical performance goals. To date, none of the specified criteria have been achieved. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information regarding grants of <FONT STYLE="white-space:nowrap">non-equity</FONT> incentive plan-based awards to the
named executive officers during fiscal year 2017: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated&nbsp;Future&nbsp;Payouts&nbsp;Under<BR><FONT STYLE="white-space:nowrap">Non-Equity</FONT> Incentive Plan<BR>Awards ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant&nbsp;Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Target</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John F. Thero</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">458,850<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">917,700<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph T. Kennedy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201,960<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">353,430<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/27/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven B. Ketchum, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179,520<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">314,160<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael W. Kalb</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164,800<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">288,400<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark W. Salyer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The amounts in the &#147;Target&#148; and &#147;Maximum&#148; columns reflect the potential payouts under the 2017 MICP. Actual bonuses awarded to the individuals were based on achievement of objectives, as discussed in
the &#147;Executive Compensation Discussion and Analysis&#148; section above. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The amounts in the &#147;Target&#148; and &#147;Maximum&#148; columns reflect the range of and alternative potential payouts under the competitive positioning of Vascepa special incentive bonus program available during
fiscal year 2017. In December 2017, the Remuneration Committee awarded Mr.&nbsp;Kennedy a $100,000 bonus under this program in recognition of certain regulatory actions initiated by the FDA relative to medical foods, dietary supplements and
synthetic <FONT STYLE="white-space:nowrap">omega-3s.</FONT> </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc467547_33"></A>Option Exercises and Stock Vested </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the number of shares acquired by the named executive officers upon the exercise of stock options and vesting of
restricted stock units in fiscal year 2017 as well as the value realized at that time. The value realized represents the aggregate difference between the fair market value of shares on the dates of exercise or vesting and the exercise prices, if
any, multiplied by the number of shares acquired upon exercise or vesting, prior to payment of any applicable withholding taxes; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares<BR>Acquired&nbsp;on&nbsp;Exercise<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value<BR>Realized&nbsp;on<BR>Exercise<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares<BR>Acquired&nbsp;on&nbsp;Vesting<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value<BR>Realized&nbsp;on<BR>Vesting<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John F. Thero</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">699,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,184,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph T. Kennedy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">357,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,215,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven B. Ketchum, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">427,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael W. Kalb</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark W. Salyer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc467547_34"></A>Outstanding Equity Awards at Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows information regarding outstanding stock option awards at December&nbsp;31, 2017 for our named executive officers;
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of Securities</B><br><B>Underlying&nbsp;Unexercised&nbsp;Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>Incentive<BR>Plan<BR>Awards:<BR>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Unearned<BR>Options</B><br><B>(#)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price</B><br><B>($/Sh)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercisable</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unexercisable</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John F. Thero</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">407,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/21/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/10/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/2/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">607,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/8/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">291,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,333<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/2/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">374,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,001<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/6/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149,998<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/6/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149,998<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/6/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">286,458<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">423,958<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph T. Kennedy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/16/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/2/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/8/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,389<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/2/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">562,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">337,505<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/6/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,104<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127,187<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of Securities</B><br><B>Underlying&nbsp;Unexercised&nbsp;Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>Incentive<BR>Plan<BR>Awards:<BR>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Unearned<BR>Options</B><br><B>(#)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price</B><br><B>($/Sh)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercisable</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unexercisable</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven B. Ketchum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/1/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/2/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/8/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,389<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/2/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,998<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/6/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,500<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/6/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,500<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/6/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">240,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/6/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,104<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,520<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael W. Kalb</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">234,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">390,624<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/1/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,520<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark W. Salyer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">700,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/2/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The shares underlying these stock options vest monthly over 48 months beginning February&nbsp;28, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The shares underlying these stock options vest monthly over 48 months beginning July&nbsp;31, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">The shares underlying these stock options vest monthly over 48 months beginning on July&nbsp;31, 2015, and relate to grants with certain financial and clinical performance milestones that were achieved during fiscal
year 2016 and 2017. Upon achievement of the milestones, the options that had vested monthly without regard to the requirement for achievement of the milestones and had been previously deferred until achievement became exercisable. Such grants will
continue to vest monthly until fully vested. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">The shares underlying these stock options vest monthly over 48 months beginning February 28, 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">The shares underlying these stock options vest monthly over 48 months beginning February 28, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">The shares underlying this stock option vest monthly over 48 months beginning on July 31, 2015, but are deferred unless and until, and are subject to the achievement of, certain financial and clinical performance
milestones are achieved, such that upon the achievement of each individual milestone, the shares underlying the options for the related grant shall be vested to the extent they would have vested on a monthly basis without regard to the requirement
for achievement of the performance criteria and will continue to vest monthly thereafter. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Twenty-five percent (25%)&nbsp;of the shares underlying this stock option vested on June&nbsp;30, 2017, and the remaining 75% of the options vest ratably over the next 36 months. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top">Twenty-five percent (25%)&nbsp;of the shares underlying this stock options vest on September&nbsp;11, 2018, and the remaining 75% of the options vest ratably over the next 36 months. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows information regarding outstanding restricted stock unit awards at
December&nbsp;31, 2017, for our named executive officers; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares&nbsp;or&nbsp;Units</B><br><B>of Stock That</B><br><B>Have&nbsp;Not&nbsp;Vested</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market&nbsp;Value&nbsp;of</B><br><B>Shares&nbsp;or&nbsp;Units&nbsp;of</B><br><B>Stock That Have<BR>Not Vested</B><br><B>($)<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity&nbsp;Incentive</B><br><B>Plan Awards:</B><br><B>Number of</B><br><B>Unearned&nbsp;Shares,</B><br><B>Units or Other</B><br><B>Rights That
Have</B><br><B>Not Vested</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity&nbsp;Incentive</B><br><B>Plan Awards:</B><br><B>Market&nbsp;or&nbsp;Payout</B><br><B>Value&nbsp;of&nbsp;Unearned</B><br><B>Shares, Units or<BR>Other
Rights That<BR>Have Not Vested</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John F. Thero</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">260,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,042,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">902,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">240,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">962,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">359,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,439,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,265,250<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,073,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,265,250<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,073,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph T. Kennedy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,937<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">244,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">283,124<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,135,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,500<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,333<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213,865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">433,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199,500<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">799,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199,500<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">799,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">260,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,042,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven B. Ketchum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,937<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">244,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,333<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213,865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199,500<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">799,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199,500<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">799,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">882,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael W. Kalb</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">882,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark W. Salyer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220,000<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">882,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The market value of the restricted stock unit awards represents the product of the closing price of Amarin stock as of December&nbsp;29, 2017, the last trading day of the year, which was $4.01, and the number of shares
underlying each such award and, with respect to performance-based awards, assumes satisfaction of the applicable performance criteria. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">These restricted stock unit awards vest in equal annual installments over three years, commencing January&nbsp;31, 2016. Amount unvested at December&nbsp;31, 2017 represents the third and final vesting tranche.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">These restricted stock unit awards vest in 16 equal quarterly installments, commencing September&nbsp;30, 2015. Amount unvested at December&nbsp;31, 2017 represents the remaining six vesting tranches. </TD></TR></TABLE>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">These restricted stock unit awards vest in equal annual installments over three years, commencing January&nbsp;31, 2017. Amount unvested at December&nbsp;31, 2017 represents the remaining two vesting tranches.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">These restricted stock unit awards vest in equal annual installments over three years, commencing January&nbsp;31, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">These restricted stock unit awards vest upon achievement of certain financial and clinical performance goals. To date, none of the specified criteria have been achieved. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">This restricted stock unit award vests in 16 equal quarterly installments on the last day of each quarter, commencing upon achievement of certain legal performance criteria in October 2015. Amount unvested at
December&nbsp;31, 2017 represents the remaining six vesting tranches. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc467547_35"></A>Pension Benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have a defined benefit plan. Our named executive officers did not participate in, or otherwise receive any special benefits under,
any pension or defined benefit retirement plan sponsored by us during fiscal year 2017. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc467547_36"></A>Nonqualified Deferred Compensation
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During fiscal year 2017, our named executive officers did not contribute to, or earn any amount with respect to, any defined
contribution or other plan sponsored by us that provides for the deferral of compensation on a basis that is not <FONT STYLE="white-space:nowrap">tax-qualified.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc467547_37"></A>Employment, Change of Control and Severance Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into employment agreements or arrangements with each of our current named executive officers. These agreements set forth the
individual&#146;s base salary, bonus compensation, equity compensation and other employee benefits, which are described above in the &#147;Executive Compensation Discussion and Analysis&#148;. In addition, these agreements provide for severance
payments and benefits upon a termination of employment under certain circumstances, as described below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>John F. Thero </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that Mr.&nbsp;Thero&#146;s employment is terminated by the Company without cause or he resigns for good reason, he will be
entitled to severance as follows: continuation of base salary for twelve (12)&nbsp;months; continuation of group health plan benefits for up to twelve (12)&nbsp;months to the extent authorized by and consistent with 29 U.S.C. &#167; 1161 et seq.
(commonly known as &#147;COBRA&#148;) with the cost of the regular premium for such benefits shared in the same relative proportion by the Company and Mr.&nbsp;Thero as in effect on the date of termination; and twelve (12)&nbsp;months of accelerated
vesting on all outstanding equity incentive awards to the extent subject to time-based vesting. In lieu of the foregoing, if Mr.&nbsp;Thero&#146;s employment is terminated by the Company without cause or he resigns for good reason, in either case,
within twenty-four (24)&nbsp;months following a change of control, he will be entitled to severance as follows: continuation of base salary for eighteen (18)&nbsp;months; continuation of group health plan benefits for up to eighteen (18)&nbsp;months
to the extent authorized by and consistent with COBRA with the cost of the regular premium for such benefits shared in the same relative proportion by the Company and Mr.&nbsp;Thero as in effect on the date of termination; a lump sum cash payment
equal to the full target annual performance bonus for the year during which the termination occurred; and 100% acceleration of vesting on all outstanding equity incentive awards. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Joseph T. Kennedy </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the
event that Mr.&nbsp;Kennedy&#146;s employment is terminated by the Company without cause, he will be entitled to severance as follows: continuation of base salary for six (6)&nbsp;months; continuation of group health plan benefits for up to six
(6)&nbsp;months to the extent authorized by and consistent with COBRA with the cost of the regular premium for such benefits shared in the same relative proportion by the Company and Mr.&nbsp;Kennedy as in effect on the date of termination; and six
(6)&nbsp;months of accelerated vesting on all outstanding equity incentive awards to the extent subject to time-based vesting. In lieu of the foregoing, if Mr.&nbsp;Kennedy&#146;s employment is terminated by the Company without cause or he resigns
for good reason, in either case, within twenty-four (24)&nbsp;months following a change of control, then he will be entitled to severance as follows: continuation of base salary for twelve (12)&nbsp;months; continuation of group health plan benefits
for up to twelve (12)&nbsp;months to the extent authorized by and consistent with COBRA with the cost of the regular premium for such benefits shared in the same relative proportion by the Company and Mr.&nbsp;Kennedy as in effect on the date of
termination; a lump sum cash payment equal to the full target annual performance bonus for the year during which the termination occurred; and 100% acceleration of vesting on all outstanding equity incentive awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Steven B. Ketchum, Ph.D. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that Dr.&nbsp;Ketchum&#146;s employment is terminated by the Company without cause, he will be entitled to severance as follows:
continuation of base salary for six (6)&nbsp;months; continuation of group health plan benefits for up to six (6)&nbsp;months to the extent authorized by and consistent with COBRA with the cost of the regular premium for such benefits shared in the
same relative proportion by the Company and Dr.&nbsp;Ketchum as in effect on the date of termination; and six (6)&nbsp;months of accelerated vesting on all outstanding equity incentive awards to the extent subject to time-based vesting. In lieu of
the foregoing, if Dr.&nbsp;Ketchum&#146;s employment is terminated by the Company without cause or he resigns for good reason, in either case, within twenty-four (24)&nbsp;months following a change of control, then he will be entitled to severance
as follows: continuation of base salary for twelve (12)&nbsp;months; continuation of group health plan benefits for up to twelve (12)&nbsp;months to the extent authorized by and consistent with COBRA with the cost of the regular premium for such
benefits shared in the same relative proportion by the Company and Dr.&nbsp;Ketchum as in effect on the date of termination; a lump sum cash payment equal to the full target annual performance bonus for the year during which the termination
occurred; and 100% acceleration of vesting on all outstanding equity incentive awards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Michael W. Kalb </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that Mr.&nbsp;Kalb&#146;s employment is terminated by the Company without cause, he will be entitled to severance as follows:
continuation of base salary for six (6)&nbsp;months; continuation of group health plan benefits for up to six (6)&nbsp;months to the extent authorized by and consistent with COBRA with the cost of the regular premium for such benefits shared in the
same relative proportion by the Company and Mr.&nbsp;Kalb as in effect on the date of termination; and six (6)&nbsp;months of accelerated vesting on all outstanding equity incentive awards to the extent subject to time-based vesting. In lieu of the
foregoing, in the event that Mr.&nbsp;Kalb is terminated without cause or he resigns for good reason, in either case, within twenty-four (24)&nbsp;months following a change of control, he will be entitled to severance as follows: continuation of
base salary for twelve (12)&nbsp;months; continuation of group health plan benefits for up to twelve (12)&nbsp;months to the extent authorized by and consistent with COBRA with the cost of the regular premium for such benefits shared in the same
relative proportion by the Company and Mr.&nbsp;Kalb as in effect on the date of termination; a lump sum cash payment equal to the full target annual performance bonus for the year during which the termination occurred; and 100% acceleration of
vesting on all outstanding equity incentive awards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Mark W. Salyer </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that Mr.&nbsp;Salyer&#146;s employment is terminated by the Company without cause, he will be entitled to severance as follows:
continuation of base salary for six (6)&nbsp;months; continuation of group health plan benefits for up to six (6)&nbsp;months to the extent authorized by and consistent with COBRA with the cost of the regular premium for such benefits shared in the
same relative proportion by the Company and Mr.&nbsp;Salyer as in effect on the date of termination; and six (6)&nbsp;months of accelerated vesting on all outstanding equity incentive awards to the extent subject to time-based vesting. In lieu of
the foregoing, in the event that Mr.&nbsp;Salyer is terminated without cause or he resigns for good reason, in either case, within twenty-four (24)&nbsp;months following a change of control, he will be entitled to severance as follows: continuation
of base salary for twelve (12)&nbsp;months; continuation of group health plan benefits for up to twelve (12)&nbsp;months to the extent authorized by and consistent with COBRA with the cost of the regular premium for such benefits shared in the same
relative proportion by the Company and Mr.&nbsp;Salyer as in effect on the date of termination; a lump sum cash payment equal to the full target annual performance bonus for the year during which the termination occurred; and 100% acceleration of
vesting on all outstanding equity incentive awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc467547_38"></A>Potential Payments upon Termination or Change in Control </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below shows the benefits potentially payable to each of our named executive officers assuming the named executive officer&#146;s
employment was terminated without cause or for good reason within twenty-four (24)&nbsp;months of a change of control and such termination occurred on December&nbsp;29, 2017, the last business day of fiscal year 2017. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Base&nbsp;Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>Payment<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accelerated<BR>Vesting&nbsp;of<BR>Options<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP><BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accelerated<BR>Vesting&nbsp;of<BR>RSUs<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP><BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Continuation&nbsp;of<BR>Health&nbsp;Benefits<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John F. Thero</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">917,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">458,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,313,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,494,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,210,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph T. Kennedy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">448,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">890,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,819,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,384,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven B. Ketchum, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">448,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,034,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,289,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,975,606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael W. Kalb</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">412,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">819,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,231,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,651,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark W. Salyer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">455,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">364,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">882,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,783,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The value of the accelerated vesting of options equals the difference (if positive) between the option exercise price and the closing price per share of our ADSs on December&nbsp;29, 2017 ($4.01), multiplied by the
number of shares that would have been accelerated upon a termination occurring on December&nbsp;29, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The value of the accelerated vesting of restricted stock units equals the closing price per share of our ADSs on December&nbsp;29, 2017 ($4.01) multiplied by the number of restricted stock units that would have been
accelerated upon a termination occurring on December&nbsp;29, 2017. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below shows the benefits potentially payable
to each of our named executive officers assuming the named executive officer&#146;s employment was terminated by the Company without cause (and, in the case of Mr.&nbsp;Thero, he resigned for good reason) other than within twenty-four
(24)&nbsp;months following change of control and assuming such termination occurred on December&nbsp;29, 2017, the last business day of fiscal year 2017. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Base&nbsp;Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>Payment<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accelerated<BR>Vesting&nbsp;of<BR>Options<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP><BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accelerated<BR>Vesting&nbsp;
of<BR><FONT STYLE="white-space:nowrap">Time-Based</FONT><BR>RSUs<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP><BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Continuation&nbsp;of<BR>Health&nbsp;Benefits<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John F. Thero</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">611,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,332,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,605,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,566,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph T. Kennedy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">267,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">924,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,428,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven B. Ketchum, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">467,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">903,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael W. Kalb</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">494,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark W. Salyer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">227,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The value of the accelerated vesting of time-based options equals the difference (if positive) between the option exercise price and the closing price per share of our ADSs on December&nbsp;29, 2017 ($4.01), multiplied
by the number of shares that would have been accelerated upon termination. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The value of the accelerated vesting of time-based restricted stock units equals the closing price per share of our ADSs on December&nbsp;29, 2017 ($4.01) multiplied by the number of time-based restricted stock units
that would have been accelerated upon termination. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc467547_39"></A>CEO Pay Ratio </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to a mandate of the Dodd-Frank Act, the SEC adopted a rule requiring annual disclosure of the ratio of the median employee&#146;s
total annual compensation to the total annual compensation of the principal executive officer (&#147;<B><I>PEO</I></B>&#148;). The PEO of our Company is John F. Thero. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our compensation philosophy must be consistent and internally equitable to motivate our employees to create shareholder value.
The purpose of the new required disclosure is to provide a measure of pay </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
equity within the organization.&nbsp;We are committed to internal pay equity, and our Remuneration Committee monitors the relationship between the pay our PEO receives and the pay our <FONT
STYLE="white-space:nowrap">non-executive</FONT> employees receive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As illustrated in the table below, our 2017 PEO to median employee pay
ratio was approximately 25:1. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PEO 2017 Compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,408,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Median Employee 2017 Compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">135,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Ratio of PEO to Median Employee Compensation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>25:1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We identified the median employee using annualized base salary for 2017, bonus(es) earned in 2017, and
aggregate grant date fair values for equity awards granted in 2017 for all individuals who were employed by us on December&nbsp;31, 2017, the last day of our fiscal year (whether employed on a full-time, part-time or seasonal basis). Employees on
leave of absence were excluded from the list and reportable wages were annualized for those employees who were not employed for the full calendar year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pay ratio reported above is a reasonable estimate calculated in a manner consistent with SEC rules, based on our internal records and the
methodology described above.&nbsp;The SEC rules for identifying the median compensated employee allow companies to adopt a variety of methodologies, to apply certain exclusions and to make reasonable estimates and assumptions that reflect their
employee populations and compensation practices.&nbsp;Accordingly, the pay ratio reported by other companies may not be comparable to the pay ratio reported above, as other companies have different employee populations and compensation practices and
may use different methodologies, exclusions, estimates and assumptions in calculating their own pay ratios. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc467547_40"></A>DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc467547_41"></A><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon recommendation of the Remuneration Committee, the Board approved an amended <FONT STYLE="white-space:nowrap">non-employee</FONT> director
compensation program effective December&nbsp;10, 2012, as amended on May&nbsp;20, 2013, and March&nbsp;11, 2014. The amended <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation program was intended to approximate the 50th
percentile of <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation within the Company&#146;s peer group. A summary of the <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation arrangements for fiscal year
2017 is set forth below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Retainer&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Annual Board Retainer Fee:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Chairman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All <FONT STYLE="white-space:nowrap">non-employee</FONT> directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Annual Chairman Retainer Fees:</B>*<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Committee Chairman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remuneration Committee Chairman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nominating and Corporate Governance Committee Chairman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Annual Committee Member Retainer Fees:</B>*<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remuneration Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nominating and Corporate Governance Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">These fees are in addition to the Annual Board Retainer Fee, as applicable. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The annual
retainers are paid in equal installments in arrears within 30 days of the end of each calendar quarter, or upon the earlier resignation or removal of the <FONT STYLE="white-space:nowrap">non-employee</FONT> director. For <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors who join the Board during the calendar year, annual retainers are prorated based on the number of calendar days served by such director in the calendar year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-employee</FONT> directors are given an annual election option, which option is to be exercised within ten
calendar days of the end of each quarter, of receiving their annual retainers in the form of either (i)&nbsp;cash or (ii)&nbsp;unregistered <FONT STYLE="white-space:nowrap">non-ADR</FONT> ordinary shares, with any such issuances to be priced at the
greater of (i)&nbsp;the closing price of the Company&#146;s ADSs on NASDAQ on the date which is ten calendar days after the end of each quarter or (ii)&nbsp;&pound;0.50&nbsp;per share (i.e., par value per ordinary share). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, upon their initial appointment or <FONT STYLE="white-space:nowrap">re-election</FONT> to the Board, <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors receive equity awards with a grant date fair value of $135,000, split equally in value between option awards and restricted stock units. The restricted stock units are subject to deferred
settlement upon the director&#146;s separation of service with the Company (&#147;<B><I>DSUs</I></B>&#148;) and vest in equal installments over three years on each anniversary of the date of grant. The grant date for such awards is date of initial
appointment or <FONT STYLE="white-space:nowrap">re-election,</FONT> as the case may be, and the exercise price of any option award is equal to the closing market price on NASDAQ of the ADSs representing the Company&#146;s Ordinary Shares on such
date. In addition, for so long as the <FONT STYLE="white-space:nowrap">non-employee</FONT> director remains on the Board, the <FONT STYLE="white-space:nowrap">non-employee</FONT> director receives annual equity awards with a grant date fair value of
$90,000, split equally in value between option awards and DSUs. Such option awards vest in full upon the earlier of the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the date of grant or the annual general meeting of shareholders
in such anniversary year. Such DSUs vest in equal annual installments over three years, in each case upon the earlier of the anniversary of the date of grant or the annual general meeting of shareholders in such anniversary year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, a <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Chairman of the Board that continues on the Board following the
Company&#146;s annual general meeting of shareholders (and who was not first elected to the Board at such meeting) will be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
eligible to receive an annual equity award with a grant date fair value of $20,000, split equally in value between option awards and DSUs. Such awards will have a grant date and exercise price
identical to other annual equity awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All equity awards will be made pursuant to the terms of the Company&#146;s Equity Incentive
Plan, as amended and in effect from time to time. In the event of a change of control (as defined in the Equity Incentive Plan), all option awards and DSUs shall immediately become fully vested. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-employee</FONT> directors are also reimbursed for their reasonable <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with attending Board and committee meetings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
May&nbsp;15, 2017, the Company awarded options representing the right to purchase 21,146 ordinary shares and 14,706 restricted stock units to each of Mr.&nbsp;O&#146;Sullivan, Ms.&nbsp;Peterson, Mr.&nbsp;Stack, Mr.&nbsp;van Heek and
Mr.&nbsp;Zakrzewski in connection with their service on the Board. The options vest in full upon the earlier of the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the grant date or the Company&#146;s 2018 annual general meeting of
shareholders, while the restricted stock units vest in equal annual installments over three years, in each case upon the earlier of the anniversary of the grant date or the annual general meeting of shareholders in such anniversary year, commencing
in 2018. The total grant-date fair value of each of these awards is $45,005 and $45,000, respectively, based on a closing price of $3.06 on NASDAQ of the ADSs representing the Company&#146;s Ordinary Shares on the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, on May&nbsp;15, 2017, the Company awarded an option to purchase 25,845 ordinary shares and 17,974 restricted stock units to
Dr.&nbsp;Ekman in connection with his service on the Board and as <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Chairman of the Board. The option vests in full upon the earlier of the <FONT STYLE="white-space:nowrap">one-year</FONT>
anniversary of the grant date or the Company&#146;s 2018 annual general meeting of shareholders, while the restricted stock units vest in equal annual installments over three years, in each case upon the earlier of the anniversary of the date of
grant or the annual general meeting of shareholders in such anniversary year, commencing in 2018. The total grant-date fair value of these awards is $55,006 and $55,000, respectively, based on a closing price of $3.06 on NASDAQ of the ADSs
representing the Company&#146;s ordinary shares on the date of grant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the compensation paid in fiscal year 2017 to the Company&#146;s <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees<BR>Earned&nbsp;or<BR>Paid&nbsp;in<BR>Cash<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP><BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP><BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lars G. Ekman, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick J. O&#146;Sullivan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kristine Peterson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Stack</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jan van Heek</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph S. Zakrzewski</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The value of the stock awards reflects the aggregate grant date fair value, calculated in accordance with FASB ASC 718, excluding the effect of estimated forfeitures. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The value of the option awards reflects the aggregate grant date fair value, calculated in accordance with FASB ASC 718 using the Black-Scholes option-pricing model, excluding the effect of estimated forfeitures.
Assumptions used in the calculations for these amounts are set forth in Note 12 to our financial statements included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed with the SEC on February&nbsp;27, 2018.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2013, our Board established Stock Ownership Guidelines for its <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors. The guidelines require that each <FONT STYLE="white-space:nowrap">non-employee</FONT> director maintain an equity interest in the Company at least equal to three times the amount of such
director&#146;s annual cash retainer. Equity interests that count toward the satisfaction of the ownership guidelines include the value of Ordinary Shares beneficially owned (other than unvested restricted stock) or issuable upon the settlement of
vested restricted stock units. <FONT STYLE="white-space:nowrap">Non-employee</FONT> directors have five years from the date of the commencement of their appointment as a director to attain these ownership levels. If a
<FONT STYLE="white-space:nowrap">non-employee</FONT> director does not meet the applicable guideline by the end of the five-year period, the director is required to hold a minimum of 50% to 100% of the shares received upon the exercise or vesting of
any future equity awards until the applicable guideline is met, net of shares sold or withheld to exercise stock options and pay withholding taxes. The Remuneration Committee, however, may make exceptions for any director on whom this requirement
could impose a financial hardship. As of the date of this Proxy Statement, all of the Company&#146;s <FONT STYLE="white-space:nowrap">non-employee</FONT> directors have satisfied these ownership guidelines, or have time to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the amount of vested and unexercised stock options, unvested stock unit awards and vested stock unit awards subject
to deferred delivery as of December&nbsp;31, 2017; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unexercised&nbsp;Vested<BR>Stock&nbsp;Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unvested&nbsp;Stock&nbsp;Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Vested&nbsp;but&nbsp;Deferred<BR>Stock&nbsp;Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lars G. Ekman, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">288,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick J. O&#146;Sullivan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kristine Peterson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Stack</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jan van Heek</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">240,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph S. Zakrzewski</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,196,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc467547_42"></A>REPORT OF THE AUDIT COMMITTEE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee oversees the accounting and financial reporting processes of the Company and the audits of the Company&#146;s financial
statements, evaluates auditor performance, manages relations with the Company&#146;s independent registered public accounting firm and evaluates policies and procedures relating to internal control systems. The Audit Committee operates under a
written Audit Committee charter that has been adopted by the Board. All members of the Audit Committee currently meet the independence and qualification standards for Audit Committee membership set forth in the listing standards provided by NASDAQ
and the SEC, and the Board has determined that Audit Committee Member Jan van Heek is an &#147;audit committee financial expert,&#148; as the SEC has defined that term in Item&nbsp;407 of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee members are not professional accountants or auditors. The members&#146; functions are not intended to duplicate or to
certify the activities of management and the independent registered public accounting firm. The Audit Committee serves a board-level oversight role in which it provides advice, counsel and direction to management and the auditors on the basis of the
information it receives, discussions with management and the auditors, and the experience of the Audit Committee&#146;s members in business, financial and accounting matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee oversees the Company&#146;s financial reporting process on behalf of the Board. The Company&#146;s management has the
primary responsibility for the financial statements and reporting process, including the Company&#146;s system of internal controls. In fulfilling its oversight responsibilities, the Audit Committee reviewed with management the audited financial
statements included in the Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2017. This review included a discussion of the quality and the acceptability of the Company&#146;s financial
reporting, including the nature and extent of disclosures in the financial statements and the accompanying notes. The Audit Committee also reviewed the progress and results of the testing of the design and effectiveness of its internal controls over
financial reporting pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act of 2002. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee also reviewed with the
Company&#146;s independent registered public accounting firm, which is responsible for expressing an opinion on the conformity of the audited financial statements with accounting principles generally accepted in the United States of America, their
judgments as to the quality and the acceptability of the Company&#146;s financial reporting and such other matters as are required to be discussed with the Committee by Public Company Accounting Oversight Board (&#147;<B><I>PCAOB</I></B>&#148;)
AU380, <I>Communications with Audit Committees</I>, and SEC Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> Rule 207, <I>Communication with Audit Committees</I>. The Audit Committee has received the written disclosures and the letter from the
independent registered public accounting firm required by the Public Company Accounting Oversight Board. The Audit Committee discussed with the independent registered public accounting firm their independence from management and the Company,
including the matters required by the applicable rules of the Public Company Accounting Oversight Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the matters
specified above, the Audit Committee discussed with the Company&#146;s independent registered public accounting firm the overall scope, plans and estimated costs of their audit. The Committee met with the independent registered public accounting
firm periodically, with and without management present, to discuss the results of the independent registered public accounting firm&#146;s examinations, the overall quality of the Company&#146;s financial reporting and the independent registered
public accounting firm&#146;s reviews of the quarterly financial statements, and drafts of the quarterly and annual reports. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In reliance
on the reviews and discussions referred to above, the Audit Committee recommended to the Board of Directors that the Company&#146;s audited financial statements should be included in the Company&#146;s Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:32%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Submitted by the Audit
Committee of the Board of Directors </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:43%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Jan van Heek (Chairman) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:43%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Kristine Peterson </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:43%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Patrick J. O&#146;Sullivan </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc467547_43"></A>SHAREHOLDER PROPOSALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> under the Exchange Act of 1934, as amended, shareholder proposals intended to
be included in the 2019 Annual General Meeting proxy materials must be received by the Secretary of the Company no later than December 21, 2018, or otherwise as permitted by applicable law; <I>provided, however</I>, that if the 2019 Annual General
Meeting date is advanced or delayed by more than 30 days from the anniversary date of the 2018 Annual General Meeting, then shareholders must submit proposals within a reasonable time before the Company begins to print and send its proxy materials.
Proposals received after this timeframe will not be included in the Company&#146;s proxy materials for the 2019 Annual General Meeting. The form and substance of these proposals must satisfy the requirements established by the Company&#146;s
Articles, the Nominating and Corporate Governance Committee charter and the SEC, and the timing for the submission of any such proposals may be subject to change as a result of changes in SEC rules and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Companies Act, in order for a shareholder proposal to be presented at an Annual General Meeting, such proposal must have been
requisitioned either by shareholders representing 5% of the voting rights of all members having a right to vote on such proposal at the Annual General Meeting or by at least 100 shareholders who have a right to vote on such proposal at the relevant
Annual General Meeting and who hold shares in the Company on which there has been paid up an average sum, per member, of at least &pound;100. Such proposal must have been signed or otherwise authenticated by all requisitionists and submitted to the
Company not later than (1)&nbsp;six weeks before the Annual General Meeting to which the requests relate, or (2)&nbsp;if later, the time at which notice of that meeting is given by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, shareholders who intend to nominate a director to be elected at the 2019 Annual General Meeting must provide the Secretary of
the Company with written notice of such nomination between 7 and 42 days prior to the date of such meeting, together with written notice signed by the director nominee regarding his or her willingness to be elected. Any shareholder seeking to
recommend a director candidate or any director candidate who wishes to be considered by the Nominating and Corporate Governance Committee, the committee that recommends a slate of nominees to the Board for election at each annual general meeting,
must also provide the Secretary of the Company with: the name and address of the shareholder seeking to recommend a director candidate; a representation that the shareholder is a record holder of the Company&#146;s securities (or, if the shareholder
is not a record holder, evidence of ownership in accordance with Rule <FONT STYLE="white-space:nowrap">14a-8(b)(2)</FONT> of the Exchange Act); the name, age, business and residential address, educational background, current principal occupation or
employment for the preceding five full fiscal years of the proposed director candidate; a description of the qualifications and background of the proposed director candidate, which addresses the minimum qualifications and other criteria for Board
membership approved by the Board from time to time; a description of all arrangements or understandings between the shareholder and the proposed director candidate; the consent of the proposed director candidate to be named in the proxy statement
relating to the Company&#146;s annual general meeting and to serve as a director if elected at such annual general meeting; and any other information regarding the proposed director candidate that is required to be included in a proxy statement
filed pursuant to SEC rules, if then required. The Nominating and Corporate Governance Committee will consider all director candidates who comply with these requirements and will evaluate these candidates using the criteria described above under the
caption, &#147;Nomination of Directors.&#148; Director candidates who are then approved by the Board will be included in the Company&#146;s proxy statement for that annual general meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc467547_44"></A>DELIVERY OF PROXY MATERIALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2017, including audited
financial statements, accompanies this Proxy Statement. Copies of our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2017, and the exhibits thereto are available from the Company
without charge upon written request of a shareholder. Copies of these materials are also available online through the SEC at <I>www.sec.gov</I>. The Company may satisfy SEC rules regarding delivery of proxy materials, including this Proxy Statement
and the Annual Report, by delivering a single set of proxy materials to an address shared by two or more Company shareholders. This delivery method can result in meaningful cost savings for the Company. In order to take advantage of this
opportunity, the Company may deliver only a single set of proxy materials to multiple shareholders who share an address, unless contrary instructions are received prior to the mailing date. Similarly, if you share an address with another shareholder
and have received multiple copies of our proxy materials, you may write or call us at the address and phone number below to request delivery of a single copy of the proxy materials in the future. We undertake to deliver promptly upon written or oral
request a separate copy of the proxy materials, as requested, to a shareholder at a shared address to which a single copy of the proxy materials was delivered. If you hold Ordinary Shares as a record shareholder and prefer to receive separate copies
of proxy materials either now or in the future, please contact the Company&#146;s investor relations department at Amarin Corporation plc, c/o Amarin Pharma, Inc., 1430 Route 206, Bedminster, NJ 07921 or by telephone at <FONT
STYLE="white-space:nowrap">(908)&nbsp;719-1315.</FONT> If you hold Ordinary Shares in the form of ADSs through the Depositary or hold Ordinary Shares through a brokerage firm or bank and you prefer to receive separate copies of proxy materials
either now or in the future, please contact the Depositary, your brokerage firm or bank, as applicable. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EACH SHAREHOLDER IS URGED TO
COMPLETE, DATE, SIGN </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND PROMPTLY RETURN THE ENCLOSED PROXY. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc467547_45"></A>PROXY FORM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMARIN CORPORATION PLC </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For use at the Annual General Meeting to be held at The Shelbourne Hotel, 27 St. Stephen&#146;s Green, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dublin 2, Ireland at 2:00 p.m. on Monday, 14&nbsp;May 2018. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="96%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">I/We</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">(Name in full block capitals please)</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="96%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">of</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">being (a)&nbsp;member(s) of Amarin Corporation plc (the <B>&#147;Company&#148;</B>) hereby appoint the Chairman of the meeting or (<I>see</I><I></I><I>&nbsp;note 6 below</I>)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">as my/our proxy to attend, speak and vote for me/us and on my/our behalf as identified by an &#147;X&#148; in the appropriate box below at the annual general meeting of the Company to be held at 2:00 p.m. on Monday,
14&nbsp;May 2018 and at any adjournment of the meeting. This form of proxy relates to the resolutions referred to below.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">I/We instruct my/our proxy to vote as follows:</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Resolutions</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>For</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Against</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Abstain</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><I>(see note 2)</I></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Discretionary</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><I>(see note 3)</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">1.&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinary resolution to <FONT STYLE="white-space:nowrap">re-elect</FONT> Mr.&nbsp;Patrick&nbsp;J.
O&#146;Sullivan as a director.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">2.</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinary resolution to <FONT STYLE="white-space:nowrap">re-elect</FONT> Mr.&nbsp;John&nbsp;F.
Thero as a director.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">3.</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinary resolution (advisory, <FONT STYLE="white-space:nowrap">non-binding</FONT> vote) to
approve the compensation of the Company&#146;s &#147;named executive officers.&#148;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">4.</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">Ordinary resolution to appoint Ernst&nbsp;&amp; Young LLP as auditors of the Company and to authorize the Audit Committee of the Board of Directors of the Company to fix their
remuneration.</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Dated this
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;</U> 2018 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;Signature(s)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notes: </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Please indicate with an &#147;X&#148; in the appropriate box how you wish the proxy to vote. In the absence of any indication, the proxy will exercise his/her discretion as to whether and how he/she votes. The proxy may
also vote or abstain from voting as he/she thinks fit on any other business which may properly come before the meeting. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">If you mark the box &#147;abstain&#148;, it will mean that your proxy will abstain from voting and, accordingly, your vote will not be counted either for or against the relevant resolution. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">If you mark the box &#147;discretionary&#148;, the proxy can vote as it chooses or can decide not to vote at all. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The form of proxy should be signed and dated by the member or his attorney duly authorised in writing. If the appointer is a corporation this proxy should be under seal or under the hand of an officer or attorney duly
authorised. Any alteration made to the form of proxy should be initialed. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">To be valid, this form of proxy, together with a duly signed and dated power of attorney or any other authority (if any) under which it is executed (or a notarially certified copy of such power of attorney or other
authority) must be signed and dated and lodged at the Company&#146;s registrars at the address below, so as to be received by 8:00 a.m. on Thursday, 10&nbsp;May 2018. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">A proxy need not be a member of the Company. A member may appoint a proxy of his/her own choice. If you wish to appoint someone else, please delete the words &#147;the Chairman of the meeting&#148; and insert the name
of the person whom you wish to appoint in the space provided. The Chairman of the meeting will act as your proxy, whether or not such deletion is made, if no other name is inserted. A member may appoint more than one proxy in relation to the meeting
provided that each proxy is appointed to exercise rights attached to different shares. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top">In the case of joint holders, signature of any one holder will be sufficient, but the names of all the joint holders should be stated. The vote of the senior holder (according to the order in which the names stand in
the register of members in respect of the holding) who tenders a vote in person or by proxy will be accepted to the exclusion of the vote(s) of the other joint holder(s). </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top">Completion and return of a form of proxy will not preclude a member from attending the meeting and voting in person. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Address for lodgment of Proxies: </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Equiniti </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aspect House </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Spencer Road </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lancing </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">West Sussex </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United Kingdom </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BN99 6DA </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g467547g27o50.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g467547g27o50.jpg
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M 0$! 0$! 0$! 0'_P  1" %- EP# 1$  A$! Q$!_\0 '@ !  ,! 0 # 0$
M          <("08% 0,$ @K_Q !8$   !@(  00.!0@( P4'!0$! @,$!08
M!P@1$A>6"1,4%2$V-U97=7:TM=06D[/3U3$U4U5TDK+1(C(T05%AE)48<K8E
M)E1SL2,S0D-$148D)U)C9('_Q  8 0$! 0$!                 P(!!/_$
M # 1  ( ! 4$ @,  @(# 0$    ! A$Q42&!D;'!$C)!<6'1 Z'P(N$3\4)2
M8H*B_]H # ,!  (1 Q$ /P#_ '\8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8!'L/MG65A08.(&^5692E9IY78H8R99/C2DS'D<KOF4
M:DW545?F:,F3R4<+-"+-TH9HYFCK!$H*O" ?R&W-7C6AN07^I#5BN2-!G@G&
M QH.%(LD\DGW2"W,Y5:\JE9$C?U%*TJG8B&-"J$?"!(*:B:J9%4CD424(51-
M1,P'343. &(<ARB)3D.40,4Q1$# (" B X!_> , 8 P!@# & , 8 P!@# &
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ME%*NCN-IK"^N=4+7=4$*:ELA"K2JM(4MBYCID1K9+*6,--JG4(1.-!R<YRD
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MJV;V?F?ASG!QT?I['VUKQ<K_ *DBO<$,!47I;'MX.C & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MEJ=6L=F]LY4G<]]MP>]R1R**.QC]]D+DCL-*44J21D0MZ'#&WX1BNCQ9;"1
MT2;4*2CH\0"I>6_JA8BO"0:85$0G_9SW+#/J+6X#3PZ]18ED:S5: A7(UI-
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8!0[B,>O&^PRIH.W*).\$8;F)+JIDYPK/>4>:0Y0Y1Y Y1Y
M.4>0,K!3/A$HF^IXOQY^"':_)2)IZ$*9^]$!EXT! 72X@("]1 0$!4Y! 0\
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MN"& J+TMCV\'1@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M/)K<?4ZOVJ6=55[6YQT?I[&9N7(%W>%[Q4L7M"'PUGDHZY<LK!3/A%F\P;&
M, Y^V>*MF]GYGX<YP<='Z>Q]M:\7*_ZDBO<$,!47I;'MX.C & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M#X:SR4=<N65@IGPBS>8-C & <_;/%6S>S\S\.<X..C]/8^VM>+E?]217N"&
MJ+TMCV\'1@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MBJF8JB2J9C$4(8IBF$H@.#CH_3V/UUKQ<K_J2*]P0P%1>EL>W@Z, 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@&5UV\<[=[3S_Q5WEU1>EL0=7[>Y)/#QY38[U;+^YGS,=,
M^&:@KERC0C)%2%N('R73?[7#?%FF:@[EGLS,?:\MT9X98B: <.7DV1]=2O\
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M@=0GU^WC&[ZK5>A(UV*CIA-*5($=68)-G#@Z[L34(Z<-4V#14KA4@J=TI%<
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M]'5$ZHU_\/R4W=ZLK)66B.$V=KR@1=!M,A&4>GQS]I%J*M7S&LPK1XV5!1,
M4;N6[)-9%0 $0 Z9RF !$.7PYU-S6+JO/R<:4G@J/P9^Y8B6ZX=Z?4K'6YUS
M8:M7)YRA. @@XF82,E%T4.X&JG:4E7S5=1-+MAC'[60P$YYC&Y.<(CDXVT\'
M+#EE($FL4J_18M+7&O6Y1(A0Z8B03"82I5>#3*)A  $PE(Q* F$"@ CR<O(
M!_<&3G.I24J'9X P#G[9XJV;V?F?ASG!QT?I['VUKQ<K_J2*]P0P%1>EL>W@
MZ, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M/MK7BY7_ %)%>X(8"HO2V/;P=& , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M'.<''1^GL?;6O%RO^I(KW!# 5%Z6Q[>#HP!@# & , 8 P!@# & , 8 P!@#
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M#X:SR4=<N65@IGPBS>8-C & <_;/%6S>S\S\.<X..C]/8^VM>+E?]217N"&
MJ+TMCV\'1@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M^<3Z/"TAH+BOJT](2&UVM=VM>M.$JFC;A&Z<<@QM=IIM\D;.#FSU1S(.85E
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MHB,.KR !@$?_ 'J7^>=55[6YQT?I[&9^7(%V^%\Q2U2Q<XQ2_P#>$/RB ?\
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M.]AA(1"R$@SB81)\HWHZ+2#AFC4Q3RLJBFYL:J \Y--W>HZ$U#)*<43AHO\
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M8I55FY;.R',@NW=)JI*-EDE#)KD4(9,Q@.41''1^F?U6IB("NP #*1P"$+%
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M2<X%GO*7GIF,7G!RARAR\H<H<N5@IG]$8^YY;(AZOF L]"&,(%*67C3&,80
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M4!'PAEH.U9[LC'W/+9'SJ!5)#9-2564312)(G$ZBIRIID#N-R'*8YQ I0Y1
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MVK5B3UM#/)*N0,@\4<RY5'3Z(CW;E0$Y1V1,#KN&ZBI@(0I2$ QA I2@4.0
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M4W=ZLK)66B.!VE4:FQU[;';*L5YF[0BE%$'+6%C6[A$X*) !TEDFQ%$S@ B
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M,&>0F"]Q8$*P7I;'[Z-Q': V=L;8>H-=;HUA>=IZE6(WV;KRJ7:O3MQHBQG
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MK9O9^9^'.<''1^GL(!4$*K"KF 1*C7XY4P%Y.403CD3B <O('*(!R!RB <N
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M;<DC;JPLJ>(5*1-*?BE%#CVQ+P%(1V)C#_D ".=2<U@ZKP<;4GBJ/R9N?2&
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MP7PO^M$+]4X*LNI,(Y:$N&H[@$JA'$65<N-2;+INSF$?VA1T4R+&9E::T8O
M[J54;LGC@Z)CN2)*@,GBZFT?7]/S>T)B GK;+]*-JC[=),[/.O)Q**D6==C(
M%QWM7?'5<B:4/'FDI)TY56=.W:X LJH5ND.!4]G;VKV6V:JP@5Y-:$DJ_=*#
ML:K3*38K]*-N&M+A#7>LJR46==J68@G$K"-X^PQ)'L:\D()Y(MHN9@I8[&;C
M@*F<)=(G;?"5C<4E98P'$EL#9E]O4 %5(NUE]KSJDQ4)>W4UZYFU3T6'0K9&
M=4KL"NUM<Y$TY*2BY&ZS\U8[#9I$/Y:DP[>X6*QN0=NHSMGL<'';9U53=7NF
MM4<*0BT,C2GFXI".FDW#=SVF755?;DE7BL5)LU(TKV!@7Q$P>MNZ  LO',BQ
MT>QCR+NG1&#-JR*Y?+G=/7!6J!$"KO'2@BHY=+ 0%'"Z@B=94QU##SC#@% ^
M*S6+./LK"RIR)SU7B(OVA]7[GJ9VH]\)B-UY-6NUU&0IUH*[#Z(.7[Q4D!?D
MGD%:"3]1;H-*B?7EK%Q<W TK63EHWG_OS0MMKG63:@-+:H5XR?3EWN#G8$\N
MTBEHNMM[<^K=?KDD_KE96EI4\ SF#U\MBF&*$RX/(6F;LTV=V1S-N *,D4:M
MX4:MJZRZAMK"WW.4F-2Z++HALW=RS@D!/0*,5K");2CJ"%=PUC'#=/6+-^$;
M&'2BCS,W+2YV_=ZO;SCL_'B<RR5@@HRT0,W69I SJ'L41)04LV*LJW,XC)=D
MM'OT"KH'370,JU<*I@LBH15,3<],Y3E P#AE]7N&&&VI=-RZ>V!=;8X>ZCU?
MJK1U#NU-=K4=ZEK1I3YA_%*6B&8.WK"R7UR>ZR1;98"K1=0EQC*^K5]<T95K
M*FFQJ>$[MZX4MO\ )H!L+5##8+_73MQ,2,,2@VZ;MPFB3KLY:8=3>H]B:?4)
MW]9NV<C%.FD+L9_)-)=D<9)O)1449!9%-(X&&3^=*:@A='4E6B5Z7GYF)-<=
M@6]NM8GYG[QD>_W:>NSF(:J"!2I1L4YGEF3%,I2B=)'NE;E<N%S&#_7ZP.9X
MA:([L5=KVPJ[,LX'8.A)6T;8UQ(S,.XLE7&R&U7L/7CUE;JTRFZO(SL ]JU^
ML*1FD5::U)(2@1<@A+D39KLGP?S(UX1=70<'3J=M.$>2207K5,2WE(:54;2+
MDT[+[#V-MJR6-27:-HIL9>>MNT;(X5C6<''QD>AW&UC$&K5 K?!V?]DEP=3<
M.&"MW1'9D3,NX5]7-I;$@]@2<?)4]C(R53?U[5%0U?#/M<S*DBE]#[E7S4>"
MM53O#>/=R-9FP=F8LS"9FNQ'*%H< SKW5JL8+==*BXV>YE1XB=_1&XK+#.(O
MM\M$[PU#K?7L9KFS1T\$BDDI0(XFHZ;,V#7JD,G+6"R1I'".P(:MNIBJ2P[/
MZR?_ &RR#O1)IOA_O&CK):&[YQ?:KLVN2]RBJNUAE47>TFMC;6"R-(0\G)%[
M^.EK1*RTBZ<RK@TK-/I!VJ*#5YW @.'30.HXF)VO8]PKE@BVZP5\E3=/J]66
M]:>34 D>$=L4;W(I/G[J]2-:?13PE)D9$S3Z)PMAL$.Q;*C+/WSH/@]S;.M:
M_N75^PM36I61;UO9%-L5)FW4.NBUEFD=9(IU%.7D6X<MGC5&19INA<L3NV;U
MH#E)+NIFZ;]L;J L,2E^I]9O-N7[<\[L6:BI"VU??%";3\W7J\^KS>2)P_S,
M9:=0A3F*EGEW5(!J#J?8["._EKFXOA+A:6C=Q5JRZB*O"#M)>MYI_P!_V6LO
M>H4+C<8VZ(R$.W=QNLMI:U/#3U5;6BMS+/:<QJR6E7EBBE9*,[[MVQ-5148>
M*.X13D(V4D4%G21B-#HCAUFL]?06JZ-7]?UA(K:OUINX:1+%%%)HPBV3A\Z?
MI0\)&MP!K"UN&!V,76:^R &->K[.-A&( S8(A@5*R\8U2?1-6E=_52=+"7*B
MZOO&KWJ;R+)-,)?6VV;3K9U=FL<@H\9$A+TT4HT,XI%L>IV*OP3Q5^>RT*[L
M%T8UL.I_WK_O_9V>@^&F@:9<OK#2G]N4B+3K/6%*0J=HLK^U1D##T%_>IR'+
M'.)8RKLQO_W!<QX)*F[G:,XIBDQ1;)&42 )S_O7T?9'\,L B[IRLJ_B9@M'V
MSM#<M=EE:DS0O$#:MF[6LNTI%I6+GWR7>5R!7^EDM2[1',F1U;G3E.]$D[;-
MG,DD_')_W]^K%G< RWLG#I%2>V'O#,_L3HVOI/37$S;-:.6L>1O8:'-\3=BN
ML7LQ:P/U'SEM?4(9O<9=CK-LDQIY:]$/7J-S-L:;&)L4*.S^G^OK$O\ [)UV
MCLBNQ,&\DBQB\9>-4W@TDVCB+J.'.J]G4_:+*-(DJZ*=!C,2].9L'?*Y64;L
M73@Z(G=$26*.'#:.X=ZMH=Q:5*M(O56EE0BV1HSN=LPCTTH:PWF?:S<@W:_T
M9F]R1;RK"VF[NNU2=GA:M3$)-$SN$4>OAUMNIUVW]8-=K5F+B3RJL%,U>ZTG
M8]0FR- DF\9<-?6-A9X!25B#.6(34 ]<L!BK%$IR$4^?04A()0\W7YKO=/1H
MX51X2Z1-VZM4C;[VR1R9Y*[;-V/=JZ:KD=HRFU[>]L,+/6NGR+B8,:DP[>&>
M)U2M0:[&T3<12DW\1(W.>F[!/VB2'7PI;_WU@3)LOA?JNSK=,6N;=LETW\?I
M1FSK,I6V,W54E=*VG:UDC1F85VZ3:V"/G2;=GX]_&KE: Q,PAI6+=-I1D1S@
MX3I1:HWH=(IU':2DU.-:95:]5&TW9'YI6Q3#>NQ#.(1E)^3,1,TE-2";,KN5
M?F33,\?++N!(45.: %(>*[6+-C9&5E3DCFJW$1>M$:JW14SM1[X3$3K^;MMI
MJ3^FV<'8!3W3YX[[Q7TCV"M))^H-T&E1-KRUBO=%AI>?A-W]J7]\S+;:YUDV
MH#:VK%>,G\[=[BYV!/.&D4M%UUO;G]8@*Q)OZY6E9:5/7VDP$ $_,LD)E<\C
M9YRSS*CLKB<<@49(/U/P<T[4UBUU9XNQ2CV6H%,HE3&0%@S8RMC)0]2*:;9M
M)>40.HY-3)*ODC+,^H8<^)3V'!0]P9N&[E!PV= 6LGX.-LT%-5N90,ZA[#$R
M,'*MBJJMS.(V69K,'R!5T#IKHF5:N%4P514353$W/3.4X 8 ,NZ[POPNS[]M
M;4E^NMM</]*ZVT_IO7MUISQ>D/4M;1E<?344-IA6#MZPL=_>*V>0;VRS)JQ-
M5DTF,*:J:[HJB,R:=&IT^9Q9XK]>"]6YM&0.ZF-:AYZ4D(J(AI*Y/I,D.4J$
MK-IW736Q]*/T0E^V I'.&M=V5)OVD@1NZ<IR4;%<G-;)+)+#/]R>MIS4L7IR
MLR%<B7H.6\G/.;"JU91K6!KL4[=1L5&N&=5K+$RC&M1+LT2$V^C6:JB#FSR]
MAFP[2>7.W1"I'O$Y5I)O66^]*A+L(79/#]7MC6ZH+SL,XLM6EF4K37K&RUNR
MP#.;K3]TSDVK5B\CY"*L,/)1$[%1;LZ\E"#-UR= \GA@TM6*'4JI8ZZZDU82
M<X>])ZP2@9\S.5>)QFN'>R["A+RDPV:13.3EK"\VQ-C-IM:_$1(&:-0BXR/:
MF.S*#QQ)#1THQ[[WN0>3[MRTO^[*9NJ6C4F2+8A)&@TS6E9K4$DZ%==?N%"6
MU/4;2\=%[4N\=I/XPR:<8\%),";\ SAV/J=S6^(#6M.@+/W!6=E[+VSQ%0""
ML(F]EZ3O=AKM*FDFU9-Q(BUL^NQ"YR5Q)07$3%3)+PF@HIL!:B%^@ #L];_V
MGKP6BD]')SG#_;-&RU@:]NN5#V!19:XQ5;2CG!4MC)2Z,_,MXI:5D%5)=R:7
M5D7SR2FI%W-SI#3DXZD'SIR94<).BZDA'V^TW15XL\EK/%U:!,04R(-8Z"J0
M3CJ,CVZ1!,*IS35JM$JN\7.9P<)5%B(BWC6PB!XVV]90NXM>6/74^[D8YA/I
MQRJ4I$G;DDX>7@Y>/L5>FF(/$';%=Q#S\3&2:;.1:/(U\+3N.19NV*[ANH%"
MG6B-;+[4D=CW2\RL6K;F?%$ZM=MEJW!/X$CRYZ21I>MZ,^UX1Q9IF0U[6WU(
MU\> OE=EI78$A<6-TNL>>S1<'*-8=@.OQZWQY+;6'61I>_1FP(RPJUZ5A-9;
M,UY$D9131P#1SLN>H=B>6@PN5!0</HJ1U_%K-&2S06SL[R0._46%5($ASQ+U
M^I_9W58KL54*U7JE!(G;0E7@XFNP[=14ZZC>*A&#>-CT3KJB958Z31LB0RJA
MA.H)1.<1,(C@%'>-W6B!JG=]B,)51DGLW7\!PP;?ACL^ZE;/IZ_W)W N"U*4
M,[2)1[_7QV):'$#:G49;8,4)=XVG*7-+H04A!#JKZF],>"Q&I-#U75$QL.>@
M9:TRB&S)6NV!Y$6B<>6)G!OH1B=(AXA62.NZ*H\=K'D7;A=51PHZ3;&[9RMD
MA <F?HH^E&-/;TELO/O)E"CV;:UTCVYV2+%LM:MHV*QRZDN<B:[A<AJY$W.X
7UJ,;=TJ-W+&P+NWJ:CYHS51 F[ /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g467547g35a60.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g467547g35a60.jpg
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M 0$! 0$! 0$!_\  $0@ OP'H P$1  (1 0,1 ?_$ !\  0 " @(# 0$
M       '" 8)! 4#"@L" ?_$ #L0  $$ P$   4# @((!@(#  4#! 8'  $"
M" D1$A,4%18A%R(*(Q@D,3(T.$%1,T)T=[.W)8$F0U+_Q  8 0$! 0$!
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M>Q(?YRYDQX P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MUSKKI)3:"BR.U$][WQWM%95+?6M[34[X^76Q#R8 P!@# & , 8 P!@# & ,
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MT0$NG@IVR>+A8D_ & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M2CA-1X!*<?3SM(B.=);YYWQO6AXFH;6C:Y$Y8(, 8 P!@# & , 8 P!@# &
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M0[N/(E+#E>EH^*KXO%IA,": AJ(5YNBE%QQUO^OO >ASYYAGEN9,7IUY>HR
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MWKYZ_-B%;2&6#N]:_P#])D C53C?_3OGG?\ TP=4?OI_DNY\@?![A@# & ,
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M/KERDEUJU3#@OI)/U*%5;W+\=3UW[CMCT?67C*[/*U-D2,CH.)>(?']JMI\
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M _P4.O[^1(:)6:,A+9;GZD.R$/*MDN_K9KI(X5*&S=.4GJETP[HO3D P!@#
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M>NOJWIATGKGKGOO? Q]=_I2U<\O[/HZX/*, 8 P!@# & , 8 P!@# & , 8
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MG3ON)SHCKY+N*=E1-:1\+?F\P4U9(,.3D;;)TM;M35-.W)W\V]K%[\Y*, 8
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M>,S_ $=J"\*&:ZHB TC4%WOHRT@]X#K%=.IE#%IK')M4\9T1C4$\\3**!9M
M'3^!PBJV=;P$8NRDX_\ 55:LCQJ3BSC4K)(^5$G&7CTQUWF&4C\.)U6&Q8B6
M7&,F\)8>7+;\IN 0.KG<"-/85:-H$+!T:XD.K,E+)@<",'B<=[Y9QI-B051[
M,-4 O*J0IL*ZIYSTCSY/!%OA[6&WW'D;+O6L;;$QSRV&\A] )1YFY5 S:J1,
M]A\G=]V:$(W2;#R<]*HO%58=*U X^*A'*IIW(08./K-FHWD/=HHQF]MV$K9>
MQ=/S=2"/G6I E2,I:>F F.&9D[C[D^^-D.X[&9%,3LCC<!"N9*?E4C_:==A"
MK&$Q)N;DQU\TCH(<U_-Y;HMVC41N7).V"# & :A;HA.Z,]&E6J"6VU9>EGI>
M=PQ37/T,(_>(YCV0MB$);UKA!KNQ K+^L\>9<??>EY$SO<RZ42;LV26]*'ER
M\\S.*U*G-7W8)/A;D?K-#(8 P!@# & =0>  I4&(QV3A1,B %VJC(L#.#FA8
M039J_+[C4@.?HKLWC=3Y:^M%PBHGU\M?/G^-8";5G&X_,*D]]TIPBUJ6R>9;
M#&NN=(U+>JIJ9AV35/Y;T.A-J(O.K.A/"V]:01U)W%N18 PX2'1B""6B2:7.
M;HT<;#1>I_TN*^K/H6-!^]$QW'"-NT!;$)41^7)"25YP)O."?<WKY_(1Q#5F
M5SDTM?+K?2KNCA'_ )=:XZ[Z^C7/MJ67G<[]U+M5P>'.<.I(3;WMY75YUT^L
M$]&M[_G24YJ.YZ_<?+_O^-.*]C[CZ?E_/U?:^GY?S\_E_.2'H^1>*>YI]F?A
MU[X\M(<[Z93B62;Y:^>]06E;SL'KG7_?OF#UM(-\<_\ 3Z^_IXUO>M;ZU\]?
M-#T?(;<.+2[LC@][O+%..T*@\ZV)(U5-;Z8R:W"X&E(*OQS_ +WY""G4YN5B
MXW_&T6[VE6R2O^ZJ\:_SUS?95H1U4K.=V/TNI6R;NKAO#A9M>MD_F1!SKKE:
MFZJ9$:^K)\V[UO\ U*;O^BY:P;-2VBHL/+BCDJ%5I*&?6NBE5(]_3RGVJ$KX
M^>?DX?J/_51M>+X9+OM.Z'#1X<>Q$B&#(6*&-&[ :,'-4&(\>Q:)<(-63%FV
MX2;-&C9!/A%NV033112XX33XYXYUK79F<W & , \2Z"#I!9LY12<-G"2B#AN
MNGPL@N@MQM-5%9)372:J2J?77"B??/7'?'6^>M;YWO6 >O/[^^ ?4%Y_K=F>
M3U0E&VNX_((/H$JBJWIZ9O.OJ4[X:L6*"Z]<%'/>_P"UP 9NXQWUQPFI&6*S
MET8YX=$VP[?@]/I_^153A7^I:YK'KN/4 O3S[<OFF?$:SO&OI!7DQ'?5W^GF
MVVOQ"C+2G:29:/&&O;@/(PCCOCOEN9!OGXU;OA1+ASM5)7CC(]M-5-:FERCV
M9_\ "K?#]5N?TC*?<4_"**UOYH^['*OZ>M^ML)#>LG$]IK/FVU.>V[SBLX61
M6*.DNN>%64CET)*LU=+#5>>1EZU6'MUQ>[(^A;@\PP!@# & , 8 P!@# & 0
MS?=PL*0KW]WKL-&3)N95Q6$& =.=LDY!9%P3^-U?7PAX^Y0=*C@Z\ME@E:1E
MT63]4'&T"YOE@]T/VV5!*?,EB^A$$M]Q4!6$M,US8DKE"$I@<AJN$6?)1U+V
MZE6T*E-O\#VT =R>:\1DS#HE&Y@5*#&0PP2F+X(,=%FK$M(.>VA)RV%A^1EL
MN<25?$&\F0IW-VTDL_MDG :[MZU3#]G$)H=8/X+0))H)NHS&EH_'RO<GW6SQ
M^SZD3 *D\(;&K*'1;4D!9$";0/:\-L9K.V>'$R>S?0;KGRK>E]U&P(,3%:UQ
M:\LC"-OUA847'EBM;1XN<;KNHE(>JZE)>(R#]+X_23X@BR8%AKQ(H)).D>?H
M[!+%)]'_ &5'\G^Y[(O^T:UJ]*1T/97=@^,Q_HN8RNHH](V#+SQ8I1U F$?K
MJQ1!"UIPA*4)HK+9*\ M!TFATI&H5J;1+#>FIIF9&BM0F\<'&.=\<K1UV$F^
M</?$-FGF+RS:UXD6$:L.ZZ$\U6O.FT1BLL[@\1)^CR@&"P[OITKL_P!A(](K
M4,;B0-,B<+/QJ2:I60NFX(>2/H)PG7Y(UBTL<7&N!(EV^OXC$8!;*];DOU*?
MQ:OO0QB"%3<"FQNJSD^\[ "S^>1!Y)1'0$0\=1@R+<!#C!&6AE7),9)P@8D[
M.Q&4, P;_P ^>9DJ>>KK8W5 8N;X3<+GMPF"E9@0' 3#*%\RJ11,.=-!HT=?
M<K#3"@5\17'%6(PJ6<1Q^V7"'%VY=HX0T#4-[VN13RX/9-D1'UG)O,;0[4U0
MGR<-@)WS.SNV%2]0+ZQ-$ME7%D1>OK99V!$(8%F\45;#8TPKU<8;EB;IZA,%
MV!J-%$VX<5+"<7K&2U_.&FTM--?3D!&.S<1C)9XYF?;BQ(=%S2T&F!ZN>[5K
M^OS=A&(64DPE$>$4(!08(F[+M-R8.V4>!S401/-IF/=AVHY\N0+YM^(;4]F4
M574TM,TZA%E.O-WFZ[K#"N*WLB,!"*]_LQL>!J5&W/B';VP1)^V%'T B0Z($
M)>7(&G,>&-E"BDCCSTT.FH;BTM+%9:\&M.C.XM?V2DPD=1QVJ'8;LVY]@5AY
MMOB%3^)24?-(4QL.$FYPR7'-53$?X'O"89J$+1R4_AS&(2 .0><BE'#MHX68
MB1KHVNOT9NI[W\J(G9!'E[29MWH&%G+#2<*B#O(J2PZ,S0)74@-0TMH=L?*$
M!<WDT9CZB0IPNX=]R6/%1J3T :'%G 0_-MMTY3<GIU;<%$UK);<E!1>$P.%#
MIH5F1B:CG\9_:XZO'IEA,7Y=N3;HK<#A*T?*K(E6O+H4:&H(&H^]*AB U^[$
M(2D_M_SQ!_UYO-S\QB9J-E:5%E8F6JJS^YFGQZ+FNJYI0PWB8R)$3SV/3V=_
M=AS(VT8K,!$M;/(G)50DF9.A"(L/OTORONQL8D*^(#2$FG=45Y$1MEG)%9-O
M652AD8[K69Q<Y5<WJRN/ZFR ;8\5E 03*0BSR-D(N7!;V'[9EXO)6DQ:/^X\
MGR[<A':>L':5Q[#K,E6D0D16?*VD?D0.X)EPI6-*V<!)O833UA/X3-I)JIB7
M<MG8%E#B?8V+.T23EP8E\BX[ZB(=XX(H V@--.-WDV/X^^(+Y3:$6C)M8)@X
MQ=!_/<FZE<9KBRI% 643]4&WT;H:8$+ $1)W#6<4GYY@L*9'U#?Z:.<_7LRN
M/19$U6(>UZ:KBKK@3Q<EW5U0<7$3&SB9D4".SJ!UJ)6!P^8S=\\FEFRH9"8.
M&X#P@#(2_'9^4F185J[58\,M$'[-JHYX7=MDUA$IMY&)7CGXB'F-1D,Z;%;3
M(2,I-+*KA*N1'GZ]35I-9_4<;:S*>0PG7(>O'TL&2(7$" N5L!KX6@M(XN6&
MR2-Z+ W7)#0L/MIG8R*">JX$]C1H@4G/5C&M6]Z"@X0) :<L>.2GAO3$S.L)
M-&EH$:7/R8J_JH8U81>9V%PF&BDPE/+!S&10M::12-O!/QU1C"ON*DP9&U9E
M(+73<5;#:B\N6@W#CJ+N1K*XW'_21RP@L"F!0WVQ(ZFH>S'X%D)$!(_"0I&L
M",7D*5@/E%3+=$"+#ZM765UYJB01'L>BCHQP[&F)5LTA<A?S[Q!"%>S@'8[N
MX0M?.+;=PAK!3P$9(U"7=3-E+-;+]L4QZT(^1O3SE'77/(0^DY6F.^&\EBGK
M?@%]5M%+<JTN_/0";#M%HR9(QF4Q!R2']**(\N=@9F%C\B9\=*)*<\Z?B6O7
M?T;ZXUUS\NMB-1@R3, 8 P!@$+>@:6#W[5I^NR1%>/$UU!YZ%3-BW2=%8%8$
M;>)&(9-!2"W::3I8$;:MEGPEPIR.D@7LK%S7#D$;)M' &K6"28T9;FX]-0Z,
M7M&OC2T,M*(HK*KH 9>Q:M'G3@0Y7X2<$8?*A#X9,8&;60;K&X8?"$'35@05
M>CF>Z<J3&JGVO8\5N_%GM,[RG(P!@# & , 8 P!@# & , 8 P!@# & , J+Z
MX\W5Y['C4>\N2*OHK/I[:[DFT@3Z0BUWRM2,&"+34UO/;X6]$GA BN!;UDNH
MD-. 4IK*R<,K!R79*3IJMQQ6U$/%Y;-OE[:FOI>Y5>Y.$K[=G'HI9N+\5>2J
MV\-^9*G\Q56E]R.5I'4F+\^LT29DYK+7RG9&83DVDDHOK@K*Y"Y?EEFVG+A$
M8@NV#,5=#1S-)/(TJ;J;;S\Z%I\$& , 8 P!@# & , 8 P"O/IRFWEV5N*"A
M73=G+8':E-7?!^WJG:(Y[+Z.M&*6D(CI5PGPMVS#S+]KKPPN23;.W @9('19
MHS=/&+=#L$X[<RBNO/DR] ^BO<<6FK"15_2=MN_'Q4VUD=7'?U2=C:YBPLQ*
M8K$K*U)$(*V^@N+;PV7. P^:KMFSHFM'2C1Y^"99#J82UAXSJV95OX>4[UY\
M]%>6T_0D;YJ"VX#Z#KJN7'="-.[/KN-^A&TO8DA4WGO%G)-K7%U^QFQ9M D1
ML8J\KKE@ W,#<MY&N$R(2L'#G.7?IAQ;+JVI4QJS/.<_HS]VBPAF?5#(JK=S
M;44=$1H_J41-U$R)]M#]RQBZ5TDV>N7;$4K+]?97^QPN2=)IJ?>$6#3T*NUK
MX8D\5L#S!8\TN8%*3?C[SS+*%IEK%*G?P(:_U-HS (J>E-J;>6I-BLV1X8UP
M!<B(D&*0H./)."1)95^__270@5N\9N7G:;8879!&OA<V,WINFJ0:>J!+V&4Q
M07E^HHVQE%$/3S,9,_+=KL+,!VS%!K:[0S2+EK/9@XO"K9&JZ.DS "+B.(M+
M8@GRY:. ]REN+S9_]*(MOC?C)/D=\7VI&JY] T8R]'#'%&VUSZ#?02,/Z9Y<
M36MR_I I,Y',1IN?:LU-&PH#&Y38,H-P:/)12%2X;SV%$';&D@H1TU?"3;KC
MI"66'4\OGWP( INNCM#RZ6@[;\YO.HP?B=0&H&^$-*[G;08RYG9")'-SXYVV
M@LXER)6PV=>+#%4H7*)/(40<B[CSA@#' W/G+Z/[Z(\.EO15?3^BY)9\8:4'
M+Y15AJ*11>IUBL]I476PF ,-#J>L/^HP]C&3#@A"7LAC4K>P@L5AAN6FG"')
MAMPU9\ G#GSCTY&3P;RO:-='+R#1F_QVZ.MR9VY:(6MC-2\DIA"+#NM0P;FK
M7NSD;#8-I#5JD_D1Z?L(6E H_,&I1_P&U:/490[#N0;3C#%0LE@MD7MCLS*\
M*?"Z4?Q.N8P6O;YJU1Y3\K^?82="5EV))CIYY!MZ-795-Q..7EBFF;MLI,H@
M"_<=>;;IIDAB;YFVE[';SE5L+[L6XQ;J?"I0U^28)7X8?RZRF-QO[2#MK&=^
MB:,O.9/6=;ON(\9#T# C\&AM>1\(I9"CR.(KZEDF.DI23.2Q\J3+]MTQR8MF
M/8M1)Z2EQ.NJKPU,JUJ@[0A"WZXG],LQI2(5W%Y?YN"DRVZO+R1%\O6M[FGM
MB/1]U@&<,T[KI@H%CE2N' -W^J2/]Q'VC$@W!N7.>$N=--.IG8WPY"M>-[*\
M5R&93 M6]B K6B;1\U*%]$ZYB%BDC;N/Q:O'4K-S0R/"58R*,1L$8GSLC;CV
MP5BRY22 )- #()Q3S4=-?DJS[-\OV2XB3.X5S;RWO03^QOAOUXW?P&F9/L$#
MKV@O=];7].IR2KN/2R6G2&^6NI3,IAUS+!(SD%$@T<C*0<NZ=O9".J7CHHKS
MS=+2^%S9/:?ATDA<L3]%#+4$-K:2]"2N^+#>.ZR?.(E,&TI\W@/+J$.C\8XL
M9@7A/<?K6&0MP,.D)/,?N2=@?*% +QO($AH8<SA&R.L]_->CICP1***(UM,(
M5> GNQ81![^K(T7+50\=P^7PB[[L<WV/X5AR=HH$ \IKB;.%6P,\A,'@XQ'R
M9\<9CBCI\*(@!6YRPPZ*+[O-8Z2^%@+C<%FE95U<7,;A1ZG/!M,QIL?KI65&
MX^'\+V5)+*"F3!9G8,7:24O91"4DV9[30/&68/G\=P.;NOM]MU0]W>I__22Z
M09?[;\]AP=<!3M%UATC9DS]I>)['FQF(P*53QRY:U]ZYK6TYA.)7'(RYY)/
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MG&(\X!+-70PLP9OFR[?C:^*,6FG#4>>8F48(, 8 P!@# & , 8 P!@# & ,
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M-ZP=,DN:JDM_ESJFEO&U.OUKV+Z^>?)HJJ2W]3['-M[2OH@.<#59JH,[&1F
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MJMK<YWOOKZ?IYUTI N$_GU]?.OGOO7.OG_.]:UOY/?3KT?T/\7J?\]:?LL=
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%@# /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g467547g76b14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g467547g76b14.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[0JJ4&AO=&]S:&]P(#,N,  X0DE- ^T
M     !  8     $  0!@     0 !.$))300-       $    'CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))300*       !   X
M0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF9@ &
M       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4
M   ! "T    &       !.$))30/X      !P  #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@  #A"24T$"       $     $   )    "0      X0DE-!!X       0
M    .$))300:      !M    !@              (P   +     & &< -P V
M &( ,0 T     0                         !              "P
M(P                                             X0DE-!!$
M  $! #A"24T$%       !     (X0DE-! P     " X    !    <    !8
M  %0   <X   !_( &  !_]C_X  02D9)1@ ! @$ 2 !(  #_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1"  6 ' # 2(  A$! Q$!_]T !  '_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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M $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4
M( !0 &@ ;P!T &\ <P!H &\ <  @ #8 +@ P     0 X0DE-! 8       <
M"  !  $! /_N  Y!9&]B90!D0     '_VP"$  $! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$" @(" @(" @(" @,# P,# P,#
M P,! 0$! 0$! 0$! 0(" 0(" P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# __  !$( ", L ,!$0 "$0$#$0'_W0 $
M !;_Q ".   " P$  P             )"@ ("P8$!0<! 0
M       0   % P$%!0$*" @/      (#! 4& 0<("0 1%!48$A,6%PH9(3$B
M(R0T)34V-W%C528G9S@Y43(S1%1D165A@9%2LK-T1RAXN&EYJ1H1 0
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%YEL'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g467547g98r96.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g467547g98r96.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X4Q@:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!'26UG/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(CX*(" @(" @(" @/'AM
M<#I#<F5A=&5$871E/C(P,3@M,#0M,354,#@Z,#8Z,S(K,#4Z,S \+WAM<#I#
M<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D;V)E($EL
M;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+WAM<#I#<F5A=&]R5&]O;#X*(" @
M(" @(" @/'AM<#I-;V1I9GE$871E/C(P,3@M,#0M,354,#@Z,#8Z,S(K,#4Z
M,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T
M93XR,#$X+3 T+3$U5# X.C V.C,R*S U.C,P/"]X;7 Z365T861A=&%$871E
M/@H@(" @(" @(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @(" @(#QR9&8Z
M06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z=VED=&@^,C4V
M/"]X;7!'26UG.G=I9'1H/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIH
M96EG:'0^,3(P/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @(" @(" @(" @
M/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@(" @(" @
M(" @(" @(" @(" \>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"06=%
M05-!0DE!040O-U%!<U5':'9D1SEZ84<Y=TE$375-04$T46ML3D$K,$%!04%!
M04)!05-!04%!045!)B-X03M!44))04%!04%104(O*S1!1&M&:V(R2FQ!1U1!
M04%!04%F+V)!25%!0F=114)!545"9U5&0F=K1T)164I#=V='0F=G3$1!;TM#
M=V]+)B-X03M$0D%-1$%W341!=U%$031014$X3T1"351&0E%417AW8D=X<V-(
M>#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(>#AF)B-X03M(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&8O.$%!15%G065!14%!=T52)B-X03M!04E205%-4D%F
M+T5!84E!04%!2$%114)!445!04%!04%!04%!05%&07=)1T%104A#06M+0W=%
M04%G241!445"05%%04%!04%!04%!)B-X03M!44%#07=11D)G8TE#46],14%!
M0T%1341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%1T4R16EC6455
M37!':$)X5WA1:5!")B-X03M5=$AH37A::3A#4GEG=D5L47I25&MQ2WE9,U!#
M3E51;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P5G1.5DM"<GDT
M+U!%)B-X03LQ3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7-799,U(Q9&YD
M-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO*T-K-5-6;'!E66U:)B-X03MQ
M8FY*,F5N-4MJ<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!
M341B445!06A%1$)#15--545&55).:$EG6GAG6D5Y)B-X03MO8DAW1DU(4C13
M3D-&5DII8W9%>DI$4D1G:&%357E7:5DW3$-",U!33F5*16=X9%5K=V=*0VAG
M6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-5%4U4%)L9%E7
M5G!B6$8Q95@Q4FQ:;61O85=P<F)',75B,E(Q9&YD-&58<#=F2#$K9C-/16A9
M84AI26U+:31Y3FIO)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K<4]K<&%A;G%+
M;7%Q-GET<G$K=B]A04%W1$%104-%44U2040X03E,-F)P=6Y(5')5;3%H2DU-
M9%0V)B-X03MA+WEJ,GA612]O>E1F*U=32"]K5W8Y359D*VI.3B\U6DEF.$%K
M5W8Y359D*VI.3B\U6DEF*U)A+S!X5C,V33 S+VQK:"]W0U)A+S!X)B-X03M6
M,S9-,#,O;&MH+S5&<B]41EAF;WI49BM74T@O04I&<B]41EAF;WI49BM74T@O
M:U=V.4U65WDR3VM24E!,3&(R.&-586QP2D=21E96)B-X03M55DI*26]!0FEQ
M42\T<CAG1#=5<T-%0E=:6'0S46=/03!:64Y'0T))0U!4<CEV.$%:<FA65$AN
M5#AT,F1%5S=T1SE266Y6;&A*5&I.)B-X03M'2EEY6$-C5G%H-6)N661C5E9:
M=DY0-69X4TQ'.7AA;&XY6&E6:35Q5$1),%5G-4MH5V]K47)3=34V9%)I<7A0
M3B\U9'9%.'$S3G%9)B-X03LT=TAK8C!4.$M&1$E84'=B2VE+4S=D12]A<&EQ
M=D(U:3AI,T9V3&-14U<X<U5,>'A0=V=*8C%*<$=I:FI646Y*;EHP24-Q0V-6
M5U$K)B-X03MA9GDO;6%667 W5B]19U<V:UE1;FE);D-S<$1C3TI*.5)A2T17
M<'!3=4MQ8R]M+SAV<F5/85,T:VEH4S-D63=G>5=S<2MM-V,V2SE9)B-X03MX
M>% W<#8Q-E5/2W)V.%9E45!6;FE75S-D-UES<R]#,V1W<%=1>$@T;&I+;6IG
M:EDT<6EB;E=V2F1T8G<S17I7>7@S1G%B-D5#3&LW)B-X03M7=TM!>6E-2U@T
M:C%6<G0K;S1&47-F;7IY0DDT4EAH3&QU05@V<DE$>CE.6F5.1$@Y<C U1EE$
M=T]&5C!F;6YY1DIP>6%L1S!5;&Q*)B-X03M0.5936DQ74F=::5952E%2.'%L
M;E92='545')I<FXX,6515FU72#%)5VMD9VE+;',W.&EX6E9+;%EY0W)'3G=R
M1%DX5V]F:$]+;S),)B-X03M54$M5,3AL:D0Y5VMU<$I:-$9J4TE.*SET47!M
M46M,4E-G8U9Q8T-P9$PU>"],=4M:;UI*-V1::VXK<6U-,C<X=E<U4TIW03E/
M<"M/)B-X03LS:UAB=7)$=&A69D0U<3AH5$]S8V)2;#--:7%P=$I62DU-:7=Y
M9V-O:#EI4C%2=D%M:'A68EDK8B]W074W-F%'1S!U3%=75S1+0T=-)B-X03M1
M<T=B,5-G5%EO4'1E<VA(*U-W8G!V:7))=C!:<'8X07EY42\X:3$O<&=6,S9-
M,#,O;&MH+W=#4F$O,'A6,S9-,#,O;&MH+S5&<B]4)B-X03M&6&9O>E1F*U=3
M2"]!2D9R+U1&6&9O>E1F*U=32"]K5W8Y359D*VI.3B\U6DEF.$%K5W8Y3591
M,G!A8G!W,#8V271945)$2E$K;78X)B-X03MP.7-644]Q96%.3CAT*UA,1R\Q
M05-.0DHY6'0Q14MH;35Y<E)D:58V;F)&5DQY-2M94&PS>D$Q>4Q/4C0Q=$EX
M3%!*3G=607!L:VER)B-X03MZ5FU8-U52-R]W06%+<#<K:V10+T%/5W%,+VM9
M=CEC5F0K:V10+S5A;W8X06M9=CEC5F0K:V10+T%/5VU,+V<Q+W)I<G8P:G O
M=T1Y)B-X03LQ4F8X:D8O<FER=C!J<"\O04,P>&8X1W8Y8U9D*VMD4"]W0U=M
M3"]G,2]R:7%N8S-/:UA.=DQB>GIW4U%423!C<V)/=$=2>%)L3R]C)B-X03M(
M1E=05&544$DP-DEK-V5S16IJ:$)K=35(2FIG679!<F-P1%51<WAA3W91-SEC
M2W%&;"M8,S5C,DXT;#-A>%)24U)S6&I8-G=X44]6)B-X03MD95E6;5!X1#%#
M465X<%1O3595-"]W071V>3-I=49N:E%*3$=#26E,=50T3U-Q:FQ!6&]P9%9O
M,4]T5SAC5E9%+TPW.'5K5F=%56U3)B-X03M)5S!R1S=L2F5%4G1%63)0<6)Q
M-D]6661X.&A25DAP-5HX;$I"2D9'26M-<E%34$UK-5=8,4Q1+W5*3UEB;'I4
M;T0T8D=O,GA64W0O)B-X03M*+VM+,F=V3&5+2T)9<C9/2T=C97-E6$-"5D59
M5GDS3E-#9V%O87!B-&IV=F=6,3DU4CAK6#1F-C9W=41+27A/6DQU4FI*-DI*
M4796)B-X03LO:4E$<W1F-514<&A64G10278U9E=A36QU:5)O=V139W58<'AC
M.'5.0R]24V%R-$A&5G$K42])64MS6DAE4EE487!+.3=+>D-!=TYB)B-X03MM
M245Y8DHV8VXR4G17:F1D.%92='8U6CAL47ER2T)&2DET>D)E>'1*3UA+,T9T
M8FDQ:6M7<F)&659#-$975UAL6'E:6C941'!-16=&)B-X03MJ0F126#!56G5M
M4$=E1U5427=03W8Y-&]9:G5E=4MT4655+TI%13A-.%!"2F)E84ME06DT63A$
M05I7:FI7<FUK871C4TYW-E9B-5E6)B-X03M53&)Y4C5'=&)T3'4R;&%'9%A-
M:DY(95-,>F0Q4DI(96HW=$ES4VAZ*S$S>%949CAV+WDY835A-DAW5'9E;E5N
M:U,W:U5M-C53<TID)B-X03MP4'1+8F@K2C9I=3-16492=BM&=DI:2TAK=D]/
M935U568V>3-)4UAK=W5*.2MD94Q3;W(X96Q13591*VME4B]Y.3!L645S;V]L
M4S%A)B-X03M'4S)2-VAN16-L=CEI4D]4;6ID86YV53$V;D-R2B\P:G O.$%Y
M,'AF.$=V.6-#=2]33VXO05!,5D8O>4U8*W5+=2]33VXO.$%,5D8O)B-X03MY
M35@K=4MU+U-/;B]!4$Q41B]W82]W0F-69"MK9% X02M7<4PO:UEV.6-69"MK
M9% O=T-7;4PO9S$O<FEQ>2]L:FPP<39E3G<V1T=3)B-X03MJ2U%184M2,4=+
M=7-);S5.3'15:U%/<&AJ<7)!169:2%DT<7,Q:4].9$@Q07%O56TS;'%104LO
M07@O5U1I<49J<W$V8F%Y5SEH83--)B-X03LW>&]:5$]F5')645,S25)416UV
M=&EQ1SE(5EEO2C5:9$1S6E1'2&1);UIF,VHX45-Q2T=H-&MS9&=3>2M.0C!W
M<7AE-SAX*V598EER)B-X03M&*UAA6$8R1E)1>3--0WA&>D579&E#:$E66D)X
M<%4Q-C%X5D9487@U=U=#,W599DDP8VYQ>'%*<D)P<F1(:6M-:G%Z3E!U0W%Q
M9U!&)B-X03M9:51863$K2$95=6LX,BMF2DE)2'1V>7E)17=2:DI*9%=O2TLV
M<3(X5')&2E5F14=5.%-$5'5307%I6#AY*V-E0TE0>3<Y3S9:,E!P)B-X03MM
M-'0U13E+3FMQ5$EQ0D9:=S4T9VUU,6%':$%66C%B869:4U<X56LQ:$1$2S9+
M,&M80D<T35)5<GE!1F%(875"5E0Y1V%B+WEY42\X)B-X03MI,2]P:7)T34I/
M;E=P4%@P62\X06E)>%9%-'$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1E5$)B-X03MD+SA!2$IV4#E3-"]7,DMP6G$S
M;7)3=DQ(;'5X,4A61$ET<2\Q93,U4G)Z2656448K1W14=C1B*T%X5D$R9FXW
M45!-96UA=D9P<&Q:)B-X03MR83!K95%S9TE+<S!S230X0SEF:6E**U@P,$MS
M:'-L=5<P,G=-16E29U)X1U@Q14PX:S1I<7)2:S1T-VUV>7=+9U<P9GI#3DEU
M<DY.)B-X03M853-6=W-W4SAA1BMC6FMI0TE5<$PX4$(O:B]!57A6:D9X-4,O
M34=36FEF3TQY5S1U+W)%8U)I;6A0;VQY>E%S.$4X8E5+,%A99T1C)B-X03MG
M1'!H5D9P-5(X*T-6+U<X>FTT:F1P47)C1VA:23-6=4MC66U#<U,W0W)J:7E"
M4G=)<3%65D=B>78K8D-882]5+T]-6#%*<$=":FUS)B-X03MO;65/3&<S1&=X
M1$TW0F=T9E5C,2M),39$07$K=SAO9FU5;'AD='%0;DE8;'1C0GA(0VQM:T1*
M52]U>4AJ649E03(K1VQE.6-+<3)H)B-X03ME5U!Z2',Y5VEU=%4X,VI58DPQ
M3V1X67):45%Q-BMN=S1H<4\V-VA4.$Q!5C5B9D9S1EIR:7%#,#(T:D=N5V]O
M*S!-9E)(4#=).7-6)B-X03M24#%I4'=F+T%*1G8O5$989E=)+T(O.$%K5R\Y
M359A*W-X*T0O=T1)="\V67$S.5EJ.$@O04]28B]W0DU682MS>"M$+T%0270O
M=T-M)B-X03M+="]722]"+RM28B]!3DU69#E9:CA(+S5&=CA!,'A6,S%I4'=F
M+VM7+W=$5$97=G)-9F<O+TET+S99<3<V>D@T4"]Y3&8K;4MU*W-X)B-X03LK
M1"\X:3,O<&ER9C%I4'=F+VM7+SE-5F0Y66HX2"\U1G8O5$97=G)-9F<O+T%#
M3&8K;4MT+U=)+T(O.$%K5R\Y359A*W-X*T0O=T1))B-X03MT+S99<3<V>D@T
M4"]!36DS+W!I<F8Q:5!W9CA!-49V+T%%>%9#6&UV-DY:3W%8;#-(8D\O,E9M
M4'!K+TE.5$961"]%,6I);TYR0F58)B-X03M:8C=(<%=S-%9V;$Q):5)5.2ME
M2W%D=F8S1C5O*V]T3EIY,FY!5&A23%-P0D1(=#-8;V%66'=9-'%M1VY)<F%B
M84)G1T%I:4EQ2S=H)B-X03M146-653E8:6I44C<X;V=7='1,5V=!+UE9+W)*
M>%925TM6<DM#,FUT8FUS2TMH84=:67%K2G=/-E-O>$<K,69N,7A603-/:')C
M869E)B-X03LR8FI5:CED:FUJ37)845EX:5I3=G=+6G5(=S$K1V]/1E=+,T@U
M4U<P,'I34&8V=DEH=2]R<5%4=EI4>'$U8W5Y8UI!459B6E188VIQ)B-X03MA
M-S1Q<5A8-5=I-&EN9VMV.59L:75$3'I-.&M%:VEP240X155N<4MY<GEB:S%A
M.&E&-W%P0W%P3"M7,3 V6$-R<G9M1D1C5'1/5T8Q)B-X03MB:T)'-2]U9E1*
M.5 P-GEK;&50>&0V-'%T:B],9E5O-4E*4C5H.'=V2F)!0T536$U$<'-W8F-&
M=5<T6&=A34MR54AR:7%J0BM79750)B-X03MO,6Q:-F@U:S%U6%5,6#%L;#%/
M,VQJ:6MM:FU%65I'.6%E-6-,*S5Q4GIP>4I)03)!5EI&-5$X=5AF;'E/-6IA
M.#%B5C%U1U9L3V]4)B-X03MW>2ML>#5B4DM(5D55.'9S;V]'=S)W2WE/>&IE
M2WET-'!"4C!I4E=(5VA#9TAP:7%V:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-6
M9&ER)B-X03MS5F%:;%93>D5"44MK;EE!1$95=6)Z3&]827!&94IC>6IR1&$Q
M=5I"5"]I=4534"M'2W1F<'%A5&4Q,'DX;E$Y2D=73S-&9F1B:#1P)B-X03M0
M*T5X5GAK.'I3:FES3FY:,4922S!K='E2-T=)2F)J+T%*2UEQ-SE'-GA,=E!Q
M>GAT+TQ:=W=X<#DP-'57+S1B1EAF-&,P>'8Y-E!7)B-X03MU=U16:W5B:6%A
M3FHT;4HS35@O0S1Q:3=05&1/<U9:8DLQ:'1663%:65DQ:D)0=GA!>%9%67%G
M8G8O:FLS;BMP8V9R8D95=3%,>DYP)B-X03LS;#-Y.5E8="M*1VEL3G9B24EW
M<%!Q4W%!;&5B24%#9'5U2W!:<#,U9RM8+T%$4&\K<4144%AR1%IV2S1K:F]E
M3&U726)+5TYE55(O)B-X03MZ<E%Q>3,V>D@T4"]!36DS+W!G5C,Q;5!W9CA!
M-49V+T%%>%9V-GA(-% X03AI,R]!2UEQ,3E::CA(+S5&=CA!,'A6=C9X2#10
M+WE,)B-X03MF*VU+=2MS4BM$+SAI,R]P:7)8,6U0=V8O:U<O.4U69#E::CA(
M+S5&=B]41EAF5UDO0B\K4F(O,'A6=C9X2#10+W=!:3,O<&ER=G)%)B-X03MF
M9R\O04-,9BMM2W1F5UDO0B\X06M7+SE-5F(K<U(K1"]W1$ET+S99<3$Y6FHX
M2"]!3U)B+W="359B*W-2*T0O05!)="]W0VU+=2MS)B-X03M2*T0O05!)="]W
M0VU+=2MS4BM$+T%0270O=T-M2V]+-SAW-DQ:>4-+-75L:6Y/-G=S1SE2=CE6
M2V-M*V=9<6]T-6DU+S=Y85IF,TDW)B-X03MU641B<40W+T%&:W=T+W=+;D96
M0F)R>E9.9$Y68F%Z9S1G<E=/938S.$YV<7AR,7(R-E5R=FEQ<BMJ-VE51#8U
M<60U2W!.6&EH:D9U)B-X03MN>55X>&E:4B]W03EC5EA,;V9L+VQZ;'-V<E5L
M86E7-U-7-6-F2C4O55EF9FEQ6DQ00W%H5E9W;T9!0D<T04$O,D]+="]722]"
M+SA!)B-X03MK5R\Y359A*W-X*T0O=T1)="\V67$W-GI(-% O04UI,R]P:7)F
M,6E0=V8X035&=B]!17A6<C9Z2#10.$$X:3,O04M9<3,Y66HX2"\U)B-X03M&
M=CA!,'A60UA,0G1)=D-+,$M82%5%2'$S631Q<5=%56-M;#)Q4TE(57=X,59G
M0U!S:G-C5E=A=D9';6HS-5)!=&)A5W1!0BMW>"]7)B-X03M4:7%/>%8R2W5X
M5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%9",S)S-E19345V3'5+1U)H5DEM
M8V5O,RMQ;C)M*V=9<6@O,#-.3B]V)B-X03M&<'0Q3T]N<5-)3%9!9CA!2T9W
M635A939X;D9896XU;'5#9E5M=&)#33=C659E-6LK87E396EG4'II8D989C1F
M=#5D-S8U=7(T;G%*)B-X03MP4VM:2&<P34%H:%EF-GE(1E5B6C9F65=56FIS
M<F%+,6I9,5I)55=-12M*0V=9<7(T<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98
M67%G)B-X03MB=CA!-#5.-2]Q6$@V,GA63$Y6,39F4E!,=&AD=S)-;"M83G9!
M,&-18SA&:T%(<4XV85-T>%AV4F-64W93=D]L-7(K:F%P.6$P4S@P)B-X03MK
M4C)4>40V>7(W;#)L:C1F65AC96U#858V*T<U2W-W*W-X*T0O=T1)="\V649D
M.5IJ.$@O04]28B]W0DU68BMS4BM$+T%0270O=T-M)B-X03M+=&9762]"+RM2
M8B]!3DU68BMS4BM$+SAI,R]P:7)V<D5F9R\O270O-EEQ,3E::CA(+S5&=B]4
M1EAF5UDO0B\K4F(O,'A6,S%M4'=F)B-X03LO:U<O.4U64WDU.#(V0D)/3&,S
M6'%4.'5,47=Q,'-I;6]!<6E";C-:;$%!1F0X5F,S;4-E5&%Z,'4X;4(R5V%7
M4#9V2%@O2T5P5UE$)B-X03LU4FY&5W96.'A4+V%E,W-&-D99-%HW='%E26M9
M5S9Q9FY'8U9B3VM7,&XK.70S9EAP-E5D<$EK<#1'3S)70TYH+W)+8U929&QB
M85A9)B-X03MO>5=6;W1Q:D=R3$1!67=4-&M+;WA612]722]"+W=$:U<O.$%4
M1EAF5TDO0B]W1&M7+SA!5$989E=)+T(O=T1K5R\X051&5W9R369G)B-X03LO
M=T1Y3&8X07!I<G9R369G+W=$>4QF.$%P:7)V<DUF9R]W1'E,9CA!<&ER9C%I
M4'=F+VM7+W=$5$989E=)+T(O*U)B+T%.359A*W-X)B-X03LK1"\X:3,O<&ER
M9C%I4'=F+VM7+SE-5F$K<W@K1"\X04ET+S99<3<V>D@T4"]W06DS+W!I<F8Q
M:5!W9B]!2D9V+U1&5W9R369G+SA!)B-X03MY3&8K;4MT+U=)+T(O=T1K5R\X
M051&54IC<T<P:3A)<E%P8V11465R9&II<71P;B]!0GIB5"]J1$@O>$59<7,Q
M<B]J:E@O.$%Z1'DO)B-X03LX44]+;WI&6%EQ-T96:S X14544WIY3$9%=3=3
M3U%Q:C5K-UEQ;"\K2G1$8F%#-D8T4G5W<S!E-TE(*U5,9%I+9E1I<G8P>&13
M9C=Z)B-X03MA5F1Y;U126E@Y2T)4-VQ:6D9L02]W0V5E2W4U95IP<41H6E=1
M2%9U570R5#=C94YR5"]G:FER6#9+,4]55G5D6&U"4#)O-V%/1T=/)B-X03MN
M9T]3>7EJ+T%*1UEQ,R]H<E)72BMS5S5V4$%8:VML,D(O<6DT85%,.4=+;RM/
M,71O;S0T-&]K4T](94I&54%)845F0T(P,DHV67%Q)B-X03M9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ;V98<DQN1VXQ:4QN37A72F5A
M,61L,UE+2S=K9#99<7!R<2ML3W%.)B-X03M(95%Y0U9794QG-G585T]V3FQ#
M:SAG=$17;4MU1W%7<%AK1FU:5$8V-$EG;4E+93%%,V(O04-0=&4R2W1T9G12
M>D9A>GEL558Q54M%)B-X03LU8W8R4C9R4F=-3S1A;4MP8EHV:&,S=6@V:$IC
M5VHR8DHV-DQ'+TMR07!Z-69%<60R2R]2,7=Q<&%T<CEX;V9L>7=V2610;#%&
M;DYV)B-X03M!,$U!67-O:T%(<4AI<FYI=F9B07%4>F5D.5,Q0W<Q4T5A0F1W
M2D9'>4=E55-+:%(S;6A-;CDQ>4E!:41B02]A-T1C;%4Q=5!-2&TS)B-X03LQ
M0TQ8>71-,%A';V5A-W1%971A531*2DE09C=9=TMS3C4U=VM$0U<Q=4EK0V]W
M*W%1,E-Y171X<7%V4&542CA023%Q9S9';F%Q<7AO)B-X03MD6&-U,7A987)D
M145E;7AV<F4R3D-++UIT2EE5;T\Y86YW<FA6=4MY;&=M16M0;%-$,55K36$S
M1%111U-N>%5L3&Q79FEF:')V>3-0)B-X03MW-V)Q<&=M<"M:5UE6,%9%57E&
M4U=U,'%%0C)E:6\S561Q-$9D2'%(;61W;E!326]3=TIC+U=L:S0P<'149VQE
M5RLY9'1S5E=R9"MB)B-X03M'02\P0S-6:D574$M465,P,E19='18=FER;6PX
M,S!B:$9:,3E+<6=H+W=#*U!,-%-E9C)&<79X9%11+T-++T-Q,4I*-7E(<4=/
M3WIA)B-X03MN17A"9S0U5E!X<7A%:#0P6&]11%AW1TMQ1GI.-3=7-FE71T,P
M:W0K9GA38G%3=G=G.&Q-:E4O8DDT:S<X93%A;%54-B]M-5%2.5=T)B-X03M*
M1#9N14YZ9$MX,"LS>"M0-'$O<U8O,E="5GDS;FUK14)T371M1E=Q-'4R6&)F
M:#A0;W0Q*T=U+VII<F$S,VUJ-$]E;%<S4G96-#-H)B-X03M.0T-E4$=S0SAQ
M:G)7;$U65VI64$UD04@P57%X:DHU2F-24T):9&=&25EX5EAF8RLS5'!I<3%T
M53AW0D-4<%5I,&E7:')#,S<R9TQB)B-X03M*37@T.71T+V]X5G%85SE106M8
M-G),1S5#*VM487IY9T563&QV5$Y#2TEE241E2&E-5F1*<E8Q>F9J-FM31U%E
M;5I,1V-"54)+<W)-)B-X03M:1D)*4#)7,BM2<4U68EA7,EIL+S!Y,U%03E9%
M:VI#33!*-#!18S4Q<2]X<4]D2U90,F-686HQ-D]Q3DIQ3FUY8S),.&946&MH
M549&)B-X03M5;35A:$9A:S<Q2%E9<6PY<'%1:C%A5U<T,35*5F%.9SA#*VMK
M86Q61E-J3DY)9TMC4U-+5B]M=V]42#E+5U,W3G$W5E=.;VI75WE")B-X03LU
M,4DY43=F8D)&2V9:,BMZ9U,P3E(P*U91:#%2<$]C87A!<E!A<5,Q5B]E07AL
M9FIB;79T=G-"6$97;G9T0VM746DU;&LY64E'.4<X)B-X03M9;C1&0E5Q27!V
M9W%#0WA7;&4Y8U9B938P;'DW=&$S5GE#-GET*S=M;E5/;DQJ>$98555+2%ID
M<3 W:UEQ,F)N4FMK+S0U53-.6FIC)B-X03MC:%I/9C,U2D)L0D-F8E!(-UA8
M-WAI<4EH,5=*4GAG,#8V0TUE,$EJ1E<T-VM-55 W6&@R3TMR+T%.2C-T0B]U
M274O*T-T4$%(+V8O)B-X03M!3#!X5G@Q2%5#1'<P<30U9C5C;'5O-DXS5U8K
M-$AB=C@X5F,Q-7)65#9E;DIX-V5P8T)4,4DV2VIJ<%$Y8U91,$5U<'EA4'%"
M=C19)B-X03LT1W!0-E-X='HK1VI60E!E:#9(878X;WA634Y-+W=#3V)A9CA9
M62\K26I&5FUT9CAC82\O04]995@O:4)X5D=9<3=&6%EQ-T9867$W)B-X03M&
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ<&DS='A/,#1I451S
M;U9P46\U;%(P0F)R5$965$9867$W1EA9<3=&6%EQ)B-X03LW1EA9<3=&541D
M+SAC;3@O,4QJ.6)9<7$V6B]X>F)4+T%)=W@O=T1%4FER2$Q855!/5CE&<FQT
M<6UK3&)W2DA02'!Z>$]P868Y.5!')B-X03MM>&,O86E73CDV9&9E9TMS9RMV
M,U@O5G5U4#A!9W)F+T%+<EE&9#EF=78X07$S6$@O0E<O+U9B1EAF6#=R+W$S
M6$@O0E<O.$$Q5WA6)B-X03LS,2LV+W=#<F1C9CA&8B\Y5G-69#EF=78K<F1C
M9CA&8B]W1%9B1EAF6#=R+T%+=#%X+W=6=B\Q5WA6,S$K-B\V=#%X+W=6=B]!
M3E9S)B-X03M69#EF=78X07$S6$@O0E<O+U9B1EAF6#=R+W$S6$@O0E<O.$$Q
M5WA683)O,U%+:CE'6$HU1VQ1,79T<U1V*RLY<U989E@W<B]!2W0Q)B-X03MX
M+W=6=B\Q5WA6,S$K-B\V=#%X+W=6=B]!3E9S5F0Y9G5V.$%Q,UA(+T)7+R]6
M8D989E@W<B]Q,UA(+T)7+SA!,5=X5C,Q*S8O=T-R)B-X03MD8V8X1F(O.59S
M5F0Y9G5V*W)D8V8X1F(O=T168D989E@W<B]!2W0Q>"]W5G8O,5=X5C,Q*S8O
M-G0Q>"]W5G8O04Y6<U9D.69U=CA!)B-X03MQ,UA(+T)7+R]68D96;S%'-C5L
M9C!:8S=!1W9+,W!V6"]I-S)X5F0Y9G5V*W)D8V8X1F(O05!68D989E@W<B]Q
M,UA(+T%!5G8O=T)6)B-X03MS5F0Y9G5V*W)D8V8X1F(O05!68D989E@W<B]Q
M,UA(+T%!5G8O=T)6<U9D.69U=BMR9&-F.$9B+T%05F)&6&98-W(O<3-82"]!
M059V)B-X03LO=T)6<U9D.69U=BMR9&-F.$9B+T%05F)&6&98-W(O<3-82"]!
M059V+W="5G-69#EF=78K<F1C9CA&8B]!4%9B1E9/5C5(,%<W85-*)B-X03LT
M1TM80DUC;DAK0E8V5C1L;#-'+UA&5F944#A!:FTR;B]'1U O:4EX5DMV33)I
M83=Q53%M*VPV<61.5T$Q;D%%:F5O4%9I9FE1<F]+)B-X03MC63)8>#,X2V=Q
M;W)Y-W!M<6%D679"<5=O='%D=S!J4T,T9&5"5E-!0D="5G1L<'-E+V9F1E4P
M>%8R2W5X5C)+=7A6,DMU>%8R2W-0)B-X03LQ>GEN-7)V=&9M,4-X.'A35T9G
M.&-33' V0GET561'9#8X-DM85E=86F8Q=%5Q>6I4<F5A,C K,71P-6IC5%%2
M2DA,8TY7<VI);U9N)B-X03M.4W@K26EU-4]"55)I<G-69&ER<U9D:7)S5F1I
M<G-664IA*U-V4$U7;U!C4#5T:TYS.#1K*W%E;3=Q<U,S16-V<$)P2D=B94Y'
M4W9V)B-X03LX.$MS-W=+-T9867$W1EA9<3=&6%EQ-T951G)D<&58;6M8;'):
M6$@Q5SAN:61,934K4#A!9'5W;W(O07E.<V9":&ER1SE-.')E64Y.)B-X03MT
M<'!T53$V8E9&:'0W;T)'-6]'36](175#-TME0W%13G4K,4XV;%=585HO>'IB
M5"]!27=X+W=$15)G5D4T<3=&6%EQ-T9867$W1EA9)B-X03MQ-T9867$W1EA'
M=$YU=4MV3TPV-B].87DK<3-M<%@R;5=.:T]-9#-344)43DQ--E%X<5I)1U!X
M*W!';DQL<U)8=6%&5TAW969F>D=.)B-X03LU24IV32MK;7II=#541DQ&1$EN
M3G<W3W-S>&MT4W%G4D]G*TAB;U0Q3TY+;4XY-3<X-EA%.7EM:V593D]:4F,O
M-DY70V55;49N4$9")B-X03MW=&IY67)004)X<G519#EX:6A%6%!N9GI434YA
M*W K6DY/5EER;65,5%=J:&55;VAQ8EE315%-<E9+,$Q$64-P<65U2W!C;FYR
M>G!E)B-X03M35TYV<"]M:7IE*W5P6C0Q=#)I0VAK:E9E1$U7=$)W*T]A349J
M.$HO6CEL57=L+TU06%HU8F57>3AY861(6E)O0F5V3$9*5VHK;VM7)B-X03LU
M=#%(<6PT*TQ-4&A**WEG>%9Q>B]-<GI%*W!.3%!Q*VY$4T=D3&U&231R<5-9
M,C P-&5/23!T;"M0,$E:5G)X-C%R=4]15E132'IP)B-X03LU9SAW,T5.:C5:
M,4<R5SET-S9F-C1B:$I),&QS:$]W:E922D%P.59557%W1R]W040W9G1+<%IR
M-5AI.'EX-F-W.'=Z4E18>D]#1$11)B-X03M)1CE.058R5E Y,D)Z.'9U059.
M.%9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<4<Q4"]!235T,R]X:&LO-&EC5E5B
M1V$V:7-R94HW2UE0)B-X03M(1VES3U505E9!4"LW3596=G)C+R],1DXY.% O
M0495>%8S,75F+VQI;2LK2"]Q<&ER=G)C+W=$>7A49F9$+S%5>%8S,75F.$$U
M67!V)B-X03MV:"\V<5EQ-S8S4"]!37-5,S-W+SE6359D.6)N+W=#5TMB-S1F
M*W%M2W4K='HO.$%,1DXY.% X03%5>%8S,75F+VQI;2LK2"]!2W%9)B-X03MQ
M-S8S4"]Y>%1F9D0O=T)6359D.6)N+S59<'9V:"\V<5EQ-S8S4#A!.'-5,S-W
M+SE63591=7!7='!Q9'0Y5S%(4U=U-V5V3#!P:$$V)B-X03LX9T-!84=4<4LT
M<6QG.&XK52M*6"]#.$A%.5%98E5G.78U.%9B6'EJ-5=335)*-5II5TU!0E9%
M9'5!;TA'9U@T+VAP-F$Y4$1&5CAV)B-X03ML9GDQ2V]75'DS17=75#%G4%-T
M=C=Y<DYY*S,Q<3=F9FER5G0U53AS5S!L=DQ"-6%I:FQT2$UL=$E)-V)L1WA#
M<5-R8S9J84Y0*T)()B-X03MG3597:GEJ-59"0DAL:455-# O9%<Q4&=1>')T
M>B]K4$@U67%V9GET-6%E5#%'.'1X8W$Q,FIT:'9Y6C8P1#!R>6M9+U-C5E9T
M4#!,)B-X03M29$YV2DPR=S!)5S$S3%535'AR07)N:WAD="]5-W-X3TMP;CEB
M;B\U67!V=F@O-G%9<3<V,U X03AS53,S=R\Y5DU69#EB;B]!3U=+)B-X03MB
M-S1F*W%M2W4K='HO=T1,1DXY.% O5E1&6&97-2\X06QI;2LK2"]Q<&ER=G)C
M+R]!0WA49F9$+T%.5DU69#EB;B\U67!V=F@O=T-Q)B-X03MM2W4K='HO.'-5
M,S-W+SA!5E1&6&97-2\K5TMB-S1F*W%M2W4K='HO05!,1DXY.% O5E1&6&97
M-2]W1&QI;2LK2"]Q<&EQ:F946%5T)B-X03ML8U)*6E1&-4DS5E)Y:#9S<$$O
M,UII<B]!4"]:/"]X;7!'26UG.FEM86=E/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+WAM<#I4
M:'5M8FYA:6QS/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z
M<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @
M/'!D9CI0<F]D=6-E<CY!9&]B92!01$8@;&EB<F%R>2 Q,"XP,3PO<&1F.E!R
M;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,]
M(FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @
M/&1C.F9O<FUA=#YA<'!L:6-A=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^
M"B @(" @(" @(#QD8SIC<F5A=&]R/@H@(" @(" @(" @(" \<F1F.E-E<3X*
M(" @(" @(" @(" @(" @/')D9CIL:3YR<C(Y-34V-#PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO9&,Z8W)E871O<CX*(" @
M(" @(" @/&1C.G1I=&QE/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @
M(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CYP9S R-CPO
M<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z
M=&ET;&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!4
M4&<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]T+W!G+R(*(" @(" @
M(" @(" @>&UL;G,Z<W1$:6T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]S5'EP92]$:6UE;G-I;VYS(R(*(" @(" @(" @(" @>&UL;G,Z<W1&;G0]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]&;VYT(R(*(" @
M(" @(" @(" @>&UL;G,Z>&UP1STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+V<O(CX*(" @(" @(" @/'AM<%109SI.4&%G97,^,3PO>&UP5%!G.DY0
M86=E<SX*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y
M/D9A;'-E/"]X;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3X*(" @(" @
M(" @/'AM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/E1R=64\+WAM<%109SI(
M87-6:7-I8FQE3W9E<G!R:6YT/@H@(" @(" @(" \>&UP5%!G.DUA>%!A9V53
M:7IE(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T
M1&EM.G<^-C$R+C P,# P,#PO<W1$:6TZ=SX*(" @(" @(" @(" @/'-T1&EM
M.F@^-SDR+C P,# P,#PO<W1$:6TZ:#X*(" @(" @(" @(" @/'-T1&EM.G5N
M:70^4&]I;G1S/"]S=$1I;3IU;FET/@H@(" @(" @(" \+WAM<%109SI-87A0
M86=E4VEZ93X*(" @(" @(" @/'AM<%109SI&;VYT<SX*(" @(" @(" @(" @
M/')D9CI"86<^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$YA
M;64^5&EM97-.97=2;VUA;E!3350\+W-T1FYT.F9O;G1.86UE/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL>3Y4:6UE<R!.97<@4F]M86X\
M+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF
M;VYT1F%C93Y296=U;&%R/"]S=$9N=#IF;VYT1F%C93X*(" @(" @(" @(" @
M(" @(" @/'-T1FYT.F9O;G14>7!E/D]P96X@5'EP93PO<W1&;G0Z9F]N=%1Y
M<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S:6]N4W1R:6YG/E9E
M<G-I;VX@-2XP-SPO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @(" @
M(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/G1I;65S
M+G1T9CPO<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y4
M:6UE<TYE=U)O;6%N4%,M0F]L9$U4/"]S=$9N=#IF;VYT3F%M93X*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F9O;G1&86UI;'D^5&EM97,@3F5W(%)O;6%N
M/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M9F]N=$9A8V4^0F]L9#PO<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @
M(" @(#QS=$9N=#IF;VYT5'EP93Y/<&5N(%1Y<&4\+W-T1FYT.F9O;G14>7!E
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SY697)S
M:6]N(#4N,#4\+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @(" @(" @(" @(" @
M(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*
M(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M93YT:6UE<V)D
M7S N='1F/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI"86<^"B @(" @(" @(#PO>&UP
M5%!G.D9O;G1S/@H@(" @(" @(" \>&UP5%!G.E!L871E3F%M97,^"B @(" @
M(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/D)L86-K
M/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X
M;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @/'AM<%109SI3=V%T8VA'<F]U
M<',^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'AM<$<Z9W)O=7!.86UE/D1E9F%U;'0@4W=A=&-H($=R;W5P/"]X;7!'
M.F=R;W5P3F%M93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E
M/C \+WAM<$<Z9W)O=7!4>7!E/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI3=V%T
M8VA'<F]U<',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX
M;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @
M(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @(" @(" @('AM;&YS.G-T179T
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%
M=F5N=",B/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.C$U
M0S0R,T,T-34T,$4X,3%"-3%&0D,R1#8S1#,W,C<V/"]X;7!-33I$;V-U;65N
M=$E$/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.C$U0S0R
M,T,T-34T,$4X,3%"-3%&0D,R1#8S1#,W,C<V/"]X;7!-33I);G-T86YC94E$
M/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z
M-$4Y,3 S0S%!03-&13@Q,3A%-#(Y.#DS149#-D,T.#4\+WAM<$U-.D]R:6=I
M;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.E)E;F1I=&EO;D-L87-S
M/F1E9F%U;'0\+WAM<$U-.E)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \>&UP
M34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C$T0S0R,T,T-34T
M,$4X,3%"-3%&0D,R1#8S1#,W,C<V/"]S=%)E9CII;G-T86YC94E$/@H@(" @
M(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.C$T0S0R,T,T-34T
M,$4X,3%"-3%&0D,R1#8S1#,W,C<V/"]S=%)E9CID;V-U;65N=$E$/@H@(" @
M(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z-$4Y
M,3 S0S%!03-&13@Q,3A%-#(Y.#DS149#-D,T.#4\+W-T4F5F.F]R:6=I;F%L
M1&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S
M/F1E9F%U;'0\+W-T4F5F.G)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \+WAM
M<$U-.D1E<FEV961&<F]M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @
M(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-$4Y,3 S0S%!03-&13@Q
M,3A%-#(Y.#DS149#-D,T.#4\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,3@M,#0M,314,3(Z,S8Z,C0K,#4Z
M,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T
M=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.C$U0S0R,T,T-34T,$4X,3%"-3%&0D,R1#8S1#,W
M,C<V/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z=VAE;CXR,#$X+3 T+3$U5# X.C V.C,R*S U.C,P/"]S=$5V=#IW:&5N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G
M96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V
M=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_
MVP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0'_P  1" #K ?T# 1$  A$! Q$!_\0 '@ !  $$ P$!              <"
M!08( 00) PK_Q !7$   !@$# 0('"0L)!@4#!0 ! @,$!08'  @2$Q$4"146
M%QB7UAE55E=889BGUR$B,3A(469WA[&W(R8R,S9QEL?8-W5XL[;P)#1!H<$E
M0K@G-5)4@?_$ !<! 0$! 0                 ! P+_Q  O$0 " 0$&!@,
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MD&'LE*D(*>EUI"O.J_<88R+^3:0ZCEP=8639TR(D]6'+46^\"3- - - - -
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MK<2L='L/.-7_ 'NOGJLR=\WZ(?/^_P#,.D/#5;B5CH]AYQJ_[W7SU69.^?\
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M9,?1.=LA/;A4FS-W/PQ-XVY$BC1%X1%0 0=K9C3CY)=B1W'&FVL6[>NJ\$S
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M]$AE%$DA/'6I*6@&@(&VK_BP[<?U#8@_A]7M"NU\WW)YT(- - - - - - -
M- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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MH*"  \HW:<2%>"4I>VZ  "J+9 J?,2E TBSZIDRDD#,6:Z[#)]-RHUAERF$
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M<N0GX7(_;T>]+]3AS[?%SWI=7G']_9KKL)P?3<H\I)GB ^0%N[1*!N/?:)R
M1214$@_SVX\BG540$0,).JV6$IS(&;K.$8KKL)P?3<J&QS  80H5L,)0.( #
MRC=IQ(#P2@7E=  !5%LB4G,2@ R+/J"F4D@+%&*Z["<'TW.36*7*(@%$M9P
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M#W\/*[H9D\\"<Q4XEYB4""?B',2 (F HF[.WB B(@7M[ $1'L[1'0%6@-?\
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M8'C ?M&\DA8:=BJ NGDJ_@(T:],XPR%C97.$W3VKQ*,<,7^?L?V+.K>@21;
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M8TS>[; 5"**5, %0PR%@D(]H $ 0$XBMV% 0$W9H#45?PF6RYZJJTQUEB1W
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M /,]D/Y5>>_\.[7O]-V@'F>R'\JO/?\ AW:]_INT \SV0_E5Y[_P[M>_TW:
M>9[(?RJ\]_X=VO?Z;M /,]D/Y5>>_P##NU[_ $W: >9[(?RJ\]_X=VO?Z;M
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M3 !^ #=)@ ,8"O!3 PA03"4#&)'@<P%.)"N7ABE4%BB214QT\BMRU\')GEY
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M7=#,GO0#0&O^??Z6$O\ B QW_P J=T*K<GV9L!H0: : : : : : : : : :
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M"J+ME1*8K15%ZI<]? K>M/(!G>NPO*QU,3 "?,0I<P &$ 9=42@-^,)0.))
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M^' IC)D?E*82G AW+0XE.5DLG(*8Z^"5O6GDX!G>NPO;8ZF)@*3F(4N8 #&
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MQM*H:$FX2I1?5A09IPDC+EE^[RAW2[Z+=-$DFZPE,P_JVY%QFAC8V&9\3Q^
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MP]_#RNZ&9/>@&@-?\^_TL)?\0&._^5.Z%5N3[,V T(- - - - - - - - -
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MI9IV5LR3":4CV-<>13>5;+0,K(N7[IJ\8H-PX3.1M9H0: : : : : : : :
M: : : : : : : : U"W)9@O^.)RN1^-I>J2<XYKEMFI3'<O7)&3G9&#CZW8E
M4[5!OHZ;;.'3VOV!I!R(UE&*4\=5:+O3<'A)5:!<Q8J5\QA^R1NZS_GQ>J94
M481-'B[-7\?8_FL<!;$I6O-;A(S&:L]TQY(-W94YE%W*7W&F.L?6F@U(D6U(
MULUXBHF6E1CYQFX9!"I[P3_8_#?QDJHLS:+*IKHJJMD%547)$DW*2BB1#'3<
M)H*+(IKD,(E5(BLJD50#%34.0 ,(AV= - - - - - - - - - - - - - -
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ME^3E^U[_ "OT._X^.7Z>H.U3\5[;=^H3#W\/*[H9D]Z : : : : : : : :
M: : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
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M?RR;9#'S-6*E8-!<<^QS<_C:2=(O[TL@FBO49ZRN7GI01^=5*XD73&\&LS-
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ACY(]\_\ VFH,.MUNX-?_ #'5Z?2_DN'-3F-/X^.7Z?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
